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PREFACE 
   
“Each disease has a nature of its own; none arises without its natural cause” 
Greek physician Hippocrates, born 460 BC – died 357 BC. 
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ABSTRACT 
Introduction and Objectives: 
 Many environmental factors and genetic risk factors have been implicated in the 
development of colorectal carcinomas. Several genetic mechanisms of tumorigenesis had 
been suggested i.e. the suppressor and the mutator pathways. The suppressor pathway 
constitutes inactivation of tumour suppressor genes: p53, APC (adenomatous polyposis 
coli) and DCC (deleted in colorectal cancer) genes or the activation of proto-oncogene: k-
ras. The mutator pathway consists of inactivation of mismatch repair (MMR) genes which 
results in inability to repair mismatched DNA (deoxyribonucleic acid) bases during 
replication.  
The aims of the study were to determine the incidence and pattern of mismatch repair 
defect by immunohistochemistry in a sample of Malaysian colorectal carcinoma cases and 
correlate this to the clinical and pathological features. Additionally, the relationship 
between p53 over-expression and the mismatch repair status of the tumours were analysed. 
Materials and Methods: 
The clinical and demographic characteristics of 298 patients with colorectal carcinomas and 
the histomorphology of their tumours were studied. Analyses of the mismatch repair genes 
as well as mutation of the tumour suppressor gene were determined by 
immunohistochemical methods using antibodies against hMLH1, hMSH2 and hMSH6 
proteins; and p53 respectively.  
Results:  
The ratio of male to female patients with colorectal carcinomas was 1.26:1. Their age 
ranged from 25 to 91 years (mean of 61 years). There was an overall predominance of left 
sided lesion (69.5%).  Forty three out of 298 cases (14.4%) showed abnormal staining 
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pattern for at least one mismatch repair proteins with majority of cases (65.1%) showing 
single hMLH1 loss. About half of the colorectal carcinomas (50.7%) were associated with 
p53 over-expression. 92.7% of tumours with p53 over-expression did not have any 
mismatch repair defect (MMR-d) and 74.4% of MMR-d tumours did not show any p53 
over-expression (p<0.001). Tumours with mismatch repair defect were located frequently 
at the right side of colon (p<0.001) while tumours showing p53 over-expression were 
significantly left sided (p<0.001).  
MMR-d tumours were more likely poorly differentiated carcinomas (p<0.001), produced 
larger amounts of mucin (p=0.007), showed exophytic growth (p=0.007) and were bigger in 
size (p=0.002) than tumours with no mismatch repair defect. However, there was no 
significant difference in age at presentation, gender, race or survival for patients with 
MMR-d tumours compared to patients without the defect.  
Discussion and Conclusion: 
In this study there were 14.4% of colorectal carcinoma cases with mismatch repair defect, 
which was comparable with that found worldwide (7 to 20%).  
The patients with MMR-d colorectal carcinomas had distinct clinical and pathological 
features. Immunohistochemical staining for MMR-d should be done on these selected 
cases. This information on the MMR-d status will definitely help clinicians in their 
management of the patients. 
There was a significant inverse correlation between loss of MMR-d protein and p53 over 
expression. MMR-d tumours and tumours with p53 over-expression also arose in 
significantly different anatomical sites. This supported the suggestion that there are at least 
two different pathways of colorectal carcinogenesis: the suppressor gene pathway and 
MMR gene inactivation (mutator) pathway. 
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CORAK DAN KEJADIAN hMLH1, hMSH2 DAN hMSH6 SERTA CIRI-CIRI 
KLINIKAL PESAKIT-PESAKT DENGAN KOLOREKTAL KARSINOMA DI 
MALAYSIA 
 
ABSTRAK 
Pendahuluan dan tujuan kajian 
Banyak faktor persekitaran dan faktor risiko genetik terlibat dalam perkembangan 
karsinoma kolorektal. Beberapa mekanisme genetik tumorigenesis telah dicadangkan 
termasuk ‘suppressor’ dan ‘mutator pathways’. Suppressor pathway merupakan inaktivasi 
gen suppressor p53, APC, dan DCC atau aktivasi proto-oncogen, k-ras. Mutator pathway 
terdiri dari inaktivasi gen mismatch repair yang tidak mampu memperbaiki basa DNA yang 
salah dan tidak se-cocok atau sepadan. Tujuan kajian ini adalah untuk menentukan kejadian 
dan corak mutasi pada gen mismatch repair DNA dalam kes-kes karsinoma kolorektal dan 
melibatkannya dengan ciri-ciri klinikal dan patoloji serta membandingkannya dengan 
kejadian mutasi p53 dalam kes-kes kanser ini. 
Bahan kajian dan metodologi 
Ciri-ciri klinikal dan demografi 298 pesakit yang menghidapi penyakit karsinoma 
kolorektal dikaji. Ciri-ciri histomorphology kanser mereka dipelajari. Analisisa gen 
mismatch repair dan  mutasi gen suppressor ditentukan dengan melaksanakan ujian imuno-
histokimia untuk hMLH1, hMSH2 dan hMSH6; dan p53 masing-masing.  
Keputusan 
Nisbah pesakit lelaki dengan pesakit wanita dengan karsinoma kolorektal adalah 1.26:1. 
Usia mereka adalah dalam lingkungan 25-91 tahun (purata = 61 tahun). Kebanyakan kes 
karsinoma kolorektal terdapat di sebelah kiri usus besar (69.5%). Empat puluh tiga daripada 
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298 kes-kes (14.4%) menunjukkan corak luar biasa dan tidak mempunyai sekurang-
kurangnya satu protein mismatch repair. Kebanyakkannya (65.1%) menunjukkan 
kehilangan hMLH1 tunggal. Lebih kurang setengah daripada karsinoma kolorektal (50.7%) 
dikaitkan dengan mutasi p53. 92.7% daripada kanser dengan mutasi p53 tidak memiliki 
kecacatan mismatch repair dan 74.4% daripada kanser dengan MMR-d tidak menunjukkan 
mutasi p53 (p <0,001). Kes-kes kanser dengan kecacatan mismatch repair sering terdapat 
di sebelah kanan usus besar (p <0.001) sedangkan kes-kes kanser yang menunjukkan 
mutasi p53 didapati di sebelah kiri usus besar (p <0.001).Kes-kes kanser MMR-d lebih 
mungkin mempunyai karsinoma yang berdiferensiasi buruk (p <0.001), menghasilkan lebih 
mucin (p = 0.007), mempunyai pertumbuhan exophytic (p = 0.007) dan lebih besar (p = 
0.002) daripada kes-kes kanser yang tidak ada kecacatan gen mismatch repair. Namun 
begitu, tidak ada perbezaan dalam usia presentasi, bangsa, jantina atau kehidupan (survival) 
untuk pesakit-pesakit dengan kanser MMR-d apabila dibandingkan dengan pesakit-pesakit 
tanpa kecacatan gen ini. 
Perbincangan dan Kesimpulan: 
Dalam kajian ini ada 14.4% kes-kes karsinoma kolorektal dengan kecacatan gen mismatch 
repair. Ini boleh dibandingkan dengan laporan-laporan terbitan di seluruh dunia (7 sampai 
20%). Para pesakit dengan kanser MMR-d memiliki ciri-ciri klinikal dan patoloji yang 
berbeza dan istimewa. Ujian imuno-histokimia untuk MMR-d harus dilakukan pada kes-kes 
yang diterpilih. Informasi berkenaan status MMR-d pasti akan membantu doktor dalam 
rawatan mereka.  
Terdapat hubungan terbalik antara kehilangan MMR-d protein dan mutasi p53. Kes-kes 
kanser MMR-d dan kes-kes kanser dengan mutasi p53 juga muncul di tempat anatomi 
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berbeza. Hal ini menyokong pendapat bahawa ada dua pathway yang berbeza dalam 
pertumbuhan kanser kolorektal iaitu ‘suppressor’ dan ‘mutator pathways’. 
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CHAPTER 1: INTRODUCTION AND OBJECTIVES OF STUDY 
 
1.1:  CANCER 
1.1.1:  GENETICS AND CANCER 
Cancer is the common term for all malignant neoplasms (Kumar, Abbas et al. 2004) and is 
characterized by uncontrolled cell proliferation.  The physiological equilibrium between 
cell division and cell death is regulated by various genes which can be broadly classified 
into proto-oncogenes and tumour suppressor genes. Growth-promoting proto-oncogenes 
encode proteins which stimulate cell division to replace cell loss and damage, whereas 
growth-inhibiting tumour suppressor genes encode proteins which slow down progression 
through the cell cycle or induce cell death to regulate overall cell numbers, thus preventing 
tumour formation.  
Gain-of-function mutations in proto-oncogenes convert these into oncogenes which encode 
proteins that induce cancer formation. Activation of proto-oncogenes into oncogenes may 
result from three mechanisms: point mutations resulting in constitutively acting protein 
products, gene amplification of DNA segments leading to over-expression of encoded 
proteins, or chromosomal translocations causing inappropriate gene expression.  More than 
100 oncogenes have been discovered, and common examples include ABL, BCL-2, ERB-B, 
MYC, RAF, K-RAS and others as shown in Table 1.1  (Hyde 2009).  
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In contrast, oncogenic mutations in tumour suppressor genes are generally loss-of-function 
mutations. Tumour suppressor genes encode proteins which regulate cell-cycle check 
points or stimulate apoptosis. Thus loss-of-function mutations in tumour suppressor genes 
result in suppression of apoptosis or unregulated progression through the cell cycle, 
bringing about tumour growth. Tumour suppressor genes in many cancers have deletions or 
point mutations which prevent production of proteins or lead to production of non-
functional proteins. Since generally one copy of a tumour-suppressor gene is sufficient to 
control proliferation, both alleles must be lost or inactivated to promote tumour 
development. Examples of tumour suppressor genes include RB1, p53, APC, BRCA1, 
BRCA2 and NF1.  
According to Knudson’s ‘multi-hit’ hypothesis of oncogenesis, a minimum of two genetic 
“hits” or mutations are required for oncogenesis – the activation of an oncogene (mutation 
of a proto-oncogene) followed by the inactivation of a tumour suppressor gene (Hyde 
2009). These result in homeostasis disruption and hyperplasia or cell proliferation. 
Malignant progression relies on the accumulation of further mutations which may be due to 
environmental influences, mutagenic chemicals, ionizing radiation, or viral infections 
involving tumour-inducing retroviruses and viral oncogenes.  
The complex genetic pathway to cancer, which incorporates Knudson’s multi-hit 
hypothesis, is epitomised in the molecular pathogenesis of colorectal carcinoma. Benign 
tumours of the large intestine develop initially as a result of inactivation of the tumour 
suppressor gene: adenomatous polyposis coli (APC) gene as illustrated in Figure 1.1 
(Snustad and Simmons 2010), causing dysplasia of  intestinal epithelium and development 
of early adenomas. Next, activation of the K-ras oncogene and inactivation of tumour 
 
5 
 
suppressor genes on chromosome 18q induce development into late-stage adenoma. One of 
the final steps in carcinogenesis involves inactivation of the p53 tumour suppressor gene 
which is required for development of colorectal carcinoma. Finally, inactivation of other 
tumour suppressor genes leads to a carcinoma gaining certain aggressive characteristics, 
such as metastatic potential.  
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Normal intestinal epithelium  
           Inactivation of APC tumour suppressor gene    
Dysplastic epithelium 
  
Early adenoma 
       Activation of K-ras oncogene 
Intermediate adenoma 
       Inactivation of tumour suppressor genes on chromosome 18q 
Late adenoma 
       Inactivation of p53 tumour suppressor gene  
Carcinoma 
       Inactivation of other tumour suppressor genes 
Metastatic colorectal cancer 
 
Figure 1.1: Pathway to metastatic colorectal carcinoma (Snustad and Simmons 2010). 
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1.1.2: CANCER AND CELL CYCLE 
The cell cycle consists of periods of growth, DNA synthesis and cell division. The length of 
the cell cycle and duration of each of its components are controlled and determined by 
specific internal and external chemical signals. The transition and progression of each 
phase require integration of these signals and precise responses to them. Incorrect sensing 
of chemical signals or improper signal response will result in inappropriate progression 
through the cell cycle and the potential for malignant transformation. 
The different phases of the cell cycle include the G1, S, G2 and M phases, with 
‘checkpoints’ between each phase that either stop or allow progression of each phase to the 
next. At a checkpoint, progression through the cell cycle is halted until a critical process 
such as DNA synthesis is completed or until damaged DNA is repaired. When these 
conditions are satisfied, the cell cycle may progress.  Cancer formation results from 
deregulation of these cell cycle checkpoints due to genetic defects described above in 
Chapter 1.1.1. 
The START checkpoint, located in the mid-G1 phase (Figure 1.2), plays an important part 
in oncogenesis. The cell receives both internal and external signals at this checkpoint to 
determine when it is appropriate to progress to the S phase of the cell cycle.  
Cells in which the START checkpoint is dysfunctional are more prone to malignant 
transformation. Where DNA damage has occurred within a cell, it is important that entry 
into the S phase is delayed to allow for damaged DNA to be repaired, otherwise replication 
of the damaged DNA will ensue and defects will be passed on to subsequent cell 
generations.  
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Normal cells are programmed to pause at the START checkpoint to ensure repair is 
completed before DNA replication commences. If the START checkpoint is dysfunctional, 
cells move into S phase without repairing damaged DNA. Over a series of cell cycles, 
mutations that result from the replication of unrepaired DNA may accumulate and cause 
further deregulation of the cell cycle. A clone of cells with a dysfunctional START 
checkpoint may then proceed to become malignant. 
 
 
 
 
Figure 1.2: Schematic diagram of START checkpoint in the mammalian cell cycle (Snustad 
and Simmons 2010).  
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1.1.3: GERMLINE AND SOMATIC MUTATIONS 
Genetic defects involved in oncogenesis may be either inherited or acquired mutations. 
These are known as germline or somatic mutations respectively. Germline mutations are 
present in all cells from conception and are hereditary. Somatic mutations arise in a single 
differentiated cell post-conception, and are not hereditary. Both germline and somatic 
mutations play important roles in oncogenesis. 
 
1.1.4: SPORADIC AND HEREDITARY CANCERS 
More than 90% of tumours occur as a result of spontaneous random mutations. These are 
caused by an accumulation of somatic mutations leading to a progressive sequence of cell 
cycle deregulation, benign hyperplasia, and malignant transformation.  
Approximately 10% of all cancers are hereditary. More than twenty different inherited 
cancer syndromes have been identified and most are due to mutations of tumour suppressor 
genes rather than  hereditary oncogenes (Snustad and Simmons 2010). Some of the more 
common inherited cancer syndromes are familial retinoblastoma, familial adenomatous 
polyposis (FAP), hereditary non-polyposis colorectal cancer (HNPCC), neurofibromatosis, 
von Hippel-Lindau disease and familial breast cancers. The different hereditary cancers and 
tumour suppressor genes involved with the proposed function of encoded proteins are 
shown in Table 1.2 (Fearon 1997). 
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1.1.5:  DNA MISMATCH REPAIR GENES 
As discussed earlier, cancer-causing mutations can arise exogenously or endogenously. 
Genetic information that may be altered endogenously includes errors or alterations in 
DNA metabolism such as DNA replication, recombination or repair. When errors in DNA 
metabolism occur during the process of DNA synthesis, many safeguard mechanisms are in 
place to maintain genomic stability. One of these is the DNA mismatch repair (MMR) 
system. 
The DNA mismatch repair system was first demonstrated in bacteria more than 30 years 
ago (Tiraby and Fox 1973). It was shown to play an important role in maintaining genomic 
stability, with defects in the genetic pathway of this system leading to elevated levels of 
spontaneous mutations (Tiraby and Fox 1973).  
The DNA mismatch repair system corrects any biosynthetic errors that occur in the 
genome, and thus acts as an important caretaker of the genome. It rectifies DNA 
mismatches generated during DNA replication and blocks DNA recombinations occurring 
between divergent sequences (Modrich and Lahue 1996; Harfe and Jinks-Robertson 2000) 
by recognising complementary base pair errors when one strand of DNA is either unpaired 
or incorrectly matched with a base pair on the complementary strand. It also contributes to 
genomic stability by controlling cell cycle checkpoints and is responsible for controlling 
programmed cell death in response to damaged DNA products (Li 1999; Stojic, Brun et al. 
2004). Damaged cells are eliminated from progressing further in the cell cycle, preventing 
tumorigenesis. Inactivation of the mismatch repair system in human cells will thus lead to 
genomic instability that may potentially result in development of hereditary and sporadic 
cancers. 
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The mismatch repair system in the Gram-negative bacteria Escherichia coli (E.coli) 
possesses similarities in repair properties to that found in humans. The mismatch repair 
system in E. coli consists of proteins encoded by MutH, MutL, MutS and MutU genes. The 
term ‘mut’ is used for mutator because mutations in these genes result in high levels of 
spontaneous mutations or generalised hypermutability in bacterial strains. The human 
homologues of the E.coli MutS and MutL have been identified.  
In the model of the mismatch repair system found in E. coli, the MutS homodimer detects 
and binds the mismatched base pair while MutL binds and locates methylation signals in 
DNA. The mismatch repair system also activates the endonuclease MutH which nicks the 
unmethylated strand of DNA initiating site for mismatch-provoked excision. This target 
mismatch repair on newly synthesised strand. While the MutS and MutL proteins in the 
E.coli are homodimers, their human counterparts function as heterodimeric complexes. 
MutL interacts with MutS to enhance mismatch recognition. Both possess ATPase activity. 
These human mismatch repair genes were named after their prokaryotic counterparts, e.g. 
human mutator L homologue 1 (hMLH1) and human mutator S homologue 2 (hMSH2).  
Three human MutS homologues (hMSH2, hMSH3 and hMSH6) have been identified. 
hMSH2 interacts with either hMSH6 or hMSH3 to form hMutSα and hMutSβ 
heterodimeric complexes respectively. Both complexes play critical roles in mismatch 
repair initiation. 
The human MMR components homologous to E.coli MutL are hMLH1, hMLH3, hPMS1 
and hPMS2. hMLH1 interacts with hPMS2, hPMS1 or hMLH3 to form three heterodimeric 
complexes: hMutLα, hMutLβ or hMutLγ respectively. hMutLα is needed for mismatch 
repair and hMutLγ for meiosis but the function of hMutLβ  remains unclear. 
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Mismatch repair proteins play an important function in correcting biosynthetic errors and 
thus a critical role in cellular mechanisms that prevent tumorigenesis. 
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1.2: COLORECTAL CARCINOMA 
1.2.1: INCIDENCE 
Next to circulatory diseases, cancer is an important medical problem in both developed 
countries and developing countries alike. It is a leading cause of death worldwide. A recent 
estimate of global cancer burden suggested that there were 10.9 million new cases, 6.7 
million deaths and 24.6 million persons living with cancer (within 5 years of diagnosis)  
worldwide in 2002 (Parkin, Bray et al. 2005).  
Colorectal cancer represents one of the major causes of cancer-related morbidity and 
mortality in the world, especially the Western world. It is common among both males and 
females, and it is estimated that about 5% of the population worldwide will develop 
colorectal cancer in their lifetime. 
The number of new cases of colorectal cancer globally has been increasing rapidly since 
1975, from 500,000 cases annually to approximately one million. Worldwide, the estimated 
incidence of colorectal cancer ranks fourth among all cancers in men (after lung, prostate 
and stomach cancer) and third in women (after breast and cervical cancer) (Parkin, Bray et 
al. 2005).  
Worldwide, colorectal cancer represents 9.4% of all incident cancers in men and 10.1% in 
women. However, the incidence of colorectal cancer varies in different parts of the world. 
In Western countries, namely North America, north, south and western Europe and 
Australasia, colorectal cancer represents 12.6% of all incident cancers in men and 14.1% in 
women. In other countries worldwide, that is excluding those above, colorectal cancer 
represents only 7.7% and 7.9% of all cases in men and women respectively (Boyle and 
Langman 2001). 
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Approximately 40% of colorectal cancers have localised disease at diagnosis, namely 
stages 0 (carcinoma-in-situ), I and II, which have excellent five-year survival rates (Jemal, 
Siegal et al. 2006). Prognosis worsens with advancing stage as patients with metastatic 
colorectal cancer have only a 5% five-year survival rate (Jemal, Siegal et al. 2006). It is 
estimated that nearly 400,000 deaths still occur from colorectal cancer worldwide annually 
and colorectal cancer is the second most common cause of death in men after lung cancer 
(Jemal, Siegal et al. 2006). 
COLORECTAL CARCINOMA IN MALAYSIA 
The Malaysian Department of Statistics  (National_Cancer_Registry 2006) reported a total 
of 24.8 million residents of the Peninsular Malaysia in the year 2006. This was made up of 
almost equal numbers of males (50.6%) and females (49.4%) with Malays being the major 
ethnic group (54.3%). The other two major ethnic groups were the Chinese and Indians, 
making up 25.1% and 7.5% of the population respectively. Other minor ethnicities, namely 
the Punjabis, Eurasians and other immigrants, contributed to the remaining 13.1% of the 
population. 
 Cancer was the cause of 10.59% of reported deaths in public hospitals in Malaysia, making 
it the third major cause of death (National_Cancer_Registry 2006). 
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  Table 1.3: Ten Principle Causes of Deaths in Ministry of Health,  
  Malaysia (MOH) Hospitals, 2006   
      
  Diseases  Percentage (%) 
1 Septicaemia  16.87 
2 Heart Diseases & Diseases of Pulmonary Circulation  15.70 
3 Malignant Neoplasms  10.59 
4 Cerebrovascular Diseases  8.49 
5 Pneumonia 5.81 
6 Accidents 5.59 
7 Diseases of the Digestive System 4.47 
8 Certain Conditions Originating in The Perinatal Period  4.20 
9 Nephritis, Nephrotic Syndrome & Nephrosis 3.83 
10  Ill-defined conditions 3.03 
  All causes 100.00 
      
 (Malaysian Cancer Statistics-Data and Figure, Peninsular Malaysia, 2006;  
 National Cancer Registry, Ministry of Health Malaysia)  
   
 
In 2006, a total of 21,773 cancer cases were diagnosed in Peninsular Malaysia and 
registered in the National Cancer Registry. This comprised of 9,974 males and 11,799 
females. The age-standardised incidence rate (ASR) for all cancers in Malaysia was 131.3 
per 100,000. The ASR among males was 128.6 per 100,000 population and among females 
was 135.7 per 100,000 population. The five most common cancers among the population in 
Peninsular Malaysia were breast, colorectal, lung, cervix and nasopharyngeal carcinomas 
(Figure 1.3).  Colorectal cancer was the most common cancer in males and second most 
common cancer in females after breast cancer. 
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Figure 1.3: Ten most common cancers, Peninsular Malaysia, 2006. 
(Source: Malaysian Cancer Statistics-Data and Figure, Peninsular Malaysia, 2006; 
National Cancer Registry, Ministry of Health Malaysia) 
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In the age demographic of fifty years old and over, colorectal cancer was the predominant 
cancer in males and the second most common among females. 
A total of 2,866 colorectal cancer cases were registered with the National Cancer Registry 
in 2006 and this represented 13.2% of all cancer cases. The incidence of colorectal cancer 
increased with age; with an overall ASR of 18.4 per 100,000 (Figure 1.4). The incidence 
was higher among males where the ASR was 21.6 per 100,000 compared to females with 
an ASR of 15.4 per 100,000.  It was also reported that the incidence was highest amongst 
Chinese where the ASR was 21.4 per 100,000 population and lower in the other 2 major 
races: Indians and Malays, with an ASR of 11.3 per 100,000 and 9.5 per 100,000 
respectively. 
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Figure 1.4: Colorectal cancer - Age specific cancer incidence per 100,000 population by 
gender, Peninsular Malaysia, 2006. 
(Source: Malaysian Cancer Statistics-Data and Figure, Peninsular Malaysia, 2006;  
National Cancer Registry, Ministry of Health Malaysia) 
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1.2.2: RISK FACTORS 
A number of environmental and genetic risk factors for the development of colorectal 
cancer have been identified. These include age, diet, physical inactivity, smoking, 
inflammatory bowel disease and genetic factors.  
DIET 
The intestinal epithelium is exposed to various types of ingested food. Increased 
consumption of dietary fibre in the form of fruits, vegetables and cereals has been said to 
have a protective effect against the formation of colorectal cancer (Graham, Dayal et al. 
1978). A high-fibre diet increases faecal bulk and decreases bowel transit time, thus 
reducing the duration of contact time of the colonic mucosa to any potential exogenous 
toxins or carcinogens. Some fibres may bind with various reactive compounds and thus 
have direct antitoxic effects against carcinogens (Ferguson and Harris 1996). 
Conversely, a diet rich in red or processed meat or high in animal fat is postulated to 
increase the risk of developing colorectal cancer. It has been found that diets high in protein 
and fat but low in fibre content are associated with formation of hydroxyl radicals in faeces 
(Erhardt, Lim et al. 1997). This may lead to oxidative injury to the DNA of colonic 
epithelial cells and subsequent neoplastic transformation. 
Substantial alcohol consumption has also been linked to the development of adenomas and 
carcinomas due to abnormal DNA methylation (Sandler, Lyles et al. 1993). 
 
21 
 
PHYSICAL ACTIVITY AND SMOKING 
Epidemiological studies have highlighted that men who are physically active have a lower 
risk of developing colorectal cancer (Giovannucci and Willett 1994). However, smoking 
and occupations associated with inhalation of dusts and fumes increase the risk of 
colorectal cancer. This is more common in males than females, thus explaining the higher 
ASR of colorectal carcinoma in males. 
INFLAMMATORY BOWEL DISEASE 
Patients with inflammatory bowel disease, including both ulcerative colitis and Crohn 
colitis, are well known to have a higher risk of developing colorectal cancer than the 
general population. The risk of developing colorectal carcinoma correlates closely with the 
duration of the disease. The risk of cancer only starts after a disease duration of 10 years 
and the risk rises by about 10% per decade. Chronic inflammation is a common basis for 
epithelial carcinogenesis. Carcinomas develop from mucosa that has undergone a series of 
morphological changes culminating in invasive carcinoma. Dysplasia is a pre-cursor to 
carcinoma in inflammatory bowel disease. 
GENETIC FACTORS 
Whilst environmental factors play a role as catalysts in genetically susceptible individuals, 
there are a number of hereditary factors that increase the likelihood of the development of 
colorectal carcinomas. There are various familial forms of colorectal cancers that include 
familial adenomatous polyposis (FAP), hereditary non-polyposis colorectal cancer 
(HNPCC) and other groups of patients with sporadic cancers whose strong family histories 
do not fulfil any criteria of known familial syndromes. 
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1.2.3: CLINICAL PRESENTATION 
Presenting symptoms of colorectal cancer may include abdominal pain, per rectal bleeding, 
symptoms of anaemia or change in bowel habit. The initial symptoms may be vague and 
non-specific. A small percentage of patients present with relatively minimal symptoms on 
diagnosis. Patients with colorectal carcinoma present differently depending on the location 
and size of the tumour. Large tumours on the left side of the colon may cause a change in 
bowel habit including constipation, watery diarrhoea or tenesmus. Tumours on the right 
side of the colon are often asymptomatic but large tumours may cause intestinal 
obstruction. Advanced tumours may present with constitutional symptoms including 
weakness, loss of appetite and weight loss. 
 
1.2.4: INVESTIGATIONS AND MANAGEMENT 
A thorough history and physical examination of the patient that includes a per-rectal 
examination is crucial in helping the clinician make a diagnosis of colorectal cancer. 
Colonoscopy and biopsy of suspicious lesions for histopathological examination is the gold 
standard in the detection of colorectal cancer.  Alternatively, procto-sigmoidoscopy and/or 
an air contrast barium enema in addition to a plain abdominal X-ray can be performed. This 
may sometimes reveal a typical apple core lesion (Figure 1.5). A double-contrast barium 
enema or CT colonography can help provide a radiographic diagnosis in cases where 
colonoscope cannot reach the tumour for some reasons for example partially obstructing 
cancer, tortuous colon or poor preparation. It is essential at the same time to examine the 
entire colon for presence of synchronous tumours. Other investigations may include stool 
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samples for occult blood and serum tumour markers such as CEA, which may be raised in 
colon cancers.  
 
 
  
Figure 1.5: Barium enema shows apple core appearance (arrow) indicating  
filling defect of tumour in the colon. 
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The role of the pathologist in helping clinicians manage the patient with colon cancer 
centres on the histopathological examination of the biopsy of the lesion seen on either 
colonoscopy or proctoscopy. This will guide a plan of management for the patient. A 
detailed histopathological report of the specimen should include tumour type, grade, depth 
of invasion, lymphovascular involvement or lymph node metastasis and the surgical 
margins. The immunohistochemical staining patterns of the mismatch repair genes, 
hMLH1, hMSH3 and hMSH6 and p53 tumour suppressor gene are usually not included in 
the histopathological report.  
Once the biopsy report has been confirmed, the stage of the tumour is determined. Staging 
of the tumour to ascertain the local and distant extent of the disease is carried out by 
physical examination particularly for ascites, hepatomegaly or lymphadenopathy, as well as 
investigations such as CT scan or MRI of the abdomen and pelvis and chest imaging. 
Surgical resection is still the main form of treatment for colorectal carcinomas with or 
without chemotherapy and radiotherapy. Surgery may be in the form of a hemicolectomy, 
anterior resection or abdominoperineal resection depending on the site of the tumour.  
The aim of postoperative (adjuvant) chemotherapy is to eradicate micrometastases and thus 
reduce the likelihood of tumour recurrence. Since the mid 1990s, it is generally 
recommended that patients with stage III disease should be treated with adjuvant 
chemotherapy as this has been shown to reduce the risk of tumour recurrence and mortality 
(Cutsem, D'Hoore et al. 2008). Combination chemotherapy consisting of 5-
fluorouracil/Capecitabine, leucovorin and oxaliplatin under the name of FOLFOX; is a 
widely accepted regimen for patients with stage III disease.  
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Radiotherapy is used neo-adjuvantly and adjuvantly for certain patients with colorectal 
carcinoma, in particular rectal cancers. Pre-operative radiotherapy aims to shrink advanced 
tumours to allow surgical resection and can improve the chance of sphincter-preserving 
surgery in low-lying tumours.  Radiotherapy also helps reduce local recurrence. 
Disadvantages of radiotherapy include the risk of damage to surrounding structures, 
including irradiation of the small intestine. 
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1.3: GENETICS AND COLORECTAL CARCINOMAS  
1.3.1: GENETIC PATHWAYS 
Genetic alterations may evolve in two distinct pathways; namely the suppressor and the 
mutator pathways (Sutherland, Haine et al. 1998). The suppressor pathways constitute the 
activation of proto-oncogenes and inactivation of tumour suppressor genes, leading to 
aneuploid tumour clones. This pathway is seen in familial adenomatous polyposis (FAP) 
and in most cases of sporadic colorectal carcinomas. On the other hand, the mutator 
pathway consists of inactivation of mismatch repair (MMR) genes which result in 
microsatellite instability (MSI). This occurs in hereditary non-polyposis colorectal cancer 
(HNPCC) and in about 12 to 16% of all sporadic colorectal cancers (Kim, Jen et al. 1994). 
 
1.3.2: HEREDITARY COLORECTAL CARCINOMAS 
Although environmental factors play an important role in the aetiology of colorectal cancer, 
genetic factors also have a significant input. A family history of colorectal cancer is an 
important element in the history of a patient newly diagnosed with colorectal cancer. Many 
patients have an affected relative who either can be a first degree (parent, sibling or child) 
or a second degree (grandparent, aunts or uncles) relative. About 20 % of colorectal 
carcinomas have a genetic basis (Giardello, J.D. et al. 2001) or 80%  of colorectal 
carcinomas occur spontaneously.  Indeed, approximately 25% of patients with colorectal 
cancer give a positive family history (Fisher and Daniels 2007; Mayer 2009). Patients with 
one or more first degree relatives with colorectal carcinoma but who do not fulfil the 
criteria for any specific genetic syndromes like FAP or HNPCC would have about twice the 
risk of developing colorectal carcinoma as an individual without any family history (Fuchs, 
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Giovannucci et al. 1994). This risk significantly increases in the fourth decade and rises 
further with age (Fuchs, Giovannucci et al. 1994). If the individual has more than one first-
degree relative or if the relative’s cancer occurred before the age of 55 years (St. John, 
McDermott et al. 1993), the risk increases even further.  
It is estimated that 5-10%  of all cases of colorectal cancer have a hereditary component 
(Lynch and de la Chapelle 2003). They can be classified into two groups: autosomal 
dominant syndromes with high penetrance and cancers with familial clustering with a 
multifactorial mode of inheritance. The mode of inheritance of the latter group is also 
autosomal dominant but with low penetrance.  
The more common highly penetrant autosomal dominant syndromes include familial 
adenomatous polyposis (FAP) and its variants such as Gardner’s syndrome and Turcot’s 
syndrome; hereditary non-polyposis colorectal carcinoma (HNPCC), Peutz-Jeghers 
syndrome, juvenile polyposis syndrome and MUTYH associated polyposis syndrome.  
HEREDITARY NON-POLYPOSIS COLORECTAL CARCINOMA 
Hereditary non-polyposis colorectal cancer is the most common hereditary colorectal 
cancer. It accounts for 6-13% of all colorectal cancers. It has an autosomal dominant 
inheritance with 80% penetrance. It is caused by mutations in DNA mismatch repair genes. 
The penetrance is greater in males and hMSH2 mutation carriers (Vasen, Wijnen et al. 
1996; Dunlop, Farrington et al. 1997; Vasen, Stormorken et al. 2001). 
Hereditary non-polyposis colorectal cancer differs from sporadic colorectal cancer in its 
clinical presentation. It has a younger age of onset with a mean of 45 years (Hamilton and 
Aaltonen 2000), and may present with synchronous or metachronous tumours (Jeong, 
Chessin et al. 2006). Affected individuals are at increased risk of developing other cancers 
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including endometrial carcinoma, small bowel carcinomas, renal and urethral cancers, 
gastric cancers and ovarian carcinomas. Tumours are usually located in the proximal colon. 
Germline mutations occur in mismatch repair genes namely: hMSH2, hMLH1, PMS1, 
PMS2 and hMSH6.  These tumours show high levels of instability at short tandem repeat 
sequences, known as microsatellite instability high (MSI-H). Several diagnostic criteria 
have been established for the diagnosis of HNPCC (Appendix 1).  Currently, in the 
modified Amsterdam criteria (Amsterdam II Criteria) HNPCC is defined by presence of 
HNPCC-associated cancers in at least three family members in two successive generations 
with one affected member diagnosed before the age of 50 years (Vasen, Watson et al. 
1999). HNPCC-associated cancers include colorectal cancer and cancers of endometrium, 
small bowel, ureter and renal pelvis. 
FAMILIAL ADENOMATOUS POLYPOSIS 
Familial adenomatous polyposis is a hereditary condition that progresses inevitably to 
colon carcinoma. It is inherited in an autosomal dominant fashion with a high penetrance of 
90%. The FAP-associated gene is known as the APC gene (adenomatous polyposis coli). 
Patients with the APC gene begin to develop numerous polyps (adenomas) after puberty 
until the entire colon eventually becomes carpeted with thousands of polyps. Affected 
patients inevitably develop colon cancer by the fourth decade of life. They also have an 
increased risk of developing adenomas at other gastrointestinal sites, namely the stomach, 
duodenum and small intestine. It is also associated with other extra-colonic malignancies 
such as papillary thyroid cancer, sarcomas and brain tumours. 
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1.3.3: SPORADIC COLORECTAL CARCINOMAS 
Most colorectal carcinomas occur sporadically without any evidence or association of 
familial or inheritable syndromes. The ‘adenoma-carcinoma sequence’ proposed by Fearon 
and Vogelstein (Kinzler and Vogelstein 1996)  is widely accepted and supported by various 
observations.  
Most sporadic colorectal carcinomas are believed to originate from mutational inactivation 
of the APC suppressor gene.  Other sporadic colorectal carcinomas may arise from somatic 
mutations of the ‘Mutated in Colorectal Cancer’ (MCC) gene, which is located close to the 
APC gene. The evolution of adenomas into carcinomas may be accompanied by 
inactivation–mutation of the ‘Deleted in Colorectal Cancer’ (DCC) gene on chromosome 
18 and also the p53 tumour suppressor gene found on chromosome 17. Additional genetic 
alterations may occur, including activation of proto-oncogenes such as c-myc and k-ras. 
The second pathway involves genetic mutations in the DNA mismatch repair genes. About 
7-20% of sporadic colorectal carcinomas are due to defects in the mismatch repair gene 
(Ionov, Peinado et al. 1993; Cunningham, Kim et al. 2001; Chapusot, Martin et al. 2003; 
Wright and Stewart 2003). 
SPORADIC MSI-H COLON CARCINOMA 
Sporadic MSI-H colorectal carcinoma is another type of cancer which differs from HNPCC 
in certain key aspects. These patients do not fulfil the criteria for HNPCC. However, the 
colorectal carcinomas have high microsatellite instability (MSI-H). Young et al. (Young, 
Simms et al. 2001) found that patients with sporadic MSI-H colorectal carcinomas 
presented at a later age as compared with HNPCC. They also found that MSI-H sporadic 
colorectal cancers affected females more frequently than males. Their findings suggested 
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that familial (HNPCC) and sporadic MSI-H cancers evolved through different and 
independent pathways but converged with respect to the pattern of mismatch repair 
deficiency. 
In their study, all cases of sporadic cancers lacked hMLH1 staining while there was a range 
of mismatch repair protein staining patterns seen in HNPCC cases. Sporadic MSI-H 
cancers had a higher frequency of features such as poor differentiation, proximal location 
and mucinous histology which differentiated them from common sporadic colorectal 
carcinomas. Approximately 90% of sporadic MSI-H tumours were located in the proximal 
colon compared to 60% of HNPCC. Peri-tumoural and tumour-infiltrating lymphocytes 
were more frequently seen in HNPCC as compared to sporadic MSI-H colorectal 
carcinomas. 
 
1.3.4: MISMATCH REPAIR GENES  
Defects in the DNA mismatch repair system result in tumour progression. Tumours arising 
from these mutations exhibit microsatellite instability (MSI), an accumulation of single 
nucleotide mutations and alterations in the length of repetitive sequences found throughout 
the genome. 
There are several types of repeated DNA sequences in the human genome including 
satellites, minisatellites, telomeric families and microsatellites. A microsatellite is a short 
sequence or runs of one to six dinucleotides that is repeated in a tandem array. The most 
common nucleotide repeats are CA (cytosine-adenine) or TG (thymine-guanine) on the 
complementary DNA strand. The repeated sequences are located adjacent to each other. 
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The number of repeats can be anywhere between two to a few hundred in a given genomic 
location, meaning that there can be several hundreds of alleles in a microsatellite location. 
When a defect occurs in the gene regulating DNA repair, replication errors result. This is 
reflected by widespread variations in short, repeating sequences of DNA microsatellites. 
Tumours exhibiting this replication error (RER) phenotype are said to have microsatellite 
instability tumour phenotype. 
Microsatellite instability is seen in hereditary non-polyposis colorectal cancers and a subset 
of sporadic colorectal carcinomas caused by germline mutations in DNA mismatch repair 
genes. 
If tumours exhibit microsatellite instability in at least 30% of loci studied, they are referred 
to as MSI-high tumours, whereas if fewer than 30% of loci are involved, they are known as 
MSI-low tumours. MSI-low tumours resemble tumours with no mismatch defect (or 
microsatellite stable) in most aspects. Microsatellite instability has been found not only in 
tumours in the colon but also in tumours of the stomach, endometrium and ovary.  
Molecular testing is the gold standard for assessing the DNA mismatch repair competency. 
This involves extracting DNA from the tumour and normal tissue and then performing 
polymerase chain reaction amplification and gel electrophoresis of a few chromosomal loci 
and comparing the microsatellite sequences. Many microsatellite markers are available for 
molecular testing, namely mononucleotide markers: BAT25, BAT26, BAT40, BAT34C4; 
dinucleotide markers: D5S346, D17S250, ACTC, D18S55, TP53, D18S61, D18S49, 
D18S34 and D10S197 and the penta-mono-tetra compound marker MYCL. Generally, a 
panel of five microsatellite markers is recommended for use. If two or more of the five 
markers demonstrate instability, the tumour is considered to be MSI-high. If only one 
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marker demonstrates instability, then it is considered MSI-low. If none of the microsatellite 
markers demonstrate instability, the tumour is considered microsatellite stable. However, 
molecular testing is extremely time consuming, labour intensive and expensive. It is also 
not widely available in most laboratories. An alternative method of detecting mismatch 
repair defect is by using immunohistochemical tests for mismatch repair proteins; namely 
against hMLH1, hMSH2, hMSH6 and hPMS2. 
More than 90% of hereditary non-polyposis colorectal carcinomas are associated with 
germline mutations of one of the mismatch repair genes, most frequently hMLH1or 
hMSH2 (Table 1.4). 
 
    
 
 
Table 1.4 Mismatch repair genes and mutation frequencies in HNPCC  
 
 Gene Frequency (%) Location 
 hMLH1 49 3p21 
 hMSH2 45 2p15 
 hPMS2 4 7p22 
 hPMS1 1 2p32 
 hMSH6 1 2p15 
 hMSH3 0 5q11-13 
       
 
Source: (Petrias and Frankel 2009)  
 
HNPCC patients are generally heterozygous for a normal and mutant allele of one of the 
MMR genes. Two hits of the DNA mismatch repair genes are required to cause a 
phenotypic effect. Inactivation of the wild-type allele occurs early in carcinogenesis whilst 
the inactivation of the normal allele may occur as result of somatic deletions, point 
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mutations or promoter methylation. The loss of a post-replicative DNA mismatch repair 
system would increase the mutation rates to over 100 to 600 fold above normal. In the 
absence of effective DNA repair, the tumour possesses the mutator phenotype. 
Sporadic carcinomas are colorectal cancers arising in patients with no family history of 
colon cancer. 12-20% of these sporadic cancers were shown to have microsatellite 
instability (Ionov, Peinado et al. 1993; Cunningham, Kim et al. 2001; Chapusot, Martin et 
al. 2003; Wright and Stewart 2003). This group of patients with microsatellite instability 
tumours share similar characteristics to patients with HNPCC tumours. 
In more than 90% of sporadic MSI tumours, the mismatch repair defect is due to 
inactivation of hMLH1. The loss of hMLH1 expression is mostly due to bi-allelic 
methylation of the hMLH1 promoter. On the other hand, hMSH2 has not been found to be 
prone to hypermethylation.  
Most MSI-high cancers are generally diploid or near diploid and carry fewer p53 mutations 
(Cottu, Muzeau et al. 1996; Lengauer, Kinzler et al. 1997; Eshleman, Casey et al. 1998). 
Mutations in mismatch repair gene cause a subset of colorectal cancer cases.  
Supporting evidence from various studies (Aarnio, Sankila et al. 1999; Millar, Pal et al. 
1999) demonstrate that carriers of mismatch repair mutations have an increased risk of 
developing colorectal cancer compared to the general population and when these patients 
develop colorectal carcinomas, the tumours also behave differently from patients with 
microsatellite stable tumours. They demonstrate better response to adjuvant 5-fluorouracil-
based chemotherapy (Hemminki, Mecklin et al. 2000) and have better prognosis and 
survival rates with lower risk of metastasis (Lim, Jeong et al. 2004). Thus, there is benefit 
in identifying patients with tumours that are microsatellite unstable or MSI-H in order to 
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manage them accordingly with appropriate therapy including screening for mutations in 
other family members.  It is important to study the constellation of phenotypic features of 
microsatellite instability tumours to identify characteristics which could predict tumours 
with mismatch repair defects. Some histopathological features are more frequently seen in 
tumours with mismatch repair defects and thus could be used as positive predictors of MSI-
H tumours. Tumours with such features could then be selected for testing either by 
immunohistochemistry or polymerase chain reaction for mismatch repair defects. 
 
1.3.5: TUMOUR SUPPRESSOR GENE: P53 
P53 is a DNA-binding protein that inhibits tumour development. It is encoded by the 
tumour suppressor gene TP53, and regulates tumorigenesis by inducing apoptotic 
mechanisms in cells that are damaged by extensive DNA mutations. This allows cells with 
accumulated mutations that would progress to malignant transformation to be removed by 
apoptosis before cell proliferation occurs. 
The p53 protein plays numerous roles in the cell. Besides its role in initiating programmed 
cell death, it is also implicated in control of cellular proliferation, differentiation, DNA 
repair and synthesis. Lack of p53 will result in loss of normal growth regulatory activity, 
loss of regulation of proliferation of cells and decreased likelihood of apoptosis of damaged 
cells. Consequently, genetic instability and mutations will not be eliminated or removed. 
Thus, p53 deletions or mutations are oncogenic. 
P53 mutations tend to be associated with advanced stages of colorectal carcinomas 
suggesting that the allelic deletions demonstrate a higher tendency to nodal metastasis and 
vascular or lymphatic invasion. 
 
35 
 
1.4: OBJECTIVES OF STUDY 
1.4.1: TUMOURS WITH MMR DEFECTS 
The main aim of this study was to delineate and compare the characteristics of colorectal 
cancers with and without mismatch repair defects. To date there are no large scale studies 
on the incidence or prevalence of mismatch repair defects in colorectal carcinomas in 
Malaysia.  
In this study, immunohistochemical staining was performed against hMLH1, hMSH2 and 
hMSH6 because majority of the familial and non-familial (sporadic) colorectal carcinoma 
with mismatch defect were due to hMLH1or hMSH2 (Liu, Parsons et al. 1996; Peltomaki 
and Vasen 1997; Herman, Umar et al. 1998; Wheeler, Loukola et al. 2000; Potocnik, 
Glavac et al. 2001; Yamamoto, Min et al. 2002) and a small minority due to hMSH6 (Wu, 
Berends et al. 1999). At the start of the study the significance of hPMS2 mutation or defect 
was not well tested. Furthermore commercial antibodies to hPMS2 were also not readily 
available then. Using the immunohistochemical method against the mismatch repair 
proteins: hMLH1, hMSH2 and hMSH6, we identified colorectal cancers with mismatch 
repair defects in a cohort of patients in Malaysia and also studied the pattern of mismatch 
repair defect present.  
CLINICAL FEATURES 
This study also identified clinical or pathological characteristics that could be positive 
predictors of patients with mismatch repair defect tumours. We studied the age, gender, 
race, past medical histories and family histories of these patients together with tumour 
stage, site and gross appearance in this group of patients. The aim was to identify 
 
36 
 
significant associations of any of these features with mismatch repair defect colorectal 
carcinomas. 
PATHOLOGICAL FEATURES 
We examined the histological features of tumours, namely the grade (differentiation), 
amount of mucin present, degree of necrosis, lymphocytic response (peri-tumoural and 
Crohn-like) and type of infiltrative border to  identify phenotypical features which were 
more frequently associated with mismatch repair defect tumours. 
SURVIVAL 
The survival of patients with mismatch repair defect tumours was compared to that of 
patients with microsatellite stable tumours.  
 
1.4.2: TUMOURS WITH P53 OVER-EXPRESSION 
Immunohistochemistry was also performed against the p53 protein to identify p53 
mutations. The aim was to delineate the group of tumours with p53 over-expression from 
those without p53 expression and study their clinical and pathological features, namely the 
staging of tumours, location, lymphocytic response and the patient survival. 
Data analysis was also performed to identify correlations between these clinical and 
pathological features including the incidence of co-existent MMR defects among tumours 
which stained positive for the p53 protein. 
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1.4.3: SUMMARY OF OBJECTIVES 
In summary, the aim of this study was to examine the incidence of mismatch repair defect 
in colorectal carcinoma cases; evaluated by immunohistochemical expression of hMLH1, 
hMSH2 and hMSH6 in a series of unselected consecutive colorectal carcinomas in the 
Malaysian population; and to correlate this to the clinical and pathological features of the 
tumours. 
 
The study objectives may be summarised as follows:- 
1. To study the incidence of mismatch repair defect in incidental cases of colorectal 
carcinoma in a local setting in Malaysia by using immunohistochemical staining 
against hMLH1, hMSH2 and hMSH6 in a series of 298 colorectal carcinoma cases 
2. To study the clinical features of colorectal cancer with mismatch repair defects 
3. To analyse the histological features of colorectal cancer with mismatch repair 
defects 
4. To compare significant clinico-pathological differences in colorectal cancer patients 
with and without mismatch repair defects 
5. To compare the survival rates of patients with and without mismatch repair defects 
6. To study the incidence of p53 over-expression in incidental unselected colorectal 
carcinomas and in tumours with mismatch repair defects  
7. To compare significant clinico-pathological differences in colorectal cancer patients 
with and without p53 over-expression. 
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CHAPTER 2: METHODOLOGY 
 
2.1: MATERIAL 
2.1.1: PATIENTS 
This retrospective study included 298 patients with histologically proven diagnosis of 
colorectal carcinoma, who were operated on in a major tertiary hospital in the southern 
state of Johor, Malaysia during a period of 4 years from January 2004 to December 2007. 
The surgical specimens were received in the Department of Pathology, Sultanah Aminah 
Hospital, Johor Bahru.  
 
2.1.2: CLINICAL PRESENTATION  
The clinical presentations, past histories and family histories of the patients were reviewed. 
Hospital records were assessed and each patient was interviewed in detail during clinical 
follow-up visits. Standardised questions were asked during this interview and a standard 
clinical proforma was used for data entry (Appendix 2: Clinical questionnaire form).  
The patients were asked if they had a history of previous malignancies (colorectal or non-
colorectal cancers) before their current presentation. This was confirmed by a review of 
hospital clinical records. The patients were also asked if they had a family history of 
cancer, and if so, their relationship with those family members and the type of malignancy. 
In some instances, phone calls were made to interview the patients who did not present for 
follow-up and information obtained was also recorded in the clinical questionnaire forms. 
The patients’ medical histories including a history of inflammatory bowel disease were also 
noted.  
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Information regarding the site of tumour, clinical stage at time of diagnosis, relapse of 
cancer and tumour metastasis was obtained from hospital clinical records and also 
transcribed into the clinical questionnaire forms.  
 
2.1.3: OUTCOME 
The length of survival was calculated from the date of first presentation to the final follow-
up date (if living) or date of death (if applicable). This was confirmed by reviewing national 
birth and death registry records from the Malaysian National Registration Office of 
Records. 
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2.2: CHARACTER OF TUMOURS 
2.2.1: ANATOMICAL LOCATION 
Tumour sites were divided into caecum, ascending colon, transverse colon, descending 
colon, sigmoid colon and rectum.  They were also grouped as right-sided for tumours 
proximal to and including the splenic flexure and left sided for those located distal to the 
splenic flexure. 
 
2.2.2: MULTIPLE TUMOURS 
The presence of multiple neoplasms in patients were classified into synchronous or 
metachronous tumours. Synchronous tumours were defined as tumours occurring in a 
patient at different locations at the same time. Metachronous tumours were defined as 
carcinomas occurring more than 6 months before or after the index cancer, usually at a 
different location. Metachronous tumours may be the same or a different type of tumour to 
the index case but must not be a metastatic lesion of the primary carcinoma. Patients from 
which this information could not be obtained were excluded from this part of the study.  
 
2.2.3: SIZE OF TUMOURS 
The size of the tumour was measured across three dimensions and the largest cross-
sectional diameter (in centimetres) was recorded as the tumour size for the purpose of this 
study. In the event where more than one malignant lesion was present, the measurement of 
the larger tumour was used for the purpose of this study. 
Tumours with a diameter larger than or equal to 5.0 cm were considered as large tumours 
and small tumours were less than 5.0 cm in diameter.  
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2.2.4: GROWTH APPEARANCE 
The growth appearance of the tumour was described according to the macroscopic 
appearance of the colectomy specimens. The tumour was described as exophytic if tumour 
growth protruded beyond the mucosal surface in a polypoidal or fungating fashion (Figure 
2.1A). The tumour was considered non-exophytic if it invaded deep into the mucosa 
forming an ulcerating or flat surface (Figure 2.1B). In the non-exophytic growth pattern, no 
external protruding growth into the lumen was seen. 
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(A)                                                                       (B)                
Figure 2.1: 
A: Picture of an exophytic colorectal carcinoma: a large polypoid tumour mass seen at the 
caecum (arrow). 
B: Picture of a non-exophytic colorectal carcinoma: an ulcerated tumour mass seen at distal 
part of colon (arrow with double arrow head). 
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2.2.5: TUMOUR STAGING   
Staging of the tumour was performed using the TNM classification of tumours of the colon 
and rectum as recommended by the American Joint Committee on Cancer (AJCC), (Edge, 
Byrd et al. 2010). 
This classification is based on the degree of local tumour invasion; number of regional 
lymph nodes involved and presence of distant metastasis. Local invasion of tumour into the 
submucosa was classified as T1, invasion into muscularis propria as T2, invasion through 
the muscle into the pericolorectal tissues as T3 and invasion beyond the surface of visceral 
peritoneum or direct invasion into or adherence to other organs or structures as T4. The 
number of lymph nodes resected and their status were obtained from the respective 
histopathological reports. Tumours were classified as N0 when regional lymph nodes 
isolated were not involved and N1 when one to three lymph nodes were involved. If more 
than three nodes were positive, the tumour was classified as N2. When no nodes were 
isolated from the specimen the status of the nodes was deemed unknown or Nx. Further 
information regarding the presence of distant metastases was obtained from clinical notes 
and results of radiological investigations. Tumours without distant metastases were 
classified as M0 and classified as M1 when distant metastases were present.   
Tumour size was not taken into consideration when determining the stage of colorectal 
carcinomas. Stage 0, or carcinoma-in-situ, was defined as tumour limited to the lamina 
propria, Stage I tumours included tumours which invaded the muscularis propria with no 
lymph node involvement or metastasis (T1-2, N0, M0). Tumours which progressed further 
into the subserosa or into the non-peritonealised pericolic and perirectal tissues and / or 
spread to adjacent organs and structures without exhibiting lymph node involvement or 
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distant metastasis were classified as Stage II tumours (T3-4, N0, M0).  Tumours with 
involvement of regional lymph nodes without distant metastasis were classified as Stage III 
tumours (T1-4, N1-2, M0). Tumours with distant metastases were classified as Stage IV 
tumours (T1-4, N0-2, M1). Appendix 3 summarises the TNM classification and the staging 
used by the AJCC. 
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2.3: HISTOPATHOLOGICAL FEATURES 
The histopathological reports of the tumours and of any previous malignancies were 
reviewed. Tumour stage was ascertained from the clinical notes or from histopathological 
reports. 
The original microscopy slides were also reviewed to determine: 
a. Histological type and grade of tumour 
b. Amount of mucin production 
c. Characteristics of the tumour-advancing front  (infiltrative or expansive) 
d. Type of lymphocytic response around the tumour (if present), and 
e. Degree of necrosis (if present) – minimal or marked. 
 
2.3.1: HISTOLOGICAL TYPE AND GRADE  
Typing and grading of tumours were performed according to the World Health 
Organisation (WHO) tumour classification system (Hamilton and Aaltonen 2000).  
The tumours were defined as adenocarcinomas when glandular formations were present. 
Grading of the tumours was based on the proportion of glandular structures seen on 
histopathological examination. When the lesion demonstrated areas that were heterogenous 
in differentiation, grading was performed on areas with the least glandular structures i.e. the 
more poorly differentiated areas. Well differentiated adenocarcinomas (Grade 1) were 
defined as lesions with glandular structures comprising more than 95% of the tumour, 
while moderately differentiated cancers (Grade 2) were comprised of 50-95% glandular 
structures. Poorly differentiated adenocarcinomas (Grade 3) were defined as those with 
glandular structures between 5-50% and undifferentiated cancers (Grade 4) were defined as 
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tumours with less than 5% glandular structures. In our study, due to the limited number of 
cases, poorly differentiated and undifferentiated tumours were grouped together for 
analysis. Figure 2.2 shows the various grades of differentiation of colorectal carcinoma. 
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Figure 2.2: Grades of differentiation of colorectal carcinomas 
 
 
 
A: Well differentiated 
adenocarcinoma, (H&E stain, 
original magnification x 100). 
 
 
 
 
 
 
 
B: Moderately differentiated 
adenocarcinoma, (H&E stain, 
original magnification x 100).  
 
 
 
 
 
 
 
C: Poorly differentiated 
adenocarcinoma, (H&E stain, 
original magnification x 200).  
 
 
 
 
 
 
 
 
D: Undifferentiated carcinoma, 
(H&E stain, original 
magnification x 200).  
 
A 
B 
C 
D 
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2.3.2: MUCIN PRODUCTION AND MUCINOUS CANCERS 
Mucinous carcinomas were defined when more than 50% of the tumour area comprised of 
secretory mucin. Signet ring cell carcinomas were defined when more than 50% of the 
tumour cells had intracellular mucin with a signet ring appearance. By convention, both 
mucinous carcinomas and signet ring cell carcinomas (Figure 2.3) were considered poorly 
differentiated adenocarcinomas.  
The amount of mucin present in the tumour was also determined.  The mucin content was 
defined as the amount of extracellular mucin in the tumour and was categorized as less than 
10%, 11-50% or more than 50% (mucinous carcinomas). Signet ring carcinomas were 
classified together with tumours producing more than 50% mucin. 
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Figure 2.3:  
A: Mucinous carcinoma with lakes of mucin present in the tumour (H & E stain, 
original magnification x 800).  
B: Signet ring carcinoma: Mucin is present intracellularly (H & E stain, original 
magnification x 400). 
 
 
A 
B 
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2.3.3: TUMOUR ADVANCING PATTERN 
Colorectal cancer infiltrates the bowel wall in two main patterns of invasive growth 
depending on the characteristics of its advancing margins. This is illustrated in Figure 2.4 
below.  
 
 
Figure 2.4: Schematic diagram of the invasive border of tumours: expanding vs. 
infiltrating.  Source: (Jass, Love et al. 1987).  
 
The tumour was defined as expanding with a circumferential growth pattern if the margins 
were reasonably well circumscribed from normal tissue. The limits of the advancing 
borders of an expanding tumour were easily visible by gross inspection of haematoxylin 
and eosin stained slides, where adjacent host tissue was easily discernible from the 
basophilic appearance of the malignant tumour even with the naked eye. Microscopic 
examination of an expanding lesion would show a well-defined smooth advancing front 
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between tumour and host muscular tissue (Figure 2.5A). As opposed to this, tumours were 
defined as diffusely infiltrative when the tumour and its host tissue could not be 
differentiated by examination of the slide with the naked eye.  This was confirmed 
histologically by the presence of tumour glands or individual tumour cells dissecting into 
the muscular tissue or mesenteric fat (Figure 2.5B).  Perineural invasion was frequently 
encountered in tumours with this growth pattern.  
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Figure 2.5: 
A: Tumour with an expansive border with distinct outline from adjacent normal 
muscular propria (H & E stain, original magnification X 40). 
B:  Tumour with infiltrating borders; infiltrates and streams into the serosal fat beyond 
the muscular layer (H & E stain, original magnification X 40). 
A 
B 
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2.3.4: LYMPHOCYTIC RESPONSE 
The form of lymphocytic response seen was categorised according to the classification 
described by Jass et al (Jass, Ajioka et al. 1996) into minimal peri-tumoural lymphocytic, 
marked peri-tumoural lymphocytic, and Crohn-like lymphoid response. Peri-tumoural 
lymphocytic response was defined when a cap of lymphocytes or lymphocytic cuff was 
present in the loose connective tissue at the deepest point of tumour penetration (Figure 
2.6A). The slides were reviewed to assess if there was minimal or a conspicuous and 
distinctive peri-tumoural cap or cuff of lymphocytes around the advancing front of the 
tumour. The former was classified as minimal and the latter classified as marked peri-
tumoural lymphocytic response. 
The tumour was considered to have Crohn-like lymphoid response (Figure 2.6B) when 
nodular or discrete lymphoid aggregates with or without germinal centres were present at 
the advancing front of the tumour, usually more than 1 mm beyond the advancing tumour 
front (Graham and Appelman 1990). Occasionally, the tumour was associated with tumour-
infiltrating lymphocytes, i.e. lymphocytes present within the tumour. Brisk lymphocytic 
response was considered to be present when lymphocytes were seen infiltrating the tumour 
and there were more than two lymphocytes present in the tumour per high power field 
(Figure 2.6C). However, this form of lymphocytic response classification was not used in 
this study. 
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Figure 2.6: Lymphocytic response in colorectal carcinoma. 
 
 
 
 
 
A: The tumour is surrounded by 
lymphocytic cuff all around. This 
is peri-tumoural lymphocytic 
response. H & E stain, original 
magnification x100.  
 
 
 
 
 
 
 
 
B: Infiltrative tumour with a 
Crohn-like lymphoid aggregate 
(follicle). H & E stain, original 
magnification x100.  
 
 
 
 
 
 
 
C: Lymphocytes  seen infiltrating 
within the tumour . This is 
tumour-infiltrating lymphocytes. 
H & E stain, original 
magnification x400.  
A 
B 
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2.3.5: TUMOUR NECROSIS  
Colorectal cancer has been known to be associated with dirty necrosis. Dirty necrosis is 
defined as the presence of cellular debris with numerous inflammatory cells within the 
glandular lumina. However, in this study, instead of identifying dirty necrosis, the tumour 
was examined for the degree of necrosis present.  
Tumours with confluent areas of necrosis of more than two low power fields (at 4x10 
magnification of Olympus BX41 microscope with diameter of 4.5 mm) were considered as 
tumours with marked necrosis and those with involvement of less than two low power 
fields as tumours with minimal necrosis.  
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2.4: STAINING PROCEDURE  
2.4.1: HAEMATOXYLIN AND EOSIN STAIN 
All routine slides were previously sectioned at 3 to 4 um thickness and stained with 
Haematoxylin and Eosin stain (H & E stain) using the Leica Autostainer XL (Appendix 4). 
This was carried out with a control slide (usually a section of an appendix) which was run 
together with each batch of staining. Old slides for the study were retrieved and reviewed. 
In instances where slides were missing from the stores, a re-cut was done from the original 
paraffin block of the tumour and the section stained with routine Haematoxylin and Eosin 
stain in the autostainer.  
 
2.4.2: IMMUNOHISTOCHEMICAL STAIN 
Two blocks of 10% formalin-fixed, paraffin wax-embedded colorectal carcinoma tissue in 
the study were selected per case studied to include a region of normal mucosa adjacent to 
the carcinoma in one of the blocks selected.  
Chapusot et al (Chapusot, Martin et al. 2002) showed that the immunohistochemical 
assessment status of tumours differed when different sampled areas were used, due to 
tumour heterogeneity. Thus, they suggested that at least two or more samples of tissue from 
the tumour should be taken from different areas of the cancer for analysis in order to 
accurately assess the mismatch repair status of the tumour by immunohistochemistry.  
Two blocks of tumour tissue were used and a total of five sections were cut from each 
block to perform immunohistochemistry for each mismatch repair proteins (namely 
hMLH1, hMSH2 and hMSH6). The fourth section was used for immunohistochemistry 
staining for the p53 protein which was also performed for all the case studies. A section 
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from each block was used for negative staining. A negative control case was one where the 
primary antibody was omitted during the immunohistochemistry staining procedure. 
Altogether, ten sections were cut and stained correspondingly by IHC. 
Tissue sections were cut into 3 um slices and mounted on glass microscopy slides which 
were pre-treated with 3-aminopropyltriethoxysilane (Appendix 5). The slides were 
deparaffinised by treatment with heated Pretreatment module
TM
 (PTM) Deparaffinization 
and Heat Induced Epitope Retrieval solution to optimise the antibody-antigen reaction.  
Non-specific background staining due to endogenous peroxidise was reduced by treatment 
with hydrogen peroxide block. The primary monoclonal antibodies were used with optimal 
dilution as listed below:-  
(i) hMLH1 clone G168-15 (catalogue number 551091) at 1:40 dilution 
(ii) hMSH2 clone G219-1129 (catalogue number 556349) at 1:100 dilution 
(iii) hMSH6 clone GTBP-44 (catalogue number 610918) at 1:800 dilution 
All the above antibodies to mismatch repair proteins (hMLH1, hMSH2 and hMSH6) were 
from BD Pharmingen.  
(iv) p53 (catalogue number LV-RM-9105-S) at 1:100 dilution.  
  
The specific primary antibody was located by a universal secondary antibody polymer 
formulation. The amino acid polymer was conjugated to horseradish peroxidase and the 
Fab fragments of goat anti-rabbit and goat anti-mouse. The polymer complex was then 
visualized with diaminobenzidine tetrachloride solution by adding the DAB chromogen 
plus. Appendix 6 lists the immunohistochemistry staining procedure used. 
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MISMATCH REPAIR PROTEIN STAINING  
Two known cases of colorectal carcinoma that had previously stained positive for all 3 
proteins: hMLH1, hMSH2 and hMSH6 were considered as intact tumours and were used as 
controls for tumours with no mismatch repair defect. These controls were used for each 
batch of staining.  Positive nuclear staining of more than 10% of tumour cells was 
considered positive for protein expression for the mismatch repair proteins: hMLH1, 
hMSH2 and hMSH6.  Loss of expression was recorded when all malignant cells showed 
absent nuclear staining or when less than 10% of tumour cells showed positive nuclear 
staining. This is needed to be demonstrated in the presence of preserved nuclear staining in 
the external positive case control as well as in normal epithelial cells and lymphocytes 
(internal control) in the case itself. Tumours with loss of expression of one or more proteins 
were considered to be tumours with mismatch repair defects (MMR-d) while tumours with 
intact expression for all three proteins were considered to be intact tumours with no loss of 
mismatch repair defect. Figures 2.7 to 2.9 show the various staining patterns for the 
mismatch repair proteins: hMLH1, hMSH2 and hMSH6 in colorectal carcinomas, 
lymphocytes and normal colonic epithelium (internal control). 
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Figure 2.7: Patterns of staining for hMLH1 protein.  
 
 
A: The normal colonic glands 
stained up for hMLH1. (IHC 
stain with hMLH1, original 
magnification x 200).  
 
 
 
 
 
B: The lymphocytes around the 
tumour stained up for hMLH1. 
MMR-d tumour showed no 
reaction to this protein stain. 
(IHC with hMLH1, original 
magnification x 200).  
 
 
 
 
 
C:  Higher magnification 
showing lymphocytes reactive 
to hMLH1. (IHC with hMLH1, 
original magnification x 400).  
 
 
 
 
 
D:  Tumour glands showed 
nuclear positive reaction to 
hMLH1 in an intact tumour. 
(IHC with hMLH1, original 
magnification x 400).  
A 
B 
C 
D 
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Figure 2.8: Patterns of staining for hMSH2 protein.  
 
A: The normal colonic glands 
stained up for hMSH2 (IHC stain 
with hMSH2, original 
magnification x 100).  
 
 
 
 
 
 
B: The lymphocytes around the 
tumour stained up for hMSH2. 
This MMR-d tumour was 
negative for hMSH2. (IHC with 
hMSH2, original magnification x 
200).  
 
 
 
C:  Low power field showed  
malignant glands reactive to 
hMSH2 in an intact tumour. 
(IHC with hMSH2, original 
magnification x 100).  
 
 
 
 
 
D:  High power field showed 
tumour glands with nuclear 
positive reaction to hMSH2. 
(IHC with hMSH2, original 
magnification x 400).  
A 
B 
C 
D 
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Figure 2.9: Patterns of staining for hMSH6 protein.  
A 
B 
C 
D 
 
A: The normal colonic glands 
and the lymphoid follicles 
stained up for hMSH6 (IHC stain 
with hMSH6, original 
magnification x 100).  
 
 
 
 
 
B: The lymphocytes within the 
tumour stained up for hMSH6 
but the tumour cells were 
negative in a MMR-d tumour. 
(IHC with hMSH6, original 
magnification x 400).  
 
 
 
 
C:  Low power field showed 
normal colonic glands (above) 
and  malignant glands (below) 
were reactive to hMSH6 in an 
intact tumour. (IHC with 
hMSH6, original magnification x 
100).  
 
 
 
D:  High power view showed 
tumour glands with nuclear 
positive reaction to hMSH6. 
(IHC with hMSH6, original 
magnification x 200).  
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P53 STAINING 
P53 mutations can be detected easily by routine immunohistochemistry. Single-stranded 
conformation polymorphism (SSCP) and DNA sequencing analyses could have been done 
to identify specific types of mutation of p53 but immunohistochemistry is a more simple 
and cost-effective method which is widely available and readily used in most laboratories. 
In fact, studies by Leahy (Leahy, Salman et al. 1996) and Gervaz (Gervaz, Bouzourene et 
al. 2001) suggested that p53 abnormalities detected at the protein level by 
immunohistochemistry provided better prognostic discrimination than those detected by 
SSCP analysis at the gene level. 
Thus in this study, mutations in p53 were detected using immunohistochemistry. P53 
mutation was detected by presence of nuclear accumulation and cytoplasmic staining was 
not considered as positive staining.  
False positive staining sometimes occurred as a result of altered regulation of the wild-type 
protein. Similarly, false negative staining appeared occasionally with some missense 
mutations and short gene deletions. 
There have been wide variations in the cut-offs used to define p53 positivity in various 
studies.  The proportion of tumour cells with positive nuclear staining used to delineate 
tumours as p53 positive range from 10% (Bosari, Viale et al. 1995; Manne, Weiss et al. 
1998), to 20% (Ward, Meagher et al. 2001),  to 50% (Edmonston, Cuesta et al. 2000; 
Jourdan, Sebbagh et al. 2003). . 
In this study, we defined p53 positivity using a cut-off value of 10% of tumour cells with 
positive nuclear staining (Feeley, Fullard et al. 1999; Gafa, Maestri et al. 2000; Gervaz, 
Bouzourene et al. 2001; Sinicrope, Rego et al. 2006) because this value demonstrated the 
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highest concordance between immunohistochemical detection of nuclear accumulation of 
p53 and point mutations of p53 gene detected by SSCP analysis (95% of point mutations 
were detected) (Grizzle, Myers et al. 1998). P53 staining was recorded as negative when 
there was only cytoplasmic staining with no nuclear staining or when the nuclear staining 
was 10% or less. Figure 2.10 shows the reactivity pattern to the p53 stain used. Nuclear 
staining for p53 protein is only detected in malignant cells and is not seen in normal 
epithelial cells of the intestinal mucosa. 
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Figure 2.10: Patterns of p53 staining. 
A 
B 
C 
D 
 
 
A: The normal colonic glands 
were negative to p53 (above) but 
the malignant glands  (below) 
showed nuclear reactive staining 
to p53 (IHC stain with p53, 
original magnification x 100).  
 
 
 
 
B: Higher power showed tumour 
glands with strong nuclei staining 
for p53 (IHC stain with p53, 
original magnification x 200).  
 
 
 
 
 
 
C: The normal colonic glands 
were negative to p53 (IHC stain 
with p53, original magnification 
x 400).  
 
 
 
 
 
 
D: The tumour cells showed 
cytoplasmic pale brown staining. 
This was regarded as negative 
staining (IHC stain with p53, 
original magnification x 400).  
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2.5: STATISTICAL ANALYSIS  
Statistical analysis was performed using the Predictive Analytic Software (PASW), 
Statistical version 18.0 software program, formerly known as Statistical Package for the 
Social Sciences (SPSS). The variables were compared using Pearson’s Chi-square test, 
student’s t-test or the Mann-Whitney U test, according to the data type. Statistical 
significance was defined as a p-value of less than 0.05.  Kaplan and Meier survival curves 
were plotted. Comparisons of survival rates and their statistical significance were tested 
using the log rank test where p<0.05 was considered significant. 
Multivariate analysis was performed using logistic regression to determine independent 
predictors of loss of mismatch repair proteins in the tumours. 
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CHAPTER 3: RESULTS 
 
3.1: INTRODUCTION 
There were a total of 304 cases of unselected consecutive colorectal carcinoma diagnosed 
during the study period from January 2004 to December 2007. Five cases were excluded 
from the series where the diagnosis of colorectal cancer was confirmed only on biopsy but 
no subsequent surgical resection of the tumour was performed within the specified study 
period. One known case of confirmed familial adenomatous polyposis (FAP) was excluded 
from the study. In this autosomal dominant disease the mutated allele is a germline 
mutation of the APC allele inherited from the affected parent. The patient starts to develop 
adenomas and then colorectal carcinoma when the second APC allele becomes mutated or 
lost. As we are looking at tumours with mismatch repair defect and not with mutated APC 
gene, we decided to exclude this case of FAP. Altogether 298 patients diagnosed with 
colorectal carcinomas were included in this study. In these cases, surgical resection of the 
colon occurred between the period January 2004 and December 2007 and the diagnosis was 
confirmed as ‘colorectal carcinoma’. 
From the 298 patients, 40 patients cannot be traced. Their clinical notes were unrecoverable 
and they were lost to follow-up. The Malaysian National Registration Office of Records 
could provide the status of these patients but clinical details that include the past history 
and family history were not available for these patients to be included in this part of the 
study. The remaining 258 patients were followed up between 1 to 54 months from the time 
of presentation, with a mean follow-up period of 18.1 months. At the end of the study 
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period, 146 patients were still alive, while a total of 112 patients had died between 1 to 45 
months from the time of presentation. 
All histopathological reports were available for analysis but in 3 cases the Haematoxylin 
and Eosin stained slides were missing from the storage room and had to be re-cut. As all 
paraffin blocks were still stored in the laboratory this did not pose any problems and the 
cases were still included in the study. 
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3.2: DEMOGRAPHICS 
3.2.1: RACIAL DISTRIBUTION 
Malaysia is a multi-ethnic society, populated by Malays, Chinese, Indians, Eurasians and 
other minority ethnic groups. According to the Department of Statistics Malaysia, Malays 
comprised more than half the population of Peninsular Malaysia (54.3%) in the year 2006 
followed by Chinese (25.1%) and Indians (7.5%) (Figure 3.1). 
 
 
Figure 3.1: Distribution of ethnic groups in Peninsular Malaysia in year 2006. 
Source:(Department_of_Statistics_Malaysia 2007). 
 
In this study, demographic analysis demonstrated a predominance of Chinese patients with 
colorectal carcinoma. There were 139 Chinese patients out of the total of 298 patients 
(46.6%), followed by 134 Malay patients (45.0%), 19 Indian patients (6.3%) and 6 patients 
of other races (2.0%) [Figure 3.2]. The hospital records for all patient admissions between 
the years studied (2004 to 2007) showed a predominance of Malays (60.0%), followed by 
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Chinese (20.8%), Indians (11.9%) and others (7.3%). There was a significant difference 
that Chinese were more likely to have colorectal carcinomas than Malays (p=0.001, 95% CI 
1.568 to 5.679, OR 2.984). 
 
  
Figure 3.2: Patients with colorectal cancer by race and gender. 
 
Considering that Malays make up the majority of the population (54.3%) in Malaysia 
(National_Cancer_Registry 2006), patients were classified into two groups of Malay and 
non-Malay patients for analysis. There were 134 Malay and 164 non-Malay patients from a 
total of 298 colorectal cancer cases. 
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3.2.2: GENDER 
In this study there were 166 male (55.7%) and 132 female (44.2%) patients with colorectal 
carcinoma, giving a male to female ratio of 1.26:1. Among Chinese patients, the male to 
female ratio was 1.40:1, Malay patients 1.20:1 and Indians 1.11:1. Evidently, the Chinese 
demonstrated a higher male predominance than the other races. 
 
3.2.3: AGE 
The age at presentation of the patients in this study ranged between 25-91 years. 
Approximately two-thirds of the patients (62.0%) were above the age of 60 years at 
presentation. The peak incidence was in the sixth and seventh decades of life. Only 54 out 
of 298 patients (18.1%) presented before or at the age of 50 years whereas 81.9% of 
patients were above the age of 50 years. 
The median age of presentation was 62.0 years and the mean age of presentation was 61.0 
years with a standard deviation of 13.0 years (Figure 3.3). 
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Figure 3.3: Distribution of patients’ age (in years). 
 
The mean age at presentation of colorectal carcinomas differed slightly for males and 
females. Males presented at a slightly older age with a mean of 61.1 years while females 
presented at 60.1 years, but this difference was not statistically significant (p = 0.934).  
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3.3: MISMATCH REPAIR DEFECT TUMOURS 
3.3.1: STAINING PATTERN AND INCIDENCE 
In two cases, the immunohistochemistry staining for hMLH1 was repeated because the 
lymphoid tissue acting as internal control and the test tumour cells did not stain up. Repeat 
staining showed positive staining in the lymphocytes and the tumour cells in both cases. 
Using immunohistochemical staining against hMLH1, hMSH2 and hMSH6 in all 298 
cases, the tumours with mismatch repair defects were able to be identified. Of a total of 298 
cases of colorectal carcinomas, 255 cases (85.6%) demonstrated normal nuclear expression 
for all mismatch repair proteins namely hMLH1, hMSH2 and hMSH6, while 43 cases 
(14.4%) showed abnormal staining patterns for at least one of the three mismatch repair 
proteins. They were labelled as mismatch repair defect tumours.  
Among mismatch repair defect tumours, 28 showed complete loss of hMLH1, 7 cases with 
loss of both hMSH2 and hMSH6, 6 cases of loss of hMSH6 and 2 cases of loss of hMSH2 
(Table 3.1). None of the cases lost all three MMR proteins.  
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TABLE 3.1: 
hMLH1, hMSH2 and hMSH6 protein expression in mismatch repair defect 
colorectal cancers (n=43). 
  
Immunohistochemistry results No. of tumours 
    
hMLH1negative/ hMSH2 positive / hMSH6 
positive 28 (65.1%) 
hMLH1 positive/ hMSH2 negative / hMSH6 
positive 2 (4.70%) 
hMLH1 positive/ hMSH2 positive / hMSH6 
negative 6 (14.0%) 
hMLH1 positive / hMSH2 negative / hMSH6 
negative 7 (16.3%) 
 
Total 43 (100%) 
  
 
Two hundred and fifty-five patients had intact protein expression by immunohistochemical 
staining analysis for all the 3 antibodies: hMLH1, hMSH2 and hMSH6 and were recorded 
as intact tumours with no loss of mismatch repair defect or non-MMR-d tumours. 
 
3.3.2: MISMATCH REPAIR DEFECT TUMOURS AND RACE 
The racial breakdown of the 43 cases of mismatch repair defect tumours in the study read 
as follows: 55.8% (24 cases) were from Malay patients, 41.9% (18 cases) from Chinese 
patients, and 2.3% (1 case) from an Indian patient (Figure 3.4).  
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Figure 3.4: Distribution of patients with mismatch repair defect tumours by ethnic groups. 
 
Although Chinese was the predominant race of patients presenting with CRC in the study, 
it was found that Malay patients had the highest proportion of mismatch repair defect 
tumours.  17.9% of Malay patients with colorectal carcinomas had mismatch repair defect 
tumours as compared to 12.9% of Chinese patients and 5.3% of Indian patients (Table 3.2).  
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Table 3.2: The different racial groups with colorectal carcinomas according to their 
mismatch repair status. 
 
 
MMR status 
Total MMR-d Non-MMR-d 
Race Chinese  18 121 139 
 12.9% 87.1% 100.0% 
Indian  1 18 19 
 5.3% 94.7% 100.0% 
Malay  24 110 134 
 17.9% 82.1% 100.0% 
Others  0 6 6 
 .0% 100.0% 100.0% 
Total  43 255 298 
 14.4% 85.6% 100.0% 
 
 
In the group of Malay patients there were 24 cases (17.9%) with mismatch repair defect 
tumours as compared to 19 cases (11.6%) of mismatch repair defect tumours in non-Malay 
patients (Table 3.3). However, this difference did not reach statistical significance (p = 
0.122).   
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Table 3.3: Distribution of patients by race: analysis of mismatch repair defect tumours 
among Malay vs. non-Malay patients. 
 
Factor Category 
All 
patients 
(n=298) 
MMR status: 
 
MMR-d 
group (n=43) 
Non-MMR-d 
group 
(n=255) 
P 
value 
Odds 
ratio  
(95% CI) 
Race Malays 
134 
(45.0%) 24 (55.8%) 110 (43.1%) 0.122 1.66 
  
 
Non-
Malays 
 
164 
(55.0%) 
 
19 (44.2%) 
 
145 (56.9%) 
   
(0.87-
3.19) 
 
 
 
 
On the other hand, as Chinese patients were the predominant racial group in this study, 
subjects were also compared as part of Chinese and non-Chinese groups. There were 18 
Chinese patients with mismatch repair defect tumours out of 139 Chinese patients (12.9%) 
compared to 25 non-Chinese patients with mismatch repair defect tumours out of 159 non-
Chinese patients (15.7%). There was no statistical difference found between Chinese and 
non-Chinese patients with colorectal carcinomas for mismatch repair defect tumours 
(p=0.497, Table 3.4). 
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Table 3.4: Distribution of patients by race: analysis of mismatch repair defect tumours 
among Chinese vs. non-Chinese patients. 
Factor Category 
All patients 
(n=298) 
MMR status: 
 
MMR-d 
group (n=43) 
Non-MMR-d 
group 
(n=255) 
P 
value 
Odds 
ratio  
(95% CI) 
Race Chinese 139 (46.6%) 18 (41.9%) 121 (47.4%) 
 
0.497 
 
1.25 
  
 
Non-
Chinese 
 
159(53.4%) 
 
25 (58.1%) 
 
134 (52.6%) 
   
(0.65-
2.41) 
 
 
 
The proportion of mismatch repair defect tumours was further analysed according to both 
gender and race combined. Analysis of female patients alone revealed a significantly higher 
proportion of mismatch repair defect tumours (19.7%) among Malay females when 
compared to non-Malay females (7.00%, p=0.031).  This suggested that mismatch repair 
defect tumours were more likely to occur in Malay females than non-Malay females [odds 
ratio (OR) = 3.24, 95% confidence interval (CI) =1.07-9.80]. However, this difference was 
not observed in the analysis of male patients alone. The proportion of mismatch repair 
defect tumours did not differ significantly between Malay male patients (16.4%) and non-
Malay male patients (15.1%) [p=0.808, Table 3.5].   
 
 
81 
 
Table 3.5: Distribution of patients by race and gender: analysis of MMR-d tumours among 
Malay vs. non-Malay female and male patients respectively. 
  
Factor Category 
All 
patients 
MMR status 
 
MMR-d  
group 
Non-
MMR-d 
group 
P 
value 
Odds 
Ratio  
    (n=298) (n=43) (n=255)   
(95% 
CI) 
Gender    Race 
           
    
All 
females 
MMR-d 
group 
Non-
MMR-d 
group     
    (n=132) (n=17) (n=115)     
Female Malay 61 12 49 0.031 3.24 
  
Non-
Malay 71 5 66   
(1.07-
9.80) 
              
    All males 
MMR-d 
group 
Non-
MMR-d 
group     
    (n=166) (n=26) (n=140)     
Male Malay 73 12 61 0.808 1.11 
  
Non- 
Malay 93 14 79  
(0.48-
2.57) 
              
  
 
3.3.3: MISMATCH REPAIR DEFECT TUMOURS AND GENDER 
Within the cohort of patients with mismatch repair defect tumours, 26 were males (60.5%) 
and 17 were females (39.5%). On the other hand, there were 140 male patients (54.9%) and 
115 female patients (45.1%) in the non-MMR-d group. This is illustrated in Table 3.6. 
Statistical analysis using the Pearson Chi-square test revealed no significant difference 
when comparing the proportion of male to. female patients between the two groups (p = 
0.497).  
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Table 3.6: Distribution of patients by gender: analysis of mismatch repair defect tumours 
among male vs. female patients.  
Factor Category 
All patients 
(n=298) 
MMR status: 
 
MMR-d 
group (n=43) 
Non-MMR-d 
group 
(n=255) 
P 
value 
Odds 
ratio  
(95% 
CI) 
 
Gender Females 132 (44.3%) 17 (39.5%) 115 (45.1%) 0.497 1.26 
  
Males 
 
166 (55.7%) 
 
26 (60.5%) 
 
140 (54.9%) 
   
(0.65-
2.43) 
 
 
 
 
3.3.4: MISMATCH REPAIR DEFECT TUMOURS AND AGE 
Patients with mismatch repair defect tumours presented at a younger age [mean age and 
standard error (SE) = 58.9 + 2.2 years, median age of 60.0 year] than patients with Non-
MMR-d tumours (mean age and standard error = 61.4 + 0.8 years, median age of 63.0 
years). However, this difference was not statistically significant (p=0.292, Figure 3.5).  
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Figure 3.5: Distribution of patients by age: mean age of presentation with one standard 
error by MMR staining status. 
 
In this study of 298 patients, there were 53 patients who were 50 years and below. In this 
younger age group, there were 11 patients with tumours showing mismatch repair defects. 
25.6% of patients with mismatch repair defect tumours were 50 years old or less as 
compared to 16.9% of patients with non-MMR-d tumours (Table 3.7). This difference did 
not reach statistical significance (p = 0.148). 
  
 
 
Non-MMR-d MMR-d 
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Table 3.7: Distribution of patients by age: analysis of mismatch repair defect tumours 
among patients aged 50 and below vs. patients aged above 50. 
 
Factor Category 
All 
patients 
(n=298) 
MMR status: 
 
MMR-d 
group (n=43) 
Non-MMR-d 
group 
(n=255) 
P 
value 
Odds 
ratio  
(95% 
CI) 
Age  
(in years) ≤ 50  53 11 (25.6%) 42(16.5%) 0.148 1.74 
  
 
> 50 
 
245 
 
32 (74.4%) 
 
213 (83.5%) 
   
(0.82-
3.73) 
 
 
 
Further analysis of the data stratified according to age demonstrated an increasing trend 
towards higher proportions of mismatch repair defect tumours in younger age groups. This 
is shown in Table 3.8.  
Overall, 43 out of 298 cases (14.3%) were mismatch repair defect tumours. There was a 
higher percentage of mismatch repair defect tumours in the younger age groups, namely in 
patients less than 31 years old (2 of 6 cases or 33.3%) and in the 31-40 age group (4 of 17 
cases or 23.5%). The percentage of MMR defect tumours decreased with age, constituting 
16.7% (5 out of 30 cases) in the 41-50 age group, 13.1% in the 51-60 age group; and 12.2% 
in the age group between 61 to 70 years old. There were only 7.1% of patients above the 
age of 80 years who had mismatch repair defect tumours (Table 3.8).   
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Table 3.8: Distribution of patients by age: analysis of mismatch repair defect tumours 
according to age group. 
Age range No. of cases No of MMR-d tumours Percentage 
 
<31 6 2 33.3% 
31- 40 17 4 23.5% 
41-50 30 5 16.7% 
51-60 84 11 13.1% 
61-70 82 10 12.2% 
71-80 65 10 15.4% 
>80 
 
14 
 
1 
 
7.1% 
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3.4: FAMILY HISTORY 
3.4.1: FAMILY HISTORY OF CARCINOMAS 
A full family history was obtained from a total of 160 patients. 40 patients were lost to 
follow-up and unable to be contacted. Another 98 patients had passed away before the start 
of the study and contact with their families was not successful.  
A total of 25 out of these 160 patients (15.6%) had a family history of previous cancer in 
one or more first degree relatives. These included a family history of cancers involving the 
lower gastrointestinal tract, stomach, oesophagus, endometrium, cervix, breast, kidney, 
prostate, brain as well as haematological malignancies (Table 3.9).  
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Table 3.9: Patients with family history of carcinomas 
 
No. Age of 
onset (yrs) 
Gender Race MMR status  Family member: cancer 
      
1 51 F Chinese Non-MMR-d Sister: Colorectal cancer 
 
2 61 M Malay Non-MMR-d Father: Gastric cancer 
3 63 F Malay Non-MMR-d Mother: Gastric cancer  
Sister: Breast cancer 
4 71 M Chinese Non-MMR-d Mother: Cervical cancer  
5 57 F Chinese Non-MMR-d Brother: Gastric cancer,  
Sister 1: Cervical cancer   
Sister2: Colorectal cancer  
6 76 F Chinese Non-MMR-d Son: Renal cell cancer 
7 56 M Chinese Non-MMR-d Brother: Colorectal cancer 
8 45 F Malay MSH2, 
MSH6 
Father: died of cancer 
Brother: Colorectal cancer 
Sister: Colorectal cancer  
9 52 M Chinese Non-MMR-d Sister 1: Gastric cancer,  
Sister2: Breast cancer 
10 52 M Malay Non-MMR-d Sister: Breast cancer 
11 46 F Malay MLH1 Father: Colorectal cancer,  
Sister: Colorectal cancer 
Brother: Gastric cancer  
12 56 F Chinese Non-MMR-d Mother: Endometrial cancer 
13 42 F Chinese Non-MMR-d Sister: Breast cancer 
14 53 F Indian Non-MMR-d Father: Oesophageal cancer,  
Brother: Colorectal cancer 
15 38 M Malay Non-MMR-d Father: Colorectal cancer 
Brother: Colorectal cancer 
Sister: Colorectal cancer  
16 45 M Indian Non-MMR-d Mother: Gastric cancer 
17 65 M Chinese Non-MMR-d Brother: Prostate Cancer 
18 81 F Chinese Non-MMR-d Son: Colorectal cancer 
19 60 M Chinese Non-MMR-d Mother: Colorectal cancer 
20 55 M Malay Non-MMR-d Sister 1: Colorectal cancer,  
Sister 2: Leukaemia 
21 35 M Malay Non-MMR-d Father: Colorectal cancer 
22 47 M Chinese Non-MMR-d Sister1: Colorectal cancer,  
Sister 2: Cervical cancer 
23 68 M Chinese Non-MMR-d Sister: Cervical and colorectal cancer 
24 56 F Malay Non-MMR-d Mother: gynaecological cancer  
(site unclear) 
25 31 M Malay Non-MMR-d Brother:  Intracranial malignancy  
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All the relatives of the 25 patients with positive family histories were first degree relatives. 
Fifteen patients had one relative with a history of cancer while ten had more than one 
relative with a history of cancer. Fourteen cases had a positive family history of colorectal 
carcinomas and a further three cases with HNPCC-associated cancers, namely cancers of 
the endometrium, small bowel or kidney. Thus, a total of 17 cases (10.6%) were with 
positive family history of colorectal carcinomas or HNPCC-associated cancers. Two 
patients (case 11 and 15) fulfilled the Amsterdam Criteria II (Appendix 1) for hereditary 
non-polyposis colorectal carcinoma, while another case (case 8) did not fully fulfil the 
criteria but was highly suspected of it. 
One patient (case no 23, Table 3.9) had a sibling (sister) suffering from multiple 
metachronous tumours that included colorectal carcinoma and cervical carcinoma. 
There were 8 patients with family members with non-HNPCC-associated cancers which 
included cancers of the prostate, stomach, oesophagus, breast, cervix, cerebral tumour and 
haematological malignancy.   
 
3.4.2: FAMILY HISTORY AND AGE 
Patients with a family history of a first degree relative with cancer presented at a 
significantly younger age than those patients without any family history of cancer. The 
mean age of these patients was 54.4 years compared to 61.5 years in patients without a 
family history of cancer. This difference was statistically significant (p=0.013). 
Of the total of 160 patients from whom a family history with or without malignancies was 
obtained, 31 patients were aged 50 years or below and 129 aged above 50 years.  A higher 
percentage of patients who presented younger had positive family history: 8 out of 31 
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patients (25.8%) presenting at age 50 years or below had a positive family history of 
malignancy as compared to only 13.2% (17 out of 129 patients) presenting older than 50 
years of age with a positive family history of malignancy. Conversely, a higher proportion 
of patients with family history (32.0%) presented earlier (at age 50 years or younger) as 
compared to 17.0% of patients presenting at the same age but with no family history (Table 
3.10). However, analysis using Fisher’s exact test showed that the difference between these 
two groups was not statistically significant (p=0.099).   
  
 
Table 3.10: Distribution of patients with positive family history of malignancy by age 
group. 
 
Factor Category 
All 
patients 
(n=160) 
No 
family 
history 
(n=135)  
Family 
history 
(n= 25) 
P 
value 
Odds ratio  
(95% CI) 
Age 
(in years) 
≤50 
 
  
31 
(19.4%) 
 
 
23 
(17.0%) 
 
8 
(32.0%) 
 0.099  
 2.29  
(0.88-
5.94) 
  > 50 
129 
(80.6%) 
 
112 
(83.0%) 
17 
(68.0%)     
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3.4.3: FAMILY HISTORY AND MISMATCH REPAIR DEFECT TUMOURS 
Only two cases with a positive family history of malignancy (case no. 8 & 11, Table 3.9) 
were found to have mismatch repair defect tumours. The MMR staining was defective for 
hMLH1 in one case, and for both hMSH2 and hMSH6 in the other. It was interesting to 
note that both these patients with mismatch repair defect tumours had two or more family 
members with colorectal carcinomas and both presented in their mid-forties.  
One of the patients (case no. 11) had three immediate relatives with GIT malignancies, two 
of which were colorectal carcinomas. Both the father and sister had colorectal carcinomas 
while her brother had gastric carcinoma. Although we did not have records of the age of 
presentation of the relatives but the patient herself presented at a young age (46 years old). 
She fulfilled the criteria for HNPCC. The other patient (case no. 8) was also in her forties 
(45 years old) when she presented with malignancy. Both her two siblings had colorectal 
carcinomas. However, we could not confirm there were 2 generations involved with 
malignancies in her case. Nonetheless, the patient was highly suspected of having HNPCC. 
It was interesting to note that both the cases (no. 8 & 11) were Malay females and in their 
forties.  
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3.5: CHARACTER OF TUMOUR 
3.5.1: MULTIPLE TUMOURS 
The records of 236 patients were studied to determine whether they had multiple malignant 
tumours (synchronous or metachronous) before or at presentation. From a total of 298 
patients, 40 cases were lost to follow up and another 12 cases were excluded as their history 
and past clinical records were not available. Of the remaining 236 patients, 34 patients 
(14.4%) were found to have multiple malignancies, ten of whom had synchronous 
malignant colorectal carcinomas (4.2%) and 24 with metachronous malignant tumours 
(10.2%). Eight patients had metachronous colorectal carcinomas (at a different site and 
time to the index tumour) while the remaining sixteen had metachronous non-colorectal 
carcinomas which included prostate carcinomas (3 cases), gynaecological malignancy 
(cervical -3 cases, endometrial -2 cases, ovarian -2 cases), breast carcinomas (3 cases) and 
renal, bronchogenic and gastric carcinomas (one case each) (Table 3.11). 
Only twenty five patients (8.3% of cases) had associated benign adenomas in their 
colectomy specimen. This may not be reflective of the true situation as we did not look into 
their scope findings or their barium enema images. Hence benign adenomas were excluded 
as multiple tumours in this study. 
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Table 3.11: Patients with metachronous non-colorectal carcinomas 
No
. 
Age of 
onset (yrs) 
Gender Race MMR status  Metachronous non-
colorectal carcinoma 
      
1 64 F Malay hMSH6 Cervical carcinoma 
2 71 F Chinese Non-MMR-d Cervical carcinoma 
3 79 F Malay Non-MMR-d Cervical carcinoma 
4 45 F Malay hMSH2 & 
hMSH6 
Ovarian carcinoma 
5 45 F Chinese Non-MMR-d Ovarian carcinoma 
6 46 F Malay hMLH1 Endometrial carcinoma 
7 89 F Malay Non-MMR-d Endometrial carcinoma 
8 79 M Malay Non-MMR-d Prostate cancer  
9 69 M Chinese Non-MMR-d Prostate cancer 
10 74 M Malay Non-MMR-d Prostate cancer 
11 54 F Malay Non-MMR-d Breast cancer  
12 77  F Chinese Non-MMR-d Breast cancer 
13 55  F Chinese Non-MMR-d Breast cancer 
14 63 M Chinese Non-MMR-d Gastric cancer 
15 53 M Malay Non-MMR-d Bronchogenic carcinoma  
16 58 F Malay Non-MMR-d Renal cell carcinoma  
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MULTIPLE TUMOURS AND MISMATCH REPAIR DEFECT TUMOURS  
Of the 34 patients with synchronous or metachronous tumours, there were nine patients 
(26.5%) with mismatch repair defect tumours. This rate was higher than that observed 
among patients with single tumours (24 of 202 patients or 11.9%). Conversely, 9 out of  33 
patients (27.3%) with mismatch repair defect tumours as compared to 25 of 203 patients 
(12.3%) with non-MMR-d tumours presented with multiple (synchronous or metachronous) 
tumours. This difference was statistically significant (p=0.032, Table 3.12).  Patients with 
mismatch repair defect tumours had an odds ratio of 2.67 of developing synchronous or 
metachronous tumours (95% CI was 1.12-6.41). 
 
Table 3.12: Distribution of patients by their presentation as single or multiple tumours 
against their MMR staining pattern. 
 
Factor Category 
All 
patients 
(n=236) 
MMR 
status: 
 
MMR-d 
group 
(n=33) 
 Non-
MMR-d 
group 
(n=203) P value 
Odds 
ratio  
(95% CI) 
Multiplicity 
of tumours 
Single 
tumours 
202  
(85.6%) 
24 
(72.7%) 
178 
(87.7%) 0.032 2.67 
          
  
Multiple 
tumours 
34  
(14.4%) 
9  
(27.3%) 
25 
(12.3%)  
(1.12-
6.41) 
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Nine cases with MMR-d colorectal carcinomas presenting with multiple tumours were 
made up 3 cases with synchronous colorectal carcinomas, 3 with metachronous colorectal 
carcinomas and another three with metachronous non-colorectal carcinoma. 
 
3.5.2: ANATOMICAL LOCATION  
In this study, the majority of the 298 unselected consecutive colorectal carcinomas were 
localised to the left side. Two hundred and seven cases (69.5%) were left sided lesions 
(defined as distal to but not including the splenic flexure). Most of the tumours were on the 
left side and all the races showed similar predilection for that site: 70.1% of Chinese 
patients, 70.5% of Malay patients, 63.2% of Indian patients and 50.0% of patients of other 
races had left sided colorectal carcinomas (Table 3.13). 
 
Table 3.13: Frequencies of location of colorectal carcinomas in patients by  
 
ethnic race. 
 
 
Race 
Total Chinese Indian Malay Others 
Site Left side  98 12 94 3 207 
 70.5% 63.2% 70.1% 50.0% 69.5% 
Right side  41 7 40 3 91 
 29.5% 36.8% 29.9% 50.0% 30.5% 
Total  139 19 134 6 298 
 100.0% 100.0% 100.0% 100.0% 100.0% 
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ANATOMICAL LOCATION AND MMR-D TUMOURS 
Out of the 43 cases of mismatch repair defect tumours, 26 were right-sided tumours 
(60.5%), in contrast to only 17 on the left side of the colon (39.5%). Mismatch repair defect 
sporadic colorectal carcinomas were found to significantly localise to the right side of the 
colon. Almost two-thirds (60.5%) of mismatch repair defect tumours occurred in the right 
side of colon; while only 25.5% of intact tumours were right-sided. Conversely, 28.6% of 
right-sided tumours were mismatch repair deficient, compared with only 8.20% of left 
sided tumours (p<0.001, Table 3.14). Right-sided tumours had an odds ratio of 4.47 (95% 
CI 2.28-8.76) for being mismatch repair deficient compared to left sided tumours.  
 
Table 3.14: Distribution of colorectal cancers by location and MMR status. 
   
MMR status: 
    
Factor Category 
All patients 
(n=298) 
MMR-d 
group 
(n=43) 
Non-
MMR-d 
group 
(n=255) 
P 
value 
Odds 
ratio  
(95% 
CI) 
Site Left 
207  
(69.5%) 
17 
(39.5%) 
190  
(74.5%)    
      <0.001 4.47  
         
  Right 
91 
(30.5%) 
26 
(60.5%) 
65 
(25.5%)  
 (2.28-
8.76) 
         
           
 
 
 
96 
 
Sixteen out of 28 cases of hMLH1 defective tumours (57.1%) were localised to the right 
side while ten cases of either hMSH2 or hMSH6 defective tumours (10 out of 15 cases or 
66.7%) were right-sided tumours. There was no significant difference between the types of 
mismatch repair defect protein loss in tumours located on the right side of the colon. 
ANATOMICAL LOCATION AND AGE 
In this study, the mean age of patients with right-sided tumours was lower than the mean 
age of patients with left sided tumours. The mean age of patients with right sided tumours 
was 59.2 + 1.5 years while the mean age for patients with left sided tumours was 61.8 + 0.9 
years. However this was not statistically significant (p=0.120).  
 
3.5.3: TUMOUR GROWTH APPEARANCE 
The majority of colorectal carcinomas in this study were endophytic tumours with deep 
ulceration. There were 199 cases (66.8%) with endophytic growth pattern while the 
remaining 99 cases (33.2%) were polypoidal or exophytic in growth, and protruded into the 
lumen.  
TUMOUR GROWTH APPEARANCE AND ANATOMICAL LOCATION 
One hundred and forty cases (70.4%) of the tumours with endophytic growth were found in 
the left side of colon (distal colon) [Table 3.15].  
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Table 3.15: Distribution of colorectal carcinomas by different growth patterns and location 
of tumours.  
 
Factor Category All patients  
Growth pattern: 
      
Odds 
ratio 
     (n=298) 
Exophytic 
(n=99) 
Endophytic 
(n=199) 
P 
value 
 (95% 
CI) 
Site Left side 207 (69.5%) 67 (67.7%) 
140 
(70.4%)     
  
Right side 
 
91 (30.5%) 
 
32 (32.3%) 
 
59 
(29.6%) 
 
0.637 
 
1.13 
(0.67-
1.91) 
 
 
Although there were more endophytic tumours (59 cases) than exophytic tumours (32 
cases) among right sided tumours in this study, there was no statistical difference between 
right and left sided tumours with regards to tumour growth appearance (p=0.637).   
Table 3.16 shows the distribution of colorectal carcinomas by each specific location, 
namely: caecum, ascending colon, transverse colon, descending colon, sigmoid colon and 
rectum, and the tumour growth appearance. In all sites, tumours were predominantly 
endophytic.  The descending colon (79.2%) and the sigmoid colon (69.4%) had the highest 
proportions of tumours with endophytic lesions. Exophytic lesions were seen most 
commonly in the transverse colon (40.9%), followed by the caecum (35.7%) and the rectum 
(35.5%), but even in these sites; remained less common than their endophytic counterparts. 
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Table 3.16: Distribution of colorectal carcinomas by location and tumour growth pattern. 
 
Factor Category   
Tumour growth 
pattern   
    
All cases 
(n=298) Exophytic  Endophytic 
Location Ascending colon 41 (13.8%) 13 (31.7%) 28 (68.3%) 
  
 
Caecum 
 
28 (9.4%) 
 
10 (35.7%) 
 
18 (64.3%) 
 
  
Descending colon 
 
24 (8.0%) 
 
5 (20.8%) 
 
19 (79.2%) 
 
  Rectum 121 (40.6%) 43 (35.5%) 78 (64.5%) 
  
 
Sigmoid colon 62 (20.8%) 19 (30.6%) 43 (69.4%) 
  
 
Transverse colon 
 
22 (7.4%) 
 
9 (40.9%) 
 
13 (59.1%) 
 
 
 
TUMOUR GROWTH APPEARANCE AND MMR STATUS 
Although approximately 2/3 of the tumours were mainly endophytic lesions and only 1/3 
were exophytic lesions, a significant percentage (22.2% or 22 of 99 cases) of exophytic 
tumours had mismatch repair protein loss as compared to only 10.6% (21 of 199 cases) of 
endophytic tumours (p=0.007, OR = 2.42, 95% CI 1.26-4.67, Table 3.17). Conversely, 
more than 2/3 (69.8%) of the non-MMR-d tumours were endophytic while less than 1/3 of 
non-MMR-d tumours were exophytic. This showed that mismatch repair defect tumours 
were significantly associated with an exophytic growth appearance. 
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Table 3.17: Distribution of colorectal carcinomas by growth pattern and mismatch repair 
status. 
 
   MMR status:    
Factor Category 
All 
patients 
(n=298) 
MMR-d 
group 
(n=43) 
Non-MMR-d 
group (n=255) 
P 
value 
Odds 
ratio  
(95% 
CI) 
Growth 
pattern Exophytic 99  22 77    
    (33.2%) (51.2%) (30.2%)  0.007 2.42 
  Endophytic 199  21 178   
(1.26-
4.67) 
   
 (66.8%) 
 
(48.8%) 
 
(69.8%) 
     
 
 
3.5.4: SIZE OF TUMOUR 
The mean size of all tumours was 4.8 cm with a standard deviation of 2.1 cm. Tumour size 
ranged from 1.0 cm to 17.0 cm (Figure 3.6). 
The majority of tumours (199 cases, 66.8%) were smaller than 5.0 cm in diameter, while 
approximately one-third of cases had a diameter larger than or equal to 5.0 cm.  
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Figure 3.6: Distribution of colorectal cancers by size (diameter in cm). 
 
 
SIZE OF TUMOURS AND GROWTH APPEARANCE 
Larger tumours (defined as tumours with a diameter of 5.0 cm and above) were found to be 
significantly associated with an exophytic growth appearance. A significantly higher 
proportion (41 out of 99 cases) of large tumours were exophytic as compared to 58 out of 
199 cases of small tumours, (41.4% vs. 29.1%, p=0.034). Conversely, 70.9% of small 
tumours (defined as tumours with a diameter of less than 5.0 cm) appeared endophytic 
(Table 3.18).  
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Table 3.18: Distribution of colon cancers by growth pattern and size of tumours. 
 
Factor Category 
All patients 
(n=298) 
Growth pattern 
     
Odds 
Ratio 
    
 
Exophytic 
(n=99) 
Endophytic 
(199) 
P 
value 
(95% 
CI) 
Size Small 
199 
(66.8%) 58 (58.6%) 
141 
(70.9%)     
  (<5cm)   
 
      
  Large 99(33.2%) 41 (41.4%) 58 (29.1%) 0.034 
1.72 
(1.04-
2.84) 
  
(>5cm) 
           
 
 
SIZE AND MMR-D TUMOURS 
The mean sizes of MMR-d tumours and non-MMR-d tumours were 5.7 + 2.4 cm and 4.7 + 
2.0 cm respectively. Mismatch repair defect tumours were larger than non-MMR-d tumours 
by a mean difference of 1.0 cm (95% CI 0.27-1.81).  
When the means of the tumours with and without mismatch repair defect were compared, 
tumours with mismatch repair protein defects were found to be significantly larger 
(p=0.009) compared to non-MMR-d tumours.  
Conversely, more than half of the MMR-d tumours were larger than 5.0 cm (53.5 %) as 
compared to only 29.8% of the non-MMR-d tumours (p=0.002, Table 3.19). This 
difference reached statistical significance. The odds ratio was 2.71 (95% CI 1.41-5.22). 
Thus, MMR-d tumours were significantly associated with larger sized tumours. 
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Table 3.19: Distribution of colon cancers by size of tumours and mismatch repair status. 
Factor Category 
All 
patients 
(n=298) 
MMR 
status: 
     
Odds 
Ratio 
    
 
MMR-d 
group 
(n=43) 
Non-MMR-d 
group 
(n=255) 
P 
value (95% CI) 
Size Small 
199 
(66.8%) 20 (46.5%) 179 (70.2%)     
  (<5.0cm)   
 
      
  Large 99(33.2%) 23 (53.5%) 76 (29.8%) 0.002 
2.71 
(1.41-
5.22) 
  
(>5.0cm) 
           
 
 
Larger tumours with diameter of 5.0 cm and above were significantly associated with a 
higher amount of mucin (more than 10%) compared to smaller tumours (p=0.011). The 
larger tumours had an odds ratio of 2.02 with a 95% confidence interval of 1.17-3.51 (Table 
3.20). 
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Table 3.20: Distribution of patients with colorectal carcinomas by size of tumours and 
amount of mucin in the tumour. 
 
Factor Category 
All 
patients  Amount of mucin:   Odds Ratio 
    (n=298) 
 
< 10% > 10 % P value (95% CI) 
      (n=228) (n=70)     
Size 
Small 
(<5.0cm) 
199 
(66.8%) 
161 
(70.6%) 38 (54.3%)     
  
 
  
 
  0.011 
2.02 (1.17-
3.51) 
  Large 
99 
(33.2%) 
67 
(29.4%) 32 (45.7%)     
  
(>5.0cm) 
           
 
 
SIZE AND OTHER FEATURES 
Tumour size, however, did not have any significant associations with tumour location 
(p=0.203), stage (p=0.406), grade (p=0.227), invasive border pattern (p=0.174) nor 
expression of p53 staining in the tumours (p=0.306). Size of tumours did not have any 
influence on survival rates (p=0.952) either. 
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3.6: HISTOPATHOLOGICAL FEATURES 
3.6.1: HISTOLOGICAL TYPE AND GRADE 
The majority of the colorectal carcinomas (246/298, 82.6%) were classified as well to 
moderately differentiated carcinomas while only 52 cases (17.4%) were classified as poorly 
differentiated carcinomas. The latter group include mucinous carcinomas, signet-ring 
carcinomas and undifferentiated carcinomas.  
HISTOLOGICAL GRADE AND MMR STATUS 
Only 34 out of 255 patients (13.3%) with non-MMR-d tumours had poorly differentiated 
carcinomas. This was in stark contrast to the group of patients with mismatch repair defect 
tumours: 18 out of 43 cases (41.9%) of mismatch repair defect tumours were poorly 
differentiated colorectal carcinomas (Figure 3.7). This revealed a statistically significant 
positive correlation between mismatch repair defects and poorly differentiated tumours as 
compared to patients with non-MMR-d tumours (p<0.001, OR 4.68, 95% CI 2.31–9.47). 
The majority of the patients with non-MMR-d tumours had well or moderately 
differentiated tumours (221 patients, 86.7%).  
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Figure 3.7: Distribution of tumour grade (differentiation) in MMR-d and  
Non-MMR-d colorectal carcinomas.  
 
Mismatch repair defect tumours 
Non- Mismatch repair defect tumours 
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MEDULLARY HISTOLOGY 
Some colon cancers have medullary histology; characterised by trabecular to sheet-like 
growth of tumour cells with abundant esoinophilic cytoplasm, vesicular nuclei and 
prominent nucleoli and no appreciable glandular formation. In the review of slides two 
cases with undifferentiated carcinomas were found to have medullary histology (Figure 
3.8A). They were composed of sheets of monomorphic cells with no glandular 
differentiation. Both showed loss of either one of the mismatch repair proteins namely 
hMLH1 (Figure 3.8B) or hMSH2. 
 
 
 
Figure 3.8: Undifferentiated carcinoma 
 
A: shows medullary histology in an undifferentiated carcinoma (H & E stain, original 
magnification X100). 
B: shows the tumour cells with no reaction to hMLH1 protein by IHC method (IHC with 
hMLH1 antibody, original magnification X200). 
A B 
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GRADE AND TYPE OF MMR DEFECT 
Out of the 18 patients with mismatch repair defect tumours which were poorly 
differentiated, 11 had tumours that were hMLH1 defective (39.3% of hMLH1 defective 
tumours) and 7 were either hMSH2 or hMSH6 defective tumours (or 46.7% of hMSH2 or 
hMSH6 deficient tumours). Thus, a higher proportion of hMSH2 or hMSH6 defective 
tumours were found to be poorly differentiated carcinomas. As the number of cases was 
small, statistical evaluation cannot be done. 
 
3.6.2: MUCIN PRODUCTION 
The amount of mucin in each tumour was evaluated and recorded as less than 10%, 11 to 
50% or more than 50% (mucinous carcinomas) as described in Chapter 2.3.2. 
Most tumours (228 cases or 76.5%) had minimal mucin, that is, less than 10% mucin. 41 
cases (13.7%) involved tumours producing between 10% and 50% mucin and 28 cases 
(9.40%) had more than 50% mucin present. 
MUCINOUS CARCINOMAS AND MMR STATUS 
Comparison of data according to the type of carcinoma, namely adenocarcinomas 
(glandular formation with less mucin production) vs. mucinous carcinomas (tumours where 
there were more than 50% mucin production) we found that there were 273 patients 
(91.6%) with adenocarcinoma of the colo-rectum, 22 patients (7.3%) with mucinous 
carcinomas and only three patients (1.00%) with signet ring cell carcinomas. Due to the 
small number of cases, mucinous carcinomas were combined with signet ring cell 
carcinomas and classified as ‘mucinous type carcinomas’ with mucin production more than 
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50% (extra-cellular or intracellular) giving a total of 25 patients with ‘mucinous type 
carcinomas’.  
11.6% of patients (or 5 out of 43 patients) with mismatch repair defect tumours had 
mucinous type carcinomas as compared to 7.8% of patients with non-MMR-d tumours (20 
patients out of 255). Although a higher proportion of mucinous type carcinomas was 
observed among mismatch repair defect tumours, this was not found to be statistically 
different (p=0.379).  
MUCIN PRODUCTION AND MMR STATUS 
Most tumours (202 out of 255 cases, 79.2%) with intact MMR protein staining had less 
than 10% mucin and only 53 cases (20.8%) of intact tumours had more than 10% mucin.  
In contrast, 17 out of 43 cases (39.5%) of mismatch repair defect tumours produced more 
than 10% mucin (Table 3.21). 
Data analysis using the Mann-Whitney U test demonstrated a significant difference in 
amount of mucin production between patients with mismatch repair defect tumours and 
non-MMR-d tumours (p=0.007). Hence, excessive mucin production was found to be 
significantly associated with MMR-d tumours.  
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Table 3.21: Distribution of colorectal carcinomas by mucin production and mismatch repair 
status. 
Factor Category 
All patients 
(n=298) 
MMR 
status: 
 
MMR-d 
group 
(n=43) 
Non-
MMR-d 
group 
(n=255) 
P 
value 
Odds 
ratio  
(95% CI) 
Mucin 
production 
Minimal 
(<10% 
mucin) 228 (76.5%) 
26 
(60.5%) 
202 
(79.2%) 0.007 2.49 
  
Marked 
(>10% 
mucin) 70 (23.5%) 
17 
(39.5%) 
53 
(20.8%)   
(1.26-
4.93) 
 
 
In summary, although there was no significant association between mucinous histology and 
mismatch repair defect tumours, there was a significant association between excessive 
amount of mucin present and tumours with mismatch repair defects. 
 
3.6.3: TUMOUR ADVANCING PATTERN 
Tumours were classified as expansive or infiltrative based on the pattern of tumour 
advancement as described by Jass et al (Jass, Ajioka et al. 1996). Overall, there were 
slightly more tumours (161 cases, 54.0%) with expansive borders than there were cases of 
infiltrating borders (137 cases, 46.0%). 
Comparisons were made to identify differences between tumour advancing patterns 
between right and left sided tumours. Out of 207 left sided tumours, there were 109 cases of 
colorectal cancers (52.7%) with expansive borders and 98 cases (47.3%) with infiltrating 
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borders. There was no significant difference between advancing tumour patterns for left 
sided tumours.  
Right sided tumours had a higher proportion of tumours with expansive borders compared 
to left sided tumours. Out of 91 right sided tumours, there were 52 cases (57.1%) of 
expansive tumours and 39 cases (42.9%) of infiltrating tumours (Table 3.22). However, this 
difference was not statistically significant either (p=0.474).  
 
Table 3.22: Distribution of colon cancers by tumour location and border pattern. 
 
 
Factor Category 
All cases 
(n=298) Location     
Odds 
Ratio 
      Left Right P value 
(95% 
CI) 
Borders 
 
Expanding 
 
161 
(54.0%) 
  
109 
(52.7%) 
 
52 
(57.1%) 
   1.20 
  
Infiltrating 
 
137 
(46.0%) 
  
98 (47.3%) 
 
39 
(42.9%) 
 
0.474 
 
(0.73-
1.97) 
 
 
 
TUMOUR ADVANCING PATTERN AND MMR STATUS 
Twenty nine out of 43 cases (67.4%) of mismatch repair defect tumours had expansive 
borders. The remainder of the mismatch repair defect tumours (14 cases) had infiltrative 
borders. This meant about a third of mismatch repair defect tumours had infiltrative 
borders. By comparison, intact tumours had almost equal numbers of expansive (132 cases, 
51.8%) and infiltrative borders (123 cases, 48.2%) respectively.  Data analysis revealed a 
non-significant trend towards an association between mismatch repair defect tumours and 
expansive borders (p=0.056).  
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3.6.4: LYMPHOCYTIC RESPONSE 
PERITUMOURAL LYMPHOCYTIC RESPONSE 
There were 216 tumours (72.5%) with marked peri-tumoural lymphocytic response but 
only 82 cases (27.5%) with minimal lymphocytic response. The presence of a marked peri-
tumoural lymphocytic response around a tumour was not associated with many of the 
characteristics of the tumour studied. Specifically, it showed no association with 
localisation of tumour (right sided vs. left sided, p=0.770), gross appearance of tumour 
(exophytic vs. endophytic lesion p=0.537) or the size of the tumour (p=0.372). It was also 
not significantly associated with either the depth of invasion (p=0.336) or tumour stage 
(p=0.057) (Table 3.23). 
 
112 
 
Table 3.23: Association of peri-tumoural and Crohn-like lymphocytic response and other 
pathological parameters 
Parameters  PTL +ve PTL -ve 
p 
value   CLR +ve CLR -ve p value 
    n, % n, %     n, % n, %   
Site                  
  Right 67 (31.0%) 24 (29.3%) 0.770  80 (29.5%) 11 (40.7%) 0.227 
  Left 149 (69.0%) 58 (70.7%)    191 (70.5%) 16 (59.3%)   
Size            
  Small** 141 (65.3%) 58 (70.7%) 0.372  180 (66.4%) 19 (70.4%) 0.678 
  Large* 75 (34.7%) 24 (29.3%)    91 (33.6%) 8 (29.6%)   
Gross app          
  Exophytic 74 (34.3%) 25 (30.5%) 0.537  90 (33.2%) 9 (33.3%) 0.990 
  Endophytic 142 (65.7%) 57 (69.5%)    181 (66.8%) 18 (66.7%)   
Stage            
  Low 124 (57.4%) 37 (45.1%) 0.057  146 (53.9%) 15 (55.6%) 0.867 
  High 92 (42.6%) 45 (54.9%)    125 (46.1%) 12 (44.4%)   
Grade            
  low 184 (85.2%) 62 (75.6%) 0.052  223 (82.3%) 23 (85.2%) 0.705 
  high 32 (14.8%) 20 (24.4%)    48 (17.7%) 
 
4 (14.8%)   
Borders            
  Expanding 120 (55.6%) 41 (50.0%) 0.390  147 (54.2%) 14 (51.9%) 0.812 
  Infiltrative 96 (44.4%) 41 (50.0%)    124 (45.8%) 13 (48.1%)   
Necrosis            
  Minimal 144 (66.7%) 53 (64.6%) 0.741  173 (63.8%) 24 (88.9%) 0.009 
  Marked 72 (33.3%) 29 (35.4%)    98 (36.2%) 3 (11.1%)   
 
Mucin            
  Minimal 172 (79.6%) 56 (68.3%) 0.039  212 (78.2%) 16 (59.3%) 0.027 
  Marked 44 (20.4%) 26 (31.7%)    59 (21.8%) 11 (40.7%)   
p53             
  negative 112 (51.9%) 35 (42.7%) 0.157  128 (47.2%) 19 (70.4%) 0.022 
  positive 104 (48.1%) 47 (57.3%)    143 (52.8%) 8 (29.6%)   
PTL= peri-tumoural lymphocytic response, CLR = Crohn-like lymphocytic response 
Large* = tumours more than or equal to 5 cm diameter; Small ** = tumours smaller than 5 cm 
diameter 
Stage low = Stage 1 & 2; Stage high = Stage 3 & 4 
Grade high =poorly differentiated; Grade low = well & moderately differentiated 
Mucin marked = > 10 % mucin present; Mucin minimal = <10 % mucin present 
p < 0.05 is significant 
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Histologically, the presence of peri-tumoural lymphocytic response occurred irrespective of 
the grade of the tumour (p=0.052), the type of invasive border pattern (p=0.390) or degree 
of necrosis (p=0.741). Almost three quarters of the tumours had a marked peri-tumoural 
lymphocytic response regardless of the expression or accumulation of p53 (p=0.157).  
The majority of the tumours that exhibited marked peri-tumoural lymphocytic response 
(79.6%) showed minimal mucin production (<10% mucin present), with only 20.4% 
showing marked mucin production. This can be compared with tumours with minimal 
lymphocytic response which had a greater percentage of marked mucin production at 
31.7% (26 out of 82 cases). This relationship between lymphocytic response and mucin 
production was statistically significant (p=0.039), and it can be concluded that the presence 
of marked peri-tumoural lymphocytic response was significantly associated with minimal 
production of mucin. Tumours with abundant mucin production were less likely to have a 
peri-tumoural lymphocytic response. 
Twenty eight cases (65.1%) of MMR-d tumours had marked peri-tumoural lymphocytic 
response. 73.7% of intact tumours had marked lymphocytic response (Table 3.24).  The 
peri-tumoural lymphocytic response was not found to be significantly different between the 
MMR-d tumours and non-MMR-d tumours (p=0.242).  
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Table 3.24: Distribution of tumours by their lymphocytic response (peri-tumoural) and 
MMR-status. 
 
 
 
Factor Category 
 
 
 
All 
patients 
(n=298) 
 
 
MMR status 
 
MMR-d 
group 
(n=43) 
Non-MMR-d 
group 
(n=255) 
P 
value 
 
Odds 
ratio  
(95% 
CI) 
 
Peri-
tumoural 
lymphocytic 
response 
Minimal 
 
82 
(27.5%) 
 
15 (34.9%) 
 
67 (26.3%) 
 
0.242 
 
0.67 
 
 
Marked 
  
216 
(72.5%) 
 
28 (65.1%) 
 
188 (73.7%) 
   
(0.34-
1.32) 
 
 
 
CROHN-LIKE LYMPHOCYTIC RESPONSE 
There were 271 cases (90.1%) with conspicuous Crohn-like lymphocytic response. Twenty 
seven cases (9.9%) did not demonstrate any response. Similar to the peri-tumoural 
lymphocytic response, conspicuous Crohn-like lymphocytic response occurred independent 
of various features of the tumour, namely: tumour site, growth appearance, size, staging 
and depth, invasive border pattern and grade (Table 3.23). 
Crohn-like lymphocytic response was also found to be associated with minimal mucin 
production. A significant number of tumours (212 cases, 78.2%) with conspicuous Crohn-
like lymphocytic response had minimal (<10%) mucin present in the tumours, with a 
smaller percentage (59.3%) of cases without Crohn-like lymphocytic response having 
minimal mucin production (p=0.027). This can be translated into the fact that 40.7% of 
cases without Crohn-like lymphocytic response had abundant (>10%) mucin production as 
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compared to about half that proportion (21.8%) in cases with Crohn-like lymphocytic 
response. In addition, it was found that the presence of conspicuous Crohn-like 
lymphocytic response was significantly associated with marked tumour necrosis. There was 
a higher proportion of marked necrosis in cases with conspicuous Crohn-like lymphocytic 
response (98 out of 271 cases, 36.2%) than in cases without Crohn-like lymphocytic 
response (11.1% of).  This difference was statistically significant (p=0.009). 
Nuclear accumulation of p53 was seen in more than half of the cases (52.8%) with Crohn-
like lymphocytic response but only in 8 out of 27 cases or 29.6% of tumours with no 
Crohn-like lymphocytic response. Conversely 70.4% of cases with no such lymphocytic 
response did not have any p53 abnormality detected by immunohistochemistry. Therefore 
conspicuous Crohn-like lymphocytic response in tumours was found to be significantly 
associated with p53 over-expression (p=0.022).  
However, there was no significant association between tumours with Crohn-like 
lymphocytic response with respect to their mismatch repair status. Crohn-like lymphocytic 
response was equally likely to be present in MMR-d tumours (88.4%) compared to non-
MMR-d tumours (91.4%) [p=0.564, Table 3.25]. 
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Table 3.25: Distribution of tumours by their lymphocytic response (Crohn-like) and MMR 
status. 
 
Factor Category 
All 
patients 
MMR status 
     
 
Odds 
Ratio 
    (n=298) 
MMR-d 
group 
(n=43) 
Non-
MMR-d 
group 
(n=255) 
P 
value 
 
 
(95% 
CI) 
 
 
Crohn-like 
lymphocytic 
response 
Incon-
spicuous 
27 
(9.1%) 5 (11.6%) 22 (8.6%)     
      
 
  0.564   
  
Conspi-
cuous 
271 
(90.9%) 38 (88.4%) 
233 
(91.4%)   
1.39 
(0.49-
3.90) 
              
 
In this study, peri-tumoural lymphocytic response was found to correlate with the presence 
of conspicuous Crohn-like lymphocytic response. 93.1% or 201 cases (out of 216 cases) 
with marked peri-tumoural lymphocytic response also showed co-existing presence of 
conspicuous Crohn-like lymphocytic response (p=0.039). 
 
3.6.5: DEGREE OF NECROSIS 
About two-thirds of colorectal cancer cases (197 cases, 66.1%) had minimal necrosis while 
another 101 cases (33.9%) demonstrated marked necrosis (Figure 3.9). 
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Figure 3.9: Colorectal carcinoma with extensive necrosis, seen replacing  
the tumour (Haematoxylin and eosin sytain, original magnification x 100). 
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NECROSIS AND SIZE 
It was found that larger tumours were more strongly associated with confluent necrosis 
(marked necrosis) compared to smaller tumours. Approximately half of the cases (49 out of 
99 cases, 49.5%) with large tumours, i.e. diameter of at least 5.0 cm had presence of 
marked necrosis compared to only 26.1% (52 out of 199) of small tumours (less than 5.0 
cm in diameter) [Table 3.26]. Larger tumours more than or equal to 5.0 cm in diameter had 
a significantly higher rate of necrosis compared to small tumours (p<0.001). 
 
Table 3.26: Distribution of colorectal carcinomas by size and degree of necrosis present. 
 
Factor Category 
All CRC 
cases 
Size of 
tumours     
Odds 
Ratio 
    (n=298) 
Small 
 (< 5cm) 
Large  
(> 5cm) P value (95% CI) 
Necrosis Little 
197 
(66.1%) 147 (73.9%) 
50 
(50.5%)     
      
 
  <0.001 
2.77 
(1.67-
4.59) 
  Marked 
101 
(33.9%) 52 (26.1%) 
49 
(49.5%)     
              
 
 
NECROSIS AND MMR STATUS 
Although only approximately one-third (33.9%) of all colon cancer cases had marked 
necrosis, more than half of the mismatch repair defect cases (24 out of 43 cases, 55.8%) 
were associated with marked necrosis. Tumours with absent or minimal necrosis were more 
frequently non-MMR-d tumours. 90.4% of tumours with no or minimal necrosis were 
 
119 
 
tumours with no mismatch repair deficiency. Conversely, 69.8% of non-MMR-d tumours 
had minimal or no necrosis (Table 3.27). 
Mismatch repair defect tumours were significantly more likely to have marked necrosis 
than non-MMR-d tumours. 55.8% of mismatch repair defect tumours had marked necrosis 
compared to 30.2% of intact tumours without the defect (p=0.001).  
 
Table 3.27: Distribution of colorectal carcinomas by MMR status and degree of necrosis 
present. 
  
 
 
Factor 
Category 
All 
patients 
(n=298) 
MMR 
status 
 
MMR-d 
group 
(n=43) 
Non-
MMR-d 
group 
(n=255) 
P 
value 
Odds 
ratio  
(95% CI) 
 
Necrosis 
Little 
197 
(66.1
%) 19 (44.2%) 
178 
(69.8%) 
  
 
0.001 2.92 
 
Marked 
 
101 
(33.9
%) 
 
24 (55.8%) 
 
77 (30.2%) 
   
(1.51-
5.64) 
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3.7: STAGING OF TUMOURS 
3.7.1: TNM STAGING 
There were 11 cases (3.69%) where staging could not be performed as no lymph nodes 
were isolated and thus the nodal status was unknown (Nx). Of the remaining 287 cases, 
there were 36 patients (12.5%) with Stage I, 108 patients (37.6%) with Stage II, 129 
patients (44.9%) with Stage III and 14 patients (4.9%) with Stage IV colorectal cancer at 
the time of operation. Liver was the main metastatic site in those patients with stage IV 
disease (10 out of 14 patients, 71.4%). Three other patients had lung metastasis while 
another had peritoneal seedling including ovarian metastasis.  
The majority of patients with colorectal carcinomas (82.5%) had either stage II or III cancer 
(Figure 3.10).  
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Figure 3.10: Distribution of cases of colorectal carcinoma by staging. 
 
 
3.7.2: DEPTH OF INVASION 
In this study, the majority of colorectal carcinomas (246 out of 298, 82.6%) were found to 
have invaded through the muscularis propria into the subserosa (T3) or perforated through 
the visceral peritoneum (T4). 38 out of 43 cases (88.4%) of tumours expressing mismatch 
repair defects were T3 or T4 tumours. Only 5 cases (10.2%) were T2 tumours and none 
were T1 tumours (Figure 3.11). A significantly higher number of tumours with mismatch 
repair defects were found to demonstrate deeper local invasion as compared to tumours 
with intact protein expression (Mann-Whitney test, p=0.039). Mismatch repair defect 
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tumours were associated with a higher degree of local invasion even though they were more 
frequently associated with an earlier stage at presentation (Figure 3.12).  
 
 
Figure 3.11: Distribution of colon cancer cases by depth of tumour invasion (T) and 
mismatch repair staining pattern. 
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Figure 3.12: Distribution of colon cancers with mismatch repair defect by stage and 
depth of invasion. 
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3.7.3: LYMPH NODES STATUS 
Unfortunately, in 11 cases (four cases of mismatch repair defect tumours and seven cases of 
non-MMR-d tumours), lymph node retrieval was not performed and as a result the status of 
the nodes was not evaluated. As the specimens were received between the years 2004 to 
2007, they had already been discarded and it was not possible to re-examine them to look 
for lymph nodes.  
In the 11 cases where the nodes were not assessed, they were classified as unknown or Nx. 
Out of the remaining 287 patients, between 1 to 79 nodes were removed with a mean of 8.8 
lymph nodes isolated per case.  
144 patients (50.2%) were found to have no lymph node involvement (N0), leaving 143 
patients (49.8%) with lymph node involvement, either N1 (when one to three lymph nodes 
were involved by carcinoma) or N2 (when more than 3 lymph nodes were involved). In 
patients with positive lymph node status, a mean of 3.4 lymph nodes were involved by 
tumour. 
18 out of 39 patients (46.2%) with mismatch repair defect tumours had nodal infiltration, 
compared to 125 out of 248 patients with non-MMR-d tumours (50.4%). Thus, there were 
relatively more patients with lymph node metastases if their tumours had no loss of 
mismatch repair defect, although this was not found to be statistically significant (p=0.622). 
There was also no significant difference in the degree of lymph node involvement between 
the mismatch repair defect tumour group and patients with non-MMR-d tumours (p=0.746, 
Table 3.28).  
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Table 3.28: Number of lymph nodes isolated and involved compared between two groups: 
MMR-d and non-MMR-d group. 
    
All 
cases 
MMR-d group 
(n=43) 
Non-MMR-d 
group (n=255) 
    (n=298)   
Nodes staging N0 144 21 (%) 123 (85.4%) 
(n=298) N1 101 13 (12.9%) 88 (87.1%) 
 N2 42 5 (11.9%) 37 (88.1%) 
 Nx 11 4  7  
   
Cases with 
nodes involved 
 
 
 
 
143 
 
 
18 
(46.2%) 
 
125 
(50.4%) 
 
     
Nodes involved 
Mean no. of 
LN 3.4 3.3 3.4 
(n=136) (range) (1-18) (1-10) (1-18) 
          
     
     
 
The tumour stage was known for 39 patients with mismatch repair defect tumours and 248 
patients with non-MMR-d tumours as lymph nodes were not available for assessment in 11 
cases.   
53.8% of patients (or 21 out of 39 patients) with mismatch repair defect tumours presented 
in Stage I or II as compared to 46.2% of patients with mismatch repair defect tumours 
presenting at Stage III or IV. With regards to Stage III tumours, 45.2% of patients with 
non-MMR-d tumours presented in this stage, an almost similar proportion to that of 
patients with mismatch repair defect tumours(43.6%). 13 out of 248 patients (5.2%) with 
non-MMR-d tumours developed metastasis at presentation but only one out of 39 patients 
(2.6%) with MMR-defective tumours presented in Stage IV (Table 3.29).  It appeared that 
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patients with mismatch repair defect tumours presented at earlier stages and fewer were 
associated with metastasis as compared to patients with intact tumours, but there was no 
significant difference between the two groups when comparing the stage of tumours at 
presentation (p=0.622).  
 
Table 3.29: Distribution of cases of colorectal cancers: comparing different stages to the 
MMR staining pattern. 
   
Category 
 
 
All 
patients 
(n=287) 
MMR status 
 
MMR-d group 
(n=39) 
Non-MMR-d 
group 
(n=248) 
P 
value 
Odds 
ratio  
(95% 
CI) 
  Stage I 36 3 (7.7%) 33 (13.3%)     
  Stage II 108 18 (46.2%) 90 (36.3%)   1.19 
 
Early Stage 
 
144 
 
21 (53.8%) 
 
123 (49.6%) 
 0.622 
(060.-
2.33) 
  Stage III 129 17 (43.6) 112 (45.2%)     
  Stage IV 14 1 (2.6%) 13 (5.2%)     
 
Late Stage 
 
143 
 
18 (46.2%) 
 
125 (50.4%) 
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3.8: TUMOUR SUPPRESSOR GENE: P53 
3.8.1: STAINING PATTERN 
There were almost equal numbers of tumours with p53 positive staining and p53 negative 
staining. One hundred and fifty one cases (50.7%) of colorectal cancers showed 
accumulation of p53 expression whereas 147 cases (49.3%) were p53 negative.  
 
3.8.2: P53 AND MISMATCH REPAIR DEFECT TUMOURS 
Analysis of the relationship between p53 and MMR status of the tumours studied showed 
that almost three quarters of mismatch repair defect tumours (74.4%) did not demonstrate 
nuclear staining for p53. Furthermore, 92.7% of tumours with p53 over-expression were 
found to be intact tumours with no loss of MMR protein (Table 3.30). Mismatch repair 
defect tumours were significantly associated with poor expression of p53 (p<0.001, OR 
3.54, 95% CI 1.71-7.34).  
 
Table 3.30: Distribution of colon cancers by p53 staining and mismatch repair status. 
Factor Category 
All cases 
(n=298) 
MMR 
status 
 
MMR-d 
group 
(n=43) 
Non-MMR-d 
group 
(n=255) P value 
Odds 
ratio  
(95% 
CI) 
p53 
staining Positive 
151 
(50.7%) 11 (7.3%) 140 (92.7%) <0.001 3.54 
  
 
Negative 
 
147 
(49.3%) 
 
32 (21.8%) 
 
115 (78.2%) 
   
(1.71-
7.34) 
 
 
 
 
 
128 
 
3.8.3: P53 AND ANATOMICAL LOCATION OF TUMOUR   
78.8% percent of p53 positive tumours were located in the left side of colon (distal to but 
not including the splenic flexure) as compared to only 21.2% on the right side (Table 3.31). 
Tumours distal to the splenic flexure were significantly more likely to have p53 over-
expression as compared to tumours located proximally (p<0.001).  
 
Table 3.31: Distribution of colon carcinomas by p53 staining and location of tumours. 
Factor Category 
All cases 
 
 (n=298) 
P53 
staining: 
 
p53 positive 
p53 
negative P value 
Odds 
ratio  
(95% CI) 
Site Left 
207 
(69.5%) 119 (78.8%) 
88 
(59.9%) <0.001 2.49 
  
 
Right 
 
91 
(30.5%) 
 
32 (21.2%) 
 
59 
(40.1%) 
   
(1.50-
4.16) 
 
 
 
 
3.8.4: P53 AND STAGING 
There was no correlation between tumour stage and the accumulation of p53 over-
expression. There were almost equal numbers of cases with p53 positive staining and 
negative staining among tumours presenting at an early stage (Stage I and II tumours) and 
at an advanced stage (Stages III and IV) (Table 3.32).  
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Table 3.32: Distribution of cases of by tumour stage: analysis of p53 staining patterns in 
early vs. late stage tumours 
  Category 
All 
patients 
 (n=287) 
P53 
staining: 
 
p53 positive 
(n=145) 
p53 negative 
(n=142) 
P 
value 
Odds 
ratio  
(95% 
CI) 
  Stage I 36  23 13     
  Stage II 108 45 63   1.30 
Early Stage 
 
144 
 
68 (47.2%) 
 
76 52.8%) 
 0.262 
(0.82-
2.07) 
  Stage III 129 71 58     
  Stage IV 14 6 8     
Late Stage 
 
143 
 
77(153.8%) 
 
66 (46.2%) 
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3.9: SURVIVAL 
3.9.1: SURVIVAL OF PATIENTS WITH CRC 
Forty patients were lost to follow-up after their initial surgery. Data regarding survival of 
these patients were not obtained. From the data available from the other 258 patients, the 
overall mean survival was 31.2 + 1.6 months (Figure 3.13). 
 
Figure 3.13: Survival curve for all patients with colorectal carcinomas 
         (Censored data represents patients alive at their last follow up visits). 
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3.9.2: SURVIVAL AND STAGING 
One of the most important features that was found to affect prognosis and hence the 
survival of patients with colorectal cancer was their lymph node status. Patients with colon 
cancers with lymph node metastases i.e. Stages III or IV had a worse prognosis than those 
with earlier stages.  
The mean survival of patients presenting with early stage cancer (Stages I or II) was 34.9 + 
2.2 months while those with late stage cancer (Stages III or IV) had a mean survival of 26.0 
+ 2.1 months. Analysis with the log rank test showed that this difference was statistically 
significant (p=0.010). Clearly, patients presenting at an earlier stage (either Stage I or II) 
had a longer survival than those who presented at a later stage.  
On the whole, patients survived longer when there was no lymph node involvement. The 
cumulative survival of 50% of patients with nodal metastases was approximately 18 
months (figure 3.14), but that of patients free from nodal involvement was close to 4 years, 
confirming that nodal involvement drastically decreased patient survival. 
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Figure 3.14: Survival curves for patients categorised according to nodal status. Arrows 
show cumulative survival of 50% of patients.  
 
3.9.3: SURVIVAL AND MMR-D TUMOURS 
The mean survival of patients with mismatch repair defect tumours was 31.4 + 4.6 months 
compared with mean survival of patients with non-MMR-d tumours at 31.0 + 1.6 months. 
Although patients with mismatch repair defect tumours had a slightly longer mean survival 
No nodal involvement: Stages I & II 
Nodal involvement: Stages III & IV 
(p=0.010) 
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time compared to patients with MSS tumours, this was not statistically significant 
(p=0.615, Figure 3.15).  
 
 
 
Figure 3.15: Survival curves for patients categorised according to mismatch repair status. 
MMR-d tumours 
Non-MMR-d  tumours 
(p=0.615) 
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There were 177 cases of colon carcinomas when rectal tumours were excluded from the 
study. Twenty-nine cases did not have clinical notes and the status of the patients was 
unknown. These were excluded. In the remaining sample of 148 patients with colon 
cancers, 27 cases had loss of mismatch repair protein by IHC testing and 121 had normal 
protein pattern. The clinical outcomes in relation to their mismatch repair status for this 
remaining group of patients were studied. The mean survival of patients with mismatch 
repair defect by IHC was 32.7 months was longer as compared to those with normal protein 
pattern of 29.9 months. However, this was not significant with a probability value of 0.377. 
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3.9.4: SURVIVAL AND P53 STATUS 
This study found that patients with tumours expressing p53 did not demonstrate any 
significant difference in survival rates compared to patients with p53 negative tumours 
(Figure 3.16, p=0.741). Patients with p53 positive tumours had a mean survival of 31.1 + 
2.2 months, whereas the mean survival of patients with p53 negative tumours was 31.4 + 
2.2 months. 
 
 
 Figure 3.16: Survival curves for patients with categorised according to p53 tumour 
staining patterns. 
 
P53 negative 
P53 positive 
(p=0.714) 
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One hundred and twenty-one cases of rectal tumours were excluded and the remaining 148 
patients with known clinical status were studied. The clinical outcomes for these patients 
with colon cancers were compared in relation to their p53 expression by IHC testing. The 
mean survival of patients with p53 over-expression was 27.7 months was shorter as 
compared to a longer survival of 30.8 months for those with negative p53 expression. 
However, this was not significant (p=0.495). 
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3.9.5: SURVIVAL AND OTHER PATHOLOGICAL FEATURES: 
ANATOMICAL LOCATION 
Comparison of survival of patients with left versus right sided tumours (without taking 
MMR-d status into consideration) revealed no significant difference (Figure 3.17). The 
mean age of survival for patients with left sided tumours was 30.6 + 1.8 months, and for 
patients with right sided tumours was 32.2 + 3.0 months. Survival rates among patients 
with right sided tumours were slightly better but this was not significantly different 
(p=0.724).  
 
Figure 3.17: Survival curve of patients categorised according to tumour location.  
 
Left side 
Right side 
(p=0.724) 
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TUMOUR ADVANCING PATTERN 
The survival of patients with tumours with expansive borders was far superior than that of 
patients whose tumours had diffuse infiltrating borders (Figure 3.18). The mean duration of 
survival was 35.0 + 2.1 months for patients with expansive tumours but only 26.8 + 2.1 
months for patients with diffuse infiltrating tumours. This difference was statistically 
significant (p=0.014). 
 
 
Figure 3.18: Survival curve for patients categorised according to border patterns (expansive 
vs. infiltrating). 
Expansive 
Infiltrating 
(p=0.014) 
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LYMPHOCYTIC RESPONSE 
Patients with tumours showing marked peri-tumoural lymphocytic response had a longer 
mean survival of 32.0 + 1.8 months as compared to those with minimal or little 
lymphocytic response (27.7 + 3.1 months, Figure 3.19). However this difference was not 
statistically significant (p=0.293). 
 
Figure 3.19: Survival curve of patients categorised according to peri-tumoural lymphocytic 
response. 
 
Marked peritumoural response 
Little peritumoural response 
(p=0.293) 
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Similarly, patients with conspicuous Crohn-like lymphocytic response also survived longer 
with a mean survival time of 31.2 + 1.6 months compared to 29.3 + 4.9 months in patients 
with no Crohn-like lymphocytic response (Figure 3.20). However, this difference also did 
not reach statistical significance (p=0.698).  
 
Figure 3.20: Survival curve of patients categorised according to presence of Crohn-like 
lymphocytic response. 
 
 
 
 
Inconspicuous Crohn like response 
Conspicuous Crohn like response 
(p=0.698) 
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OTHER FEATURES 
We found that survival was also independent of other features including tumour growth 
appearance (exophytic or endophytic), tumour size, amount of mucin production and 
degree of necrosis.  
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3.10: TREATMENT 
All 298 patients included in the study had surgical resection of the cancer: hemicolectomy, 
anterior resection or abdominoperineal excision. However, this study had not looked at the 
resection margins of the cases nor studied recurrences and their clinical outcome. 
We were only able to document 145 patients who had completed various types of 
chemotherapy, nine of which had additional pelvic radiation. Majority of the patients (94 
out of 145 cases, 64.8%) had fluorouracil (5-FU) combined with leucovorin (folinic acid) in 
either the Mayo Clinic regimen or the De Gramont colon cancer chemotherapy regimen. 
The remaining other patients were on various chemotherapy: Folfox4 (oxaliplatin), Folfiri 
(leucovorin, fluorouracil, irinotecan), oral capacetabin or a combination of the 
chemotherapy drugs. 
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3.11: SUMMARY OF RESULTS 
Patients with mismatch repair defect CRCs were equally likely to be of either gender 
(p=0.497) with no difference in their age of presentation (p=0.148) as compared to the 
group with non MMR-d tumours. They did not present at an earlier stage (p=0.622) but 
were found to be significantly associated with either synchronous or metachronous 
carcinomas (p=0.032). 
Their tumours were found frequently at the right side (p<0.001), were larger (p=0. 002) and 
had an exophytic pattern of growth (p=0.007). 
Table 3.33 summarised the association of different clinical variables with mismatch repair 
status of the tumours.  
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Table 3.33: Clinical variables with mismatch repair status of tumours 
Clinical Category All  MMR status 
P 
value Odds ratio 
Parameters   patients 
MMR-d 
gp 
Non MMR-d 
gp    (95% CI) 
Gender Male 166 26 140 0.497 1.26 
  Female 132 17 115   (0.65-2.43) 
Age < 50 years 53 22 42 0.148 1.74 
  >50 years 245 32 213   (0.82-3.73) 
Family history With fly h/0 25 2 23 NA   
(n=160) Without fly h/o 135 15 120 
 
  
Staging Stage I-II 144 21 123 0.622 1.19 
  Stage III-IV 143 18 125   (0.60-2.33) 
Multiple tumours Single tumours 202 24 178 0.032 2.67 
  Multiple tumours 34 9 25   (1.12-6.41) 
Location Left side 207 17 190 <0.001 4.47 
  Right side 91 26 65    (2.28-8.76) 
Tumour growth  Exophytic 99 22 77 0.007 2.42 
  Endophytic 199 21 178   (1.26-4.67) 
Size of tumour Small (<5cm) 199 20 179 0.002 2.71 
  Large (>5cm) 99 23 76    (1.41-5.22) 
Survival in mths   31.2 31.4 31.0 0.615   
              
gp= group, fly= family, h/o= history of, ND= not done, mths= months. 
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Colorectal carcinomas with mismatch repair defect were more likely to be poorly 
differentiated tumours (p<0.001), produced more mucin (p=0.007) and had marked degree 
of necrosis (p=0.001) as compared with tumours with no such defect. They also had a non-
significant trend towards an expansive border (p=0.056) than an infiltrative border. 
However, they did not have any association with any lymphocytic response whether peri-
tumoural or Crohn like pattern. There was a significant inverse relation with p53 over- 
expression (p<0.001).  
Table 3.34 summarised the histopathological variables with MMR-d tumours and non-
MMR-d tumours. 
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Table 3.34: Histological variables with mismatch repair status of tumours 
Histological Category All  MMR status P value Odds ratio 
Parameters   patients MMR-d gp Non MMR-d gp    (95% CI) 
Histological grade Mod-well diff 246 25 221 <0.001 4.68 
  poorly diff 52 18 34   (2.31-9.47) 
Mucin production Minimal (< 10%) 228 26 202 0.007 2.49 
  Marked (>10%) 70 17 53   (1.26-4.93) 
Tumour advancing Expanding 161 29 132 0.056 0.52 
pattern Infiltrating 137 14 123   (0.262-1.026) 
Peritumoural Minimal  82 15 67 0.242 0.67 
lymphocytic resp Marked 216 28 188   (0.34-1.32) 
Crohn-like  Minimal 27 5 22 0.564 1.39 
lymphocytic resp Marked 271 38 233   (0.49-3.90) 
Degree of  Little 197 19 178 0.001 2.92 
necrosis Marked 101 24 77   (1.51-5.64) 
P53 staining Positive 151 11 140 <0.001 3.54 
  Negative 147 32 115    (1.71-7.34) 
gp= group, mod= moderate, diff= differentiated. 
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MULTIVARIATE ANALYSIS  
The different variables that showed statistical significance after univariate analysis namely 
anatomical location, tumour shape, size, histological grade, mucin production, necrosis and 
p53 expression; were selected for multivariate analysis to determine independent covariates 
that were associated with loss of mismatch repair protein. 
Four independent variables were significantly associated with loss of expression of one of 
the mismatch repair protein tested i.e. hMLH1, hMSH2 or hMSH6. 
Poor differentiation in tumour grade had the strongest association with loss of expression of 
the mismatch repair proteins (OR=5.917, 95% CI 2.174-16.129). Right sided location, 
exophytic growth and poor p53 expression were the three other independent predictors of 
loss of expression of hMLH1, hMSH2 or hMSH6 (Table 3.35). 
 
Table 3.35: Multivariate analysis of predictors of loss of mismatch repair proteins (using 
logistic regression model). 
Feature p value Odds Ratio 95% Confidence limits 
Poor differentiation <0.001 5.92 2.17-16.13 
Right sided 0.011 2.70  1.25-5.81 
Exophytic growth 0.014 2.56 1.21-5.44 
Poor p53 expression 0.046 2.27 1.01-5.09 
Large-size 0.061 2.11 0.97-4.59 
Marked necrosis 0.079 0.50 0.23-1.08 
Mucin production 0.069 3.66 0.90-14.86 
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CHAPTER 4: DISCUSSION 
4.1: COLORECTAL CARCINOMAS: DEMOGRAPHICS 
4.1.1: INCIDENCE 
In the year 2002, carcinomas of colon and rectum accounted for more than one million new 
cases, making up 9.4% of total cancer cases worldwide. However, there was a wide 
variation in incidence of colorectal cancer worldwide. The highest incidence rates of more 
than 40 per 100,000 were in North America, Australia/New Zealand, Western Europe and 
Japan while the incidence in Asia especially South East Asia was low at about 12.5 and 9.9 
per 100,000 for males and females respectively (Figure 4.1) (Parkin, Bray et al. 2005). 
In the less developed countries and regions, the age standardised rate (ASR) for colorectal 
carcinomas was as low as 2.3 per 100,000 for males in Middle Africa while in developed 
countries like Japan or Australia the ASR was as high as 49.3 per 100,000 for males.  
The vast epidemiological differences in these different regions and countries for colorectal 
carcinomas could be explained by different environmental exposures as well as different 
dietary habits, lifestyle and culture in these areas. It may also be related to the development 
of the country which translates to an association with a Westernised diet and lifestyle. 
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Figure 4.1: Age standardised incidence per 100,000 by gender and country for colorectal 
carcinomas. 
 (Source: Parkin, D. M., F. Bray, et al. (2005).  
 
 
 
In Malaysia the age standardised incidence rate (ASR) for colorectal carcinomas was 
actually higher than the rate reported for the South East Asian region. The overall ASR in 
Malaysia was 18.4 per 100,000 for the year 2006 (National_Cancer_Registry 2006). The 
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incidence rate was higher for Malaysian males (21.6 per 100,000) as compared to 
Malaysian females at 15.4 per 100,000. This can be partially explained by the rapid 
development Malaysia has enjoyed especially over the last two decades. With Western 
influences and a higher standard of living, people have slowly embraced a Westernised 
lifestyle and diet. This pattern of Western lifestyle includes smoking, alcohol and high meat 
consumption and fast food with little vegetable content; which have all been found to 
contribute or are associated to the development of colorectal cancer. 
 
4.1.2: RACIAL DISTRIBUTION 
In addition to various environmental influences, there may be racial differences between 
people exposed to the same environmental surroundings. People of different races inherit 
different sets of genes and have different dietary habits and cultural practices. 
Malaysia is a multi-racial country. The Malaysian population is predominantly made up of 
Malays (54.3%) followed by Chinese (25.1%), Indians (7.5%).  Other races make up 13.1% 
of the remaining population (Department_of_Statistics_Malaysia 2007).  
The Malaysian National Cancer Registry 2006 reported that, 52.4% patients with colorectal 
cancer nationwide were made up of Chinese, followed by Malay, 42.7% and Indian, 5%  
(National_Cancer_Registry 2006). The age standardised rates for colorectal carcinomas 
were 15.5 and 9.5 per 100,000 for Malay males and Malay females respectively in 
Malaysia.  This was higher among both Chinese males and Chinese females at 28.0 and 
21.4 per 100,000 respectively. The ASRs for Indians were almost similar to that of Malay 
patients: 12.4 and 11.3 per 100,000 for Indian males and Indian females respectively. 
 
153 
 
Chinese patients had a higher risk of developing colorectal carcinomas than Malays or 
Indians in Malaysia.  
Similar to that reported by the Malaysian National Cancer Registry 
(National_Cancer_Registry 2006) where Chinese were noted to have higher incidence of 
colorectal carcinomas, this study also found there was a predominance of Chinese patients 
with colorectal carcinomas: 46.6% of the patients studied were Chinese compared to 45.0% 
Malays and 6.3% Indians. This was significant when it was compared to the hospital 
admission for the period studied (p=0.001, 95%CI 1.568 to 5.679).  
The higher number of Chinese patients with colorectal carcinoma may be explained by 
their relatively urbanised lifestyle and westernised diet compared to Malays or Indians in 
the country. Chinese people settled in urbanised regions and lead a more modern 
Westernised type of lifestyle than other populations of Malaysia. They are concentrated in 
higher economic and developed cities in Malaysia. Their relative financial stability also 
allowed them to afford richer meat content in their daily diet. This pattern of distribution of 
colorectal carcinomas was also seen globally where a rising incidence of colorectal cancers 
has been reported in populations or countries undergoing rapid economic development and 
a Westernised diet and lifestyle. (Parkin, Bray et al. 2005). 
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4.1.3: AGE AND GENDER  
The incidence of colorectal carcinomas increased with age. Colorectal carcinomas are rare 
before the age of 40 years. The rise in colorectal cancer incidence per 100,000 population 
with age was seen all over the world, including in Malaysia. The Malaysian National 
Cancer Registry reported a sharp rise of colorectal carcinomas from the age of 50 years 
onwards (Figure 1.4, pg. 19). Males have a higher age-specific colon cancer incidence than 
females.  
The census population of Peninsular Malaysia in the year 2006 was 24.8 million people 
with a proportion of 50.6% males to  49.4% females giving a  male to female ratio of 1.02:1 
(Department_of_Statistics_Malaysia 2007). 
This study found more males than females with colorectal carcinomas with a male to 
female ratio of 1.26:1. In the group of Malay patients, the male to female ratio was 1.20:1 
and this male predominance was even more obvious among Non-Malays with a ratio of 
1.31:1. This was despite the fact that there were generally more females than males in the 
older age group in Malaysia (more than 65 years of age) (Figure 4.2). 
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Figure 4.2: Population pyramid by age and gender, Malaysia, 2006. 
Source: (National_Cancer_Registry 2006). 
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Patients with colorectal carcinomas presented at an older age. In this study the mean age of 
61.0 years and median age of 62.0 years at presentation was found in the older age group 
but was much younger than what was reported from the United States Surveillance, 
Epidemiology, and End Results (SEER) study (Thomas and Sobin 1995) of American 
patients with colorectal cancer. The median age of presentation for colorectal cancer in 
their report was 70 years of age. This was a much older age of presentation than that found 
in this study. The reasons for this discrepancy were not immediately apparent but it could 
be postulated that the United States is a more developed country with better socio-
economic status and better health facilities, thus giving rise to greater survival into old age 
who may suffer from colorectal carcinomas. This may lead to a higher median age of 
presentation for colorectal carcinomas  
 
4.1.4: ANATOMICAL LOCATION OF TUMOURS WITH RACE AND AGE 
The United States Surveillance, Epidemiology, and End Results (SEER) study [Appendix 
7] between the years of 1975 to 1994 showed that colorectal cancers mainly arise in the 
proximal colon (38.8%) and the remaining 61.2% divided almost equally in the distal colon 
(29.6%) and rectum (28.5%) (Troisi, Freedman et al. 1998). Since 1980s, there had been a 
trend showing increasing incidence of right sided colon cancers and a decreasing incidence 
of left sided colon cancers. This change may reflect the increasing use of flexible 
colonoscopy and faecal occult blood test screening as well as an increasing population of 
elderly people. The incidence of right sided colon cancers increased with the age of the 
patients especially in women (Troisi, Freedman et al. 1998). 
 
157 
 
During embryologic development the right colon arises from the midgut while the left 
colon arises from the hindgut. The right and left colons are exposed to different luminal 
contents of faecal matter that include free oxygen radicals and chemicals broken from food 
products that are potentially carcinogenic. The left colon as compared to the right colon 
maybe exposed to more carcinogens that are implicated in carcinogenesis such as 
heterocyclic amines (breakdown from cooked meat) and reactive oxygens. In addition, the 
right and left colons have different blood supplies. The right colon (proximal to the splenic 
flexure) is supplied by the superior mesenteric artery and the left colon by the inferior 
mesenteric artery. Meguid et al (Meguid, Slidell et al. 2008) proposed that the risks of 
developing cancer differed for the right and left sided cancers because of the different 
courses of embryologic development and the exposure to different luminal contents and 
different blood supplies of the right and left colon.  
The site of colon cancers reflects the differences in risk factors, gender and racial 
differences and the patient’s age. It had been noted that in low risk areas or countries such 
as the African countries; carcinomas localised to the right side while carcinomas of the 
distal colon were more frequently seen in the high risk countries such as Japan, Australia 
and the United States (Fenoglio-Preiser, Perzin et al. 1990). 
Similar to the epidemiology in United States, colorectal carcinomas in Malaysian patients 
had also been also noted to localise to the left side. Similarly in this study, the colorectal 
carcinomas were predominantly found on the left side of colon (69.5%).  
In this study, patients of all races showed similar predilection to the left side. However, the 
Surveillance, Epidemiology and End Results (SEER) program started in 1973 by the 
National Cancer Institute in the United States found that there were differences in 
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occurrences of colorectal carcinomas among the Caucasian and African-American patients 
in the United States when separately assessed by gender and anatomic location. In their 
study, the proximal colon was defined to include the caecum, ascending, transverse and 
descending colon while the distal colon started from the sigmoid and included the rectum. 
They found that the African-American males and females had higher rates of proximal 
colon carcinomas compared to Caucasian males and females. On the other hand Caucasian 
males demonstrated higher rates for distal colorectal carcinomas than the African-American 
males. No reason was apparent from the differences in race and gender to the location of 
the tumour (Nelsonn, Persky et al. 1999).  
However, our study did not reveal the differences as reported by SEER. Most of the 
tumours (69.5%) were on the left side. No ethnic group had any specific anatomical 
location of tumour.  70.1% of Chinese patients, 70.5% of Malay patients and 60.0% of 
Indians or other races had colorectal carcinomas on the left side of colon. 
In the United States Surveillance, Epidemiology, and End Results (SEER) (Thomas and 
Sobin 1995) for the years 1973 to 1987 the age of presentation for patients with right sided 
tumours also differed from those with left sided tumours. They reported that the median age 
of presentation for patients with colorectal carcinomas on the right side was older than the 
left side. Adenocarcinomas on the right side presented at median age of 72 years as 
compared to the left sided at 69 years. On the other hand, our study found the converse to 
be true. Patients with right sided tumours presented at a non-significantly earlier age than 
those with left sided tumours (mean of 59.2 years compared to 61.8 years, p=0.120). Some 
patients with tumours on the right side may be familial cases; which presented at an earlier 
age. The other reason for the difference in ages between this study in Malaysia and the 
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results reported from United States probably lie in the status of development of the 
countries. United States is a developed country where the population enjoy a better socio-
economic status, including better health facilities and hence a larger proportion of the 
population surviving into old age as compared to developing countries including Malaysia. 
This would have led to higher numbers of older surviving people in the United States who 
may go on to develop colorectal carcinomas.  
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4.2: MMR-d COLORECTAL CARCINOMAS  
Colorectal carcinomas arise through several pathways, one of which is defect in the 
mismatch repair gene. The genes for mismatch repair are hMLH1, hMSH2, hMSH6, 
hMSH3, hPMS1 and hPMS2. Microsatellite instability (MSI) can arise because of germline 
mutation of one of the alleles followed by somatic mutation or from methylation followed 
by inactivation of the promoter gene hMLH1. High levels of defective mutations in these 
genes can lead to colorectal carcinomas.  
 
4.2.1: IMMUNOHISTOCHEMICAL TESTING VS. PCR TESTING 
The main aim of this study was to determine the pattern of mismatch repair defects in 
colorectal carcinomas in Malaysian patients by studying unselected consecutive colorectal 
carcinomas and correlating to their clinicopathological features and survival. 
Immunohistochemistry (IHC) was used to evaluate the mismatch repair status of the 
tumours rather than using the polymerase chain reaction (PCR) and gel electrophoresis to 
examine the DNA sequences; as the latter method was an expensive and time consuming 
test which was not readily available in most laboratories in Malaysia. Previous studies 
(Dietmaier, Wallinger et al. 1997; Cawkwell, Gray et al. 1999; Dieumegard, Grandjouan et 
al. 2000; Stone, Robertson et al. 2001; Lindor, Burgart et al. 2002; Valentini, Armentano et 
al. 2006) had found the use of IHC to be a good alternative and highly specific to assess the 
status of mismatch repair in these tumours. Lindor et al (Lindor, Burgart et al. 2002) tested 
over 1000 colorectal cancers for DNA mismatch repair deficiency with both methods 
namely PCR and IHC detection for hMLH1 and hMSH2. Their study showed that IHC was 
92.3% sensitive and 100% specific for screening DNA mismatch repair defects. The 
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predictive value of IHC for microsatellite stable or low-level microsatellite instability 
(MSI-L) was 96.7% and the predictive value of abnormal IHC staining was 100% for a 
high frequency microsatellite instability (MSI-H) gene. IHC distinguished MSI-H from 
MSI-L and MSS but it did not distinguish MSI-L from MSS. However, an advantage IHC 
had over PCR testing was it was able to suggest which gene was defective. This was not 
possible with PCR testing for microsatellite stability. 
Another advantage of IHC over PCR testing was the cost. Debniak et al (Debniak, 
Kurzawski et al. 2000) estimated that immunohistochemistry cost less than a quarter of the 
price of MSI testing done with the PCR and gel electrophoresis method. IHC is easy to 
perform and requires minimal expertise. The technique is readily available in many 
laboratories, hence IHC for mismatch repair protein could be introduced and be potentially 
included as a routine test in the histopathology report for all colorectal carcinomas fairly 
easily. This would delineate the subset of patients who require further genetic testing and 
also possible screening of family members for carriers. As these patients have an increased 
risk for multiplicity of tumours (metachronous or synchronous cancers) they would also 
require closer and  longer term follow-up. It had also been found that tumours with 
microsatellite instability or defective mismatch repair genes respond differently to various 
chemotherapeutic agents including 5-fluorouracil and irinotecan (Ribic, Sargent et al. 2003; 
Carethers, Smith et al. 2004; Bertagnolli, Niedzwiecki et al. 2009; Jover, Zapater et al. 
2009). Hence the mismatch repair status of the tumour would help guide the type of 
chemotherapy given to this group of patients. 
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FALSE NEGATIVE STAINING 
False negative staining with any of the mismatch repair proteins could occur during the 
process of immunohistochemistry testing. Edmonston et al (Edmonston, Cuesta et al. 2000) 
suggested that weak staining was most probably associated with problems in fixation, 
especially when both hMLH1 and hMSH2 stains were affected. Formalin fixation of more 
than 24 hours had also been shown to result in a significantly decreased stain, especially for 
hMLH1 (Monzon, Kovatich et al. 1999).  
Others (Marcus, Madlensky et al. 1999) found no alteration of immunohistochemistry 
staining for hMLH1 and hMSH2 when they used archived unstained sialinated slides kept 
between 1 to 2 years of age compared to those that were freshly sectioned. Most surgical 
specimens received in our laboratory were processed between 24 to 48 hours of fixation. 
We did not encounter any problems with immunohistochemistry staining for other markers. 
Moreover, we used freshly prepared tissue sections in this study (less than 12 hours after 
sectioning) for immunohistochemistry staining to avoid any problems in loss of staining 
due to oxidation. Using these methods, we minimised the likelihood for errors/false 
negatives during the immunohistochemistry staining process.  
The monoclonal antibody hMLH1 was very sensitive to over-fixation of tissue and 
preparation differences practised in different institutes. In the process of 
immunohistochemistry staining done in this study; precautions were taken and procedures 
were manually carried out. Hence over-staining was not seen in any of our cases, even for 
hMLH1 stains. 
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4.2.2: INCIDENCE OF MISMATCH REPAIR DEFECT TUMOURS 
Of the 298 cases of colorectal carcinomas in our series, there were 43 cases (14.4%) with 
loss of one or more mismatch repair proteins. These results were comparable with those 
published previously in other countries, in which the proportion of colorectal carcinomas 
with mismatch repair defects ranged from 7 to 20% (Ionov, Peinado et al. 1993; 
Cunningham, Kim et al. 2001; Percesepe, Borghi et al. 2001; Chapusot, Martin et al. 2003; 
Wright and Stewart 2003; Jover, Paya et al. 2004; Lin, Lin et al. 2011).  
TYPE OF MMR PROTEIN LOSS 
Mismatch repair defects in colon cancers were commonly reported to be hMLH1, hMSH2 
or hMSH6 defects. hMSH2 defects usually resulted from germline mutations (Mangold, 
Pagenstecher et al. 2005) while hMLH1 could be due to germline or somatic 
hypermethylation of its promoter (Cunningham, Christensen et al. 1998; Thibodeau, French 
et al. 1998). Similarly, Asian investigators (Lin, Lin et al. 2011) found that the majority of 
their sporadic CRC tumours showed loss of hMLH1 protein expression followed by loss of 
hMSH2 protein. In sporadic colorectal carcinomas, the predominant loss was reported to be 
hMLH1 as a result of promoter methylation (Herman, Umar et al. 1998; Lin, Lin et al. 
2011) while hereditary non-polyposis colorectal cancers could arise from either hMLH1, 
hMSH2 germline mutations (Liu, Parsons et al. 1996; Peltomaki and Vasen 1997) or 
hMLH1 promoter region methylation (Wheeler, Loukola et al. 2000; Potocnik, Glavac et al. 
2001; Yamamoto, Min et al. 2002). Wu et al (Wu, Berends et al. 1999) reported that a small 
minority of HNPCC cases could be caused by defects in hPMS2 or hMSH6 that could have 
resulted from germline mutations. It was beneficial to distinguish familial from sporadic 
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colon cancers because management for the patients and their family members differed 
between the two groups. However, immunohistochemistry testing that helped delineate the 
group of tumours with mismatch repair defect did not differentiate somatic from germline 
mutation. Further testing that included BRAF mutation assays and test for methylation of 
hMLH1 could be done to distinguish sporadic colon cancer from familial CRC (Lynch 
syndrome). When the tumour was found to be hMLH1/hPMS2 defective, BRAF mutation 
analysis or test for methylation could be done (Sharma and Gulley 2010; Geiersbach and 
Samowitz 2011). BRAF mutation was found in nearly 91% of sporadic CRCs with MSI-H 
(Davies, Bignell et al. 2002) but not in CRCs of patients with Lynch syndrome (Ikenoue, 
Hikiba et al. 2003; French, Sargent et al. 2008). Methylation testing was an alternative test 
but was a more technically challenging test than BRAF mutation assay. hMLH1 
methylation was typically found in sporadic CRCs lacking hMLH1 expression and was 
only found in 1.6% of CRCS in patients with Lynch syndrome (Farina-Sarasqueta, van 
Lijnschoten et al. 2010).  
A large majority of MMR-d tumours in many published reports (Stone, Robertson et al. 
2001; Ward, Meagher et al. 2001; Lindor, Burgart et al. 2002; Chapusot, Martin et al. 2003; 
Valentini, Armentano et al. 2006) was due to loss of either hMLH1 or hMSH2 proteins.  
In this study, our predominant mismatch repair gene loss was hMLH1. Twenty eight out of 
43 cases or two thirds of the MMR-d CRCs were deficient for hMLH1, and 15 cases (or 
one third of the cases) showed either loss of hMSH2 or hMSH6 or both. One of the cases 
with hMLH1 was a HNPCC (case 11, Table 3.9) while another case (case 8, Table 3.9) was 
highly suspected of HNPCC. Her tumour had mismatch repair defect for hMSH2 and 
 
165 
 
hMSH6. The remaining cases with MMR-d tumours had no family history and were 
considered sporadic carcinomas. 
In humans, the hMSH2 gene is located on chromosome 2p21 which was initially identified 
as an area for the gene involved in hereditary non-polyposis colorectal cancer. The hMLH1 
gene is located on chromosome 3p21 to 3p23, an area which has also been identified as an 
important candidate region within large HNPCC families that were not linked to 2p21 to 
2p22 (Lindblom, Tannergard et al. 1993) .  
Our study found that the majority of the MMR-d tumours were defective for hMLH1 (28 
out of 43 MMR-d tumours, 65.1% or 9.4% of all colorectal cases) and to a much lesser 
extent hMSH2 or hMSH6. However, there was no case with loss of all three proteins 
namely hMLH1, hMSH2 and hMSH6. Similarly, previous studies (Kakar, Burgart et al. 
2003; Wright and Stewart 2003; Chai, Zeps et al. 2004) reported  the rate of loss of hMLH1 
in colorectal cancer to be between 8.0% and 18.6% while the rate of hMSH2 loss was 
between 1.0% and 2.1%.  
HETERODIMERS OF MMR GENES 
MMR proteins interacted in the form of heterodimers; commonly hMSH2 and hMSH6; and 
hMLH1 and hPMS2 (Kolodner and Marsischky 1999). Thus mutations of hMLH1 may 
entail concurrent loss of protein of hPMS2 and similarly hMSH2 with loss of hMSH6. This 
occurred through degeneration of the corresponding heterodimerizing protein partner (Wu, 
Berends et al. 1999; Young, Simms et al. 2001). In their study of 214 colorectal carcinomas 
examined for MMR protein expression (hMSH1, hMSH2, hMSH6 and PMS2) Rigau et al 
(Rigau, Sebbagh et al. 2003) found that there were only two combinations possible when 
there were loss of two proteins, namely hMLH1/hPMS2 and hMSH2/hMSH6. Other 
 
166 
 
studies found that besides hPMS2, hMLH1 could also form heterodimers with hMLH3 or 
hPMS1.  In their study of sporadic MSI-H tumours and HNPCC, Young et al (Young, 
Simms et al. 2001) found that all tumours lacking hMLH1 showed absence of hPMS2 as 
well. The close relationship between hMLH1 and hPMS2 had also been reported by Leung 
et al and Ma et al (Leung, Kim et al. 2000; Ma, Xia et al. 2000). This suggested that 
hPMS2 may be degraded in the absence of its binding partner, hMLH1.  
On the other hand, hMSH2 commonly formed heterodimers with both hMSH6 and hMSH3 
as well. Young et al reported that many tumours lacking hMSH2 were also not staining up 
for hMSH6 (Young, Simms et al. 2001).  
In this study, 7 out of 9 cases with loss of hMSH2 were defective for hMSH6 but none of 
the cases with loss of hMLH1 were found to be defective for hMSH2 or hMSH6. There 
was also no loss of all three proteins in any of the cases. hPMS2 was not tested in this 
study. The results of this study supported the proposal that hMSH2 could form 
heterodimers with hMSH6 thus forming loss of two proteins namely hMSH2/hMSH6 but 
hMLH1 lacked any such relationship with hMSH2 or hMSH6. 
 
4.2.3: DEMOGRAPHICS OF MMR-d TUMOURS 
4.2.3.1: AGE 
Although the diagnosis of colorectal cancer at a younger age was frequent in HNPCC, most 
studies found that sporadic mismatch repair defect tumours were seen in all ages. Most 
studies did not report any significant correlation between patients with mismatch repair 
defect tumours and patients with intact tumours with regards to their mean presenting age. 
In this study, patients with MMR-d tumours presented at a slightly younger age (mean age 
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=58.9 + 2.2 years) than the patients with non-MMR--d colorectal carcinomas (mean age = 
61.4 + 0.8 years), which was not statistically significant (p=0.292). The absence of 
mismatch repair protein in these patients was a sporadic event and thus the events leading 
to tumorigenesis would take more time than it would have if it were an inherited genetic 
defect like in HNPCC. Hence we would expect the age of presentation for these patients 
with MMR-d tumours to be as old as other cases of sporadic colorectal carcinomas without 
any loss of the mismatch repair protein. Hence, the results of our study were not 
unexpected. It was noted two cases of probable HNPCC (cases no. 8 and 11, Table 3.9) 
who both had MMR-d tumours presented in their mid forties. They were included into the 
group of MMR-d tumours and this might explain the slightly lowered age of presentation of 
the group with MMR-d tumours.  
However, there were a few studies (Messerini, Vitelli et al. 1997; Molaei, Mansoori et al. 
2010), which also found that patients with MMR-d tumours presented at an earlier age 
when compared to the patients with microsatellite stable tumours. Misserini et al studied 
sporadic mucinous and non-mucinous colorectal carcinomas and found that the mean age of 
patients with microsatellite instability was younger at 56.6 years of age when compared to 
their microsatellite stable cases with the mean age of 65.0 years. This was even more 
striking for the studies conducted by Molaei et al. They found the mean age of presentation 
for patients with mismatch repair defect was very much younger at 42.8 years as compared 
to 53.0 years for those with no mismatch repair protein defect. They reported that patients 
had an odds ratio of 5.95 (95% CI 2.69-13.18) of presenting at an age younger than 50 
years among tumours with mismatch repair defect (p<0.001). It was not certain whether 
they had excluded the cases with HNPCC. 
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Similarly there were a few studies looking at the characteristics of patients selected solely 
on the basis of early age of onset. These studies demonstrated that there was a trend 
towards a higher pathogenetic mutation detection rate when the patients were diagnosed at 
a younger age (Table 4.1). There was a higher percentage of cases with mismatch repair 
protein when the age of presentation was younger. Liu et al (Liu, Farrington et al. 1995) 
studied 31 cases of colorectal carcinoma presenting before 35 years of age who did not 
have any family history fulfilling the Amsterdam criteria II and found 58% of the patients’ 
tumours had microsatellite instability.  
 
Table 4.1 : Association between age at onset of colorectal cancer and  
 
mismatch repair gene mutations. 
   
Age 
range 
(years) 
No. of  index 
cases  
hMLH1 mutation 
carrier: 
hMSH2  mutation 
carrier: 
Published 
references 
   No. of cases          % No. of cases         %   
<30 50 7                              14 7                              14 
Farrington et al 
(Farrington, Lin-
Goerke et al. 1998) 
<40 12 1                              8.3 1                              8.3 
Syngal et al 
(Syngal, Fox et al. 
1999) 
<45 38 1                              2.6 2                               5.3 
Fornasarig et al 
(Fornasarig, Viel et 
al. 2000) 
     
 
 
The results of our study showed that the incidence rate of mismatch repair defects occurring 
in colorectal cancer decreased with age of presentation (Table 3.8). There was a higher 
number of cases of sporadic mismatch repair defect tumours in patients presenting at a 
younger age compared to older patients. MMR defect-associated colon cancers occurred 
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frequently in early-age onset patients with or without a family history of cancer. This 
suggested that genetic defects namely loss of mismatch repair protein would have occurred 
early in the multi-step process of tumorigenesis. 
 
4.2.3.2: RACE 
Although Chinese patients were the predominant racial group with colorectal carcinomas in 
our study, it was found that Malay patients had the highest proportion of colorectal 
carcinomas with mismatch repair defects. However there was no significant difference 
between the major ethnic races (Malays vs. Non- Malays (p=0.122) and Chinese vs. Non- 
Chinese (p=0.497) for colorectal carcinomas with mismatch repair defect.  
In one other study in Malaysia, Tan et al (Tan, Ng et al. 2007) studied Chinese and non-
Chinese patients and found no difference in the rates of MMR-d tumours and intact 
tumours between the racial groups.  
Similarly, most published reports suggested no differences between ethnic groups for 
patients with MMR-d tumours and microsatellite stable tumours. Two studies (Carethers, 
Smith et al. 2004; Hatch, Lightfoot et al. 2005)  looking at Caucasian and African-
American patients with colorectal carcinoma found no difference in frequencies in the rate 
of mismatch repair defects between the two racial groups. However, one report (Ashktorab, 
Smoot et al. 2003) found that African-American patients had a significantly higher 
frequency of MSI tumours than  Caucasian patients.  
Although the incidence rates of micro-satellite tumours did not differ for various racial 
groups in the same region in most reports, interestingly incidence rates of MSI-tumours had 
been noted to differ from country to country or region to region. Microsatellite instability 
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had been reported all over to occur in 7 to 20% of colon tumours (Ionov, Peinado et al. 
1993; Cunningham, Kim et al. 2001; Chapusot, Martin et al. 2003; Wright and Stewart 
2003). However studies done in Mediterranean region found a lower rate of 7 to 8% 
(Percesepe, Borghi et al. 2001; Jover, Paya et al. 2004). In a recent study in Taiwan the 
investigators (Lin, Lin et al. 2011) found only 6.4% of the CRC tumours to have high 
frequency MSI (MSI-H). This was a large scale sporadic CRC study done in an Asian 
population that included 1,173 sporadic CRC tumours. On the other hand, in Iran, the rate 
of MSI-tumours was almost double this figure: Molaei et al (Molaei, Mansoori et al. 2010) 
reported it to be as high as 14%.  
It had been proposed that dietary, toxic or other environmental factors could be causes of 
epigenetic disruption of hMLH1 (such as promoting hypermethylation of the gene) in a 
particular population. Red meat ingestion, higher frequency of using different cooking 
practices that increased intake of heterocyclic amines like frying, barbequing or boiling 
(Wu, Shibata et al. 2001), as well as high consumption of high-grade alcoholic beverages 
(Slattery, Anderson et al. 2001) were possible risk factors as these were frequently 
practised in countries with high MSI incidence rates.  
In their extensive review on mismatch repair genes and colorectal cancer, Mitchell et al 
(Mitchell, Farrington et al. 2002) found little ethnic or population variations from the 
available gene variant data. However, they cautioned a need for accurate and extensive 
population-based review of data before population differences in the spectrum and 
frequency of mismatch repair gene variants would become apparent. Perhaps the 
differences in incidence rates between different populations may be due to their different 
lifestyle as mentioned above and to a lesser extent the inherent genetic properties. 
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4.2.3.3: GENDER 
Although there was no significant difference of MMR-d tumours for gender or race, our 
study found a significant Malay predilection amongst the female patients for MMR-d 
tumours (p value =0.031). This was not seen among male patients in our study. It was 
interesting to note that Malay females instead of non-Malay females were significantly 
associated with MMR-d tumours. The reason for this race selection only occurring in 
females of this ethnic group (Malay) was not apparent in this study. Perhaps a more 
detailed analysis and comparison of the cultural and social habits of Malay females with 
other racial groups in the country could be undertaken in the future to explore this finding. 
On the other hand, we did not find any statistical difference for gender predilection for 
tumours with mismatch repair defect (p=0.497). Male and female patients were equally 
likely to develop MMR-d tumours. However, many other studies (Ionov, Peinado et al. 
1993; Thibodeau, French et al. 1998; Ward, Meagher et al. 2001; Wright and Stewart 2003; 
Chai, Zeps et al. 2004) found a strong association of tumours with mismatch repair gene 
defect for females. They found gender differences in the colorectal tumours with mismatch 
repair defects; with females more likely to develop colorectal cancers with mismatch repair 
defects. This had been directly attributed to the effects of oestrogens. The effect of 
oestrogens in females was studied by Slattery et al (Slattery, Potter et al. 2001) who showed 
that the risk of MSI-phenotype colon cancer was actually reduced by presence of 
oestrogens but increased when there was withdrawal of oestrogens. They found a reduction 
of risk of MMR-d in tumours when the women were pregnant or were on oral 
contraceptives. Similarly, use of hormone replacement therapy (HRT) resulted in a lowered 
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risk of MSI phenotype tumours but on the other hand former users of HRT had an elevated 
risk of MSI tumours after ceasing HRT. This was also noted in their earlier papers 
(Kampman, Potter et al. 1997). Oestrogenic exposure in women thus protected them from 
MSI tumours but oestrogen withdrawal in post-menopausal women increased the risk to 
this gene defect. It was found that women were more likely to have MSI phenotype CRC as 
they aged as compared to men. On the other hand, women at a younger age were less likely 
than younger men to have these tumours because of the presence of oestrogens.  
Breivik et al (Breivik, Lothe et al. 1997) proposed that oestrogens could inhibit the pathway 
to colon carcinoma involving the mismatch repair gene defect when they observed that 
younger women had a lowered prevalence of MSI colon cancers than older women. They 
noted as well as others (Gaglia, Atkin et al. 1995) that women with inherited colon cancer 
syndromes such as HNPCC had reduced risk (by approximately 50%) of developing 
colorectal adenomas as compared to their male relatives.  
The effects of oestrogens are linked to the oestrogen receptors in the colon. Issa et al (Issa, 
Ottaviano et al. 1994) showed that methylation associated inactivation of oestrogen 
receptors in the colon was associated with aging and that colon tumours arose from cells 
that had lost or reduced oestrogen receptors. Decreased circulating oestrogens will lead to 
reduced oestrogen receptors and this will be associated with microsatellite instability colon 
cancers. On the other hand, the presence of circulating oestrogen in premenopausal women 
or those on HRT or obese women reduced the risk of losing these oestrogen receptors and 
thus reduced the risk of colon tumours (Figure 4.3). 
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Figure 4.3: Oestrogens, oestrogen receptors and prevention of colon tumours  
Source: (Slattery, Potter et al. 2001) 
 
It was uncertain why or how oestrogen levels and oestrogen receptors were associated with 
MSI tumours. The roles of endogenous (reproductive status), exogenous (HRT) and 
metabolic (obesity-associated) oestrogens in preventing ER methylation and thus MMR 
genes were unclear. There had been several hypotheses about this. Slattery et al (Slattery, 
Potter et al. 2001) hypothesised that at least one major mismatch repair gene may be 
oestrogen responsive and thus loss of oestrogen could result in loss of DNA mismatch 
repair capacity. 
Whatever the possible explanations may be, the data observed in these studies (Issa, 
Ottaviano et al. 1994; Gaglia, Atkin et al. 1995; Breivik, Lothe et al. 1997; Kampman, 
Potter et al. 1997; Slattery, Potter et al. 2001) supported the finding that hormones play an 
important aetiological role in colon cancer via the MSI related pathway and that oestrogens 
prevented MSI tumours whether endogenous, exogenous or obesity associated.  
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The excess of microsatellite instability colon cancers in women were explained by the 
excess of these tumours at an older age when there was a reduction or withdrawal of 
oestrogens at the time when these women became post-menopausal. In fact, there were 
fewer MSI phenotype tumours in pre-menopausal young women than young men.  
 
4.2.4: FAMILY HISTORY  
Aside from genetic mutations seen in familial type of colon cancers, there was evidence 
that people with close relatives who had colorectal carcinomas had an increased risk of 
colon cancers. First-degree family members of patients (parent, sibling or child) with 
colorectal carcinomas without any evidence of the inherited cancer syndromes namely 
HNPCC or FAP had approximately twice the risk of getting colon cancers compared to 
those without a family history(Fuchs, Giovannucci et al. 1994). They were also more likely 
to develop the disease at a younger age than people without family history of colon cancers.  
Worldwide, about 15-20% of patients with colorectal cancers had a positive family history 
(Lynch and Smyrk 1996; Aaltonen, Salovaara et al. 1998).  
In this study, there were 25 patients out of 160 patients (15.6%) who gave positive family 
history of previous carcinomas in their immediate family members. This was consistent 
with what was found worldwide.  
However, there was no statistical difference between patients with and without family 
history in terms of the MMR staining status of their tumours (p=1.00). There were only two 
patients with MMR-d tumours out of 25 patients (8%) who had family members with 
malignancies as compared to 15 patients with MMR-d tumours out of 135 patients (11.1%) 
who had no family history. 
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One of the two patients with MMR-d tumours who had a family history of cancer (case no. 
11, Table 3.9) fulfilled the revised diagnostic criteria for HNPCC (Amsterdam Criteria II, 
Appendix I). Three relatives including the patient herself had colon carcinomas. Another 
fourth relative, her sibling (brother) suffered a non-HNPCC related carcinoma: gastric 
carcinoma. There were two generations involved: patient herself and siblings and their 
father. Furthermore, she presented with colon carcinoma at age of 46 years. Her tumour 
was found on the left side and showed loss of mismatch repair protein for hMLH1.  
The other patient (case no. 8, Table 3.9) was a suspected familial HNPCC who did not meet 
the full criteria for diagnosis of hereditary non-polylposis colorectal cancer by Amsterdam 
Criteria II. This patient and two other siblings had colon carcinomas. There was no history 
of two consecutive generations that were affected by any HNPCC-related carcinomas but 
she had presented at an early age of 45 years. This patient’s tumour was localised to right 
side and had MMR-d of hMLSH2 and hMSH6. The patient was unsure of the cause of 
death of her parents and could not say whether they had any malignancies in their lifetimes.  
One more patient (case no. 15) in the list of patients with family histories appeared to have 
fulfilled the criteria for HNPCC using the Amsterdam Criteria II. He had three first degree 
relatives suffering colon carcinomas: his two siblings and father. He presented at an early 
age of 38 years old. His tumour was localised to the right side. However, his tumour was 
found to be intact tumour with no mismatch repair defect by immunohistochemical 
methods. It would be beneficial in this case to counter check this by doing a molecular test 
of mismatch repair gene by PCR and gel electrophoresis methods. However, our laboratory 
did not run the molecular test and it was not outsourced elsewhere due to the cost it might 
incur. Another possibility was that it may be a true case of HNPCC microsatellite stable 
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tumour as it was known there was a small proportion of patients with HNPCC whose 
tumours were microsatellite stable. 
Hereditary non-polyposis colorectal carcinoma (HNPCC) or Lynch syndrome is an 
autosomal dominant disorder also associated with defects in mismatch repair genes leading 
to microsatellite instability. It accounts for 5% of all colon cancers in the Western 
population. Patients with this autosomal disorder may have colorectal carcinomas, 
endometrial carcinomas and cancers of the small intestine, ureter or renal pelvis. It is an 
early-onset inheritable malignancy and characterised by a few clinicopathological 
characteristics. HNPCC usually presents before 50 years of age. 
In the most recently revised diagnostic criteria used for hereditary non-polyposis colorectal 
carcinoma: the Amsterdam Criteria II, there must be at least three relatives with HNPCC-
associated cancer to diagnose HNPCC in a patient. This may include colorectal cancer, 
cancer of endometrium, small bowel, ureter or renal pelvis and at least two successive 
generations affected with at least one patient diagnosed before the age of 50 years and one 
of whom should be a first-degree relative of the other two. Familial adenomatous polyposis 
should be excluded and the tumours should be verified by histopathological examination 
(Vasen, Watson et al. 1999).  
HNPCC predominantly localizes to the right side and has a decreased risk of developing 
rectal cancer. It was found that rectal tumours had the lowest rate (1.2 to 4.7%) of loss of 
expression of mismatch repair proteins (Chapusot, Martin et al. 2003; Wright and Stewart 
2003). Of these MMR-d rectal cancers, only a small proportion (1/7) was from HNPCC 
patients (Wright and Stewart 2003).  
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There may be some adenomas present in HNPCC patients but they usually are not as 
numerous as those seen in familial adenomatous polyposis (FAP). Patients are frequently 
seen with development of multiple tumours (metachronous or synchronous) with an 
increased risk of developing extra-intestinal tumours. The colorectal carcinomas are usually 
poorer differentiated, with increased production of mucin associated with marked host 
lymphocytic infiltration in the form of peri-tumoural lymphocytic response or Crohn-like 
lymphocytic response. HNPCC is associated with improved survival compared to non-
HNPCC colorectal cancer.  
In many ways, the pathology of HNPCC tumours is similar with that of sporadic colorectal 
carcinomas with microsatellite instability. Some studies showed no distinction between 
familial and non-familial sporadic MSI carcinomas.  
In our study of the 43 patients with tumours showing MMR-protein defect, there were only 
2 patients with suspected or diagnosed HNPCC, by Amsterdam Criteria II. More than 95% 
of cases (41/43 patients) were not HNPCC but were found to have mismatch repair defect 
tumours. This supported the fact that MMR gene alterations associated colorectal 
carcinomas were not restricted to HNPCC or highly selected families with colorectal 
carcinomas but could also be found in sporadic colorectal carcinomas. 
From a total of 298 patients, only 160 patients (53.7%) could give a full family history and 
this was only about half the number of cases studied. Forty patients were lost to follow-up 
and another 98 patients had passed away. Attempts made to contact the relatives of these 
patients who had passed away for more information were futile. This was mostly due to 
change of address or contact. Some of the relatives whom we were able to contact could not 
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recall whether their elderly relatives who had passed away had any immediate family 
members with malignancies. 
In this present era, people migrate and readily move across long distance to look for work 
and settle down far away from their original hometown, breaking family ties and 
communication frequently. Families no longer live in same village or town but are spread 
across the globe. It is thus difficult to trace family trees and keep up with news of family 
members who have migrated off to distant places. Thus proper family history is getting 
difficult to obtain nowadays. Families also have become smaller in numbers and thus 
family history plays a less important role nowadays. 
In our study, 25 patients gave strong family history of malignancies in their immediate 
family members. Twelve of them or about half were with family history of colorectal 
carcinomas. Nine patients had two or more family members with malignancies, two of 
whom had MMR-d tumours. One of the patients had 3 siblings with malignancies of 
different sites including colorectal carcinoma (case no. 5, Table 3.9) while another two 
patients had 3 family members (each), all with gastrointestinal malignancies (cases nos. 11, 
15, Table 3.9). These two patients had very strong family history and the malignancies 
were similar to the patients. They were also very young (46 years old and 38 years old) 
when they presented with colorectal carcinomas. One of them (case no.11, Table 3.9) had 
hMLH1 defect. The number of patients whom we could get family history was small in our 
study and we could not prove any significant association of family history with mismatch 
repair defect tumours.  
However, some published reports found that patients with mismatch repair defect were 
more likely to have a positive family history (Lothe, Peltomaki et al. 1993; Thibodeau, 
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Bren et al. 1993; Molaei, Mansoori et al. 2010) than patients with microsatellite stable 
tumours. Moleai et al in Iran had found a positive independent association between patients 
with MMR-d tumours and a positive family history of malignancies. In Iran, there was a 
high familial trend of between 29.4 to 35.1% of patients with colorectal cancers 
(Mahdavinia, Bishehsari et al. 2005; Azadeh, Moghimi-Dehkordi et al. 2008). Moleai’s 
study showed 46.0% of patients with colorectal cancers had positive family history of 
cancers and almost half of these were with family history of colorectal carcinomas. This 
suggested a high familial inheritance of colorectal carcinomas in their country which was 
not seen in our study in Malaysia. They also found a correlation between a positive family 
history and mismatch repair defect tumours. However, they could not find a significant 
relationship between early onset of colon carcinomas (before age of 50) and positive family 
history.  
Many patients with colorectal carcinomas having family members with malignancies did 
not fulfil any of the familial syndromes (FAP, HNPCC or rarer syndromes) nor have any 
mutation defect noted in their tumours. This familial cluster of malignancies may be pure 
coincidental occurrence or due to other germline mutations.  
However, germline mutation was strongly suspected when there was high frequency of the 
same tumour or associated tumours (like endometrial and colorectal  cancers) in a family or 
when the age of presentation was early in onset and there were multiple tumours 
(metachronous or synchronous) in a patient. 
It was in fact noted by Campbell and Dunlop (Campbell, Spence et al. 1994; Dunlop, 
Farrington et al. 1997) that approximately 1% of the entire population had either two first-
degree relatives affected by colon cancers or one relative affected at or younger than 45 
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years of age. This suggested a genetic mutation causing or bringing about tumorigenesis of 
colon cancers.  
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4.3: CHARACTER OF TUMOUR   
4.3.1: MULTIPLE TUMOURS 
Multiple neoplasms can be synchronous or metachronous. Synchronous tumours occurred 
twice as frequently as metachronous tumours in patients with colon cancers (Parkash 1977; 
Lasser 1978). Hereditary colorectal carcinoma was characterised by the development of 
multiple primaries. The presence of multiple primaries was used as one of the criteria for 
the diagnosis of hereditary non-polyposis colorectal carcinomas in the Bethesda Criteria 
(Appendix 1).  
Synchronous tumours can be in the forms of adenomas and carcinomas. They are tumours 
occurring in a patient at different locations at the same time. Although synchronous 
neoplasms affected about 35.9% of the cases, some of these included adenomas (Slater, 
Aufses et al. 1990). Synchronous carcinomas were seen less frequently. Our study had 
included only synchronous and metachronous malignancies and excluded benign 
neoplasms like adenomas as explained in Chapter 3.4.1.  
A proportion of patients with colorectal carcinomas had more than one primary cancer in 
the colon at the time of diagnosis (Slater, Aufses et al. 1990; Fante, Roncucci et al. 1996). 
The incidence rate in various studies was said to be about 1.5 to 12% (Parkash 1977; Lasser 
1978; Langevin and Nivatvongs 1984; Slater, Aufses et al. 1990). Hemminki et al 
(Hemminki, Li et al. 2001) found that the relative risk was 2.2 for developing a second 
colorectal carcinoma in patients with synchronous carcinomas. 
Metachronous tumours are secondary neoplasms occurring more than 6 months apart from 
the index cancer which must not be a metastatic lesion of the primary carcinoma. 
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According to Kiefer et al (Kiefer, Thorson et al. 1986) metachronous tumours occurred in 
1.6% of patients with colon cancers.  
Our study confirmed what others found (Cawkwell, Gray et al. 1999; Gryfe, Kim et al. 
2000) that patients with MMR-d colorectal cancers were more prone to have multiple 
malignancies (synchronous or metachronous). Nine out of 34 patients (or 26.5%) who had 
multiple malignancies were with mismatch repair defect tumours as compared to 11.9% of 
patients with multiple malignancies who had non-MMR-d tumours (p=0.032). Patients with 
mismatch repair defect tumours had an odds ratio of 2.67 with a 95% confidence interval of 
1.12 to 6.41 of developing multiple malignancies (synchronous or metachronous). Other 
studies (Sengupta, Yiu et al. 1997; Brown, Finan et al. 1998; Pedroni, Tamassia et al. 1999; 
Dykes, Qui et al. 2003; Lawes, Pearson et al. 2005) also found that the incidence of 
mismatch defect in multiple cancers was significantly higher than in single cancers. 
Patients with multiple tumours had a higher chance of having mismatch repair defect 
tumours and conversely patients with mismatch repair defect tumours were more likely to 
develop multiple tumours. This would be expected. Patients with the mismatch repair 
defect would be more prone to having multiple malignancies as the other tissue (in the gut 
as well as extra-intestinal) would be likely to have this genetic defect (mismatch repair 
defect) and as a result more prone to developing malignancies. 
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4.3.2: ANATOMICAL LOCATION  
Most of the colorectal carcinomas were found in the left side of the colon. Sixty-nine point 
five percent of the cases were localised to the left side of colon in our study. On the other 
hand we showed a significant predilection of MMR-d colorectal carcinomas to the right 
side of the colon (p<0.001). Right sided tumours had an odds ratio of 4.47 with a 95% 
confidence interval of 2.28 to 8.76 of being mismatch repair deficient compared to left 
sided tumours. 
Our results were similar and comparable to many other published reports (Feeley, Fullard et 
al. 1999; Gafa, Maestri et al. 2000; Chapusot, Martin et al. 2003; Wright and Stewart 2003; 
Lim, Jeong et al. 2004; Hameed, Goldberg et al. 2006; Molaei, Mansoori et al. 2010). In 
most studies, there was a significant predilection of MMR-defective tumours to the right 
side although majority of all colorectal carcinomas were predominantly found on the left 
side of the colon.  
In one large series (Wright and Stewart 2003) it was found  that not only were the MMR-d 
tumours located more on the right side but that the proportion of MMR-d tumours 
increased progressively along the proximal colon and abruptly declined after the splenic 
flexure where the demarcation of right and left colon lies. The reason for this was not 
apparent. Wright et al (Wright and Stewart 2003) found that the incidence of MMR-d 
tumours on the right side increased from caecum (32%) to ascending to transverse colon 
(41%) and then rapidly decreased on the left side from splenic flexure, reaching the lowest 
in the rectum (4.7%). In addition, Chapusot et al (Chapusot, Martin et al. 2003) also found 
that right sided location was a clinically useful positive predictor of mismatch repair status 
expression. It had a positive predictive value of 33%, second only to poor differentiation. 
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The negative predictive value was 97%. The strong association of right sided tumours with 
mismatch repair defect makes us more likely to perform immunohistochemical stains on 
right sided tumours to detect these tumours. 
However, Wright (Wright and Stewart 2003) further found that hMSH2 defective tumours 
were similar to intact tumours in that they were more likely to be found on the left side. 
Wright et al and Kruschewski et al (Kruschewski, Noske et al. 2002)  found that the 
predominant proportion of MMR-d tumours that were localised to the right side were 
hMLH1 defective tumours. Wright found 83% of hMLH1 defective tumours were right 
sided.  
Our study did not find such an occurrence. We found instead that more hMSH2 or hMSH6 
defective tumour cases were at the right side rather than hMLH1 defective tumours. 
Although Wright et al and others (Kruschewski, Noske et al. 2002; Wright and Stewart 
2003) found that hMLH1 defective tumours were more likely than hMSH2 defective 
tumours to localise to the right side, other studies (Marcus, Madlensky et al. 1999) disputed 
these findings and found no difference to the type of mismatch repair protein defect in right 
and left colonic tumours. 
 
4.3.3: GROWTH APPEARANCE  
The appearance of colorectal carcinomas can be described as fungating or exophytic if their 
growth protrudes into the colonic lumen. The mass effect of tumour may cause obstruction 
to the luminal contents of the intestine. However, in the proximal colon, the contents may 
be fluid and can easily pass through the obstruction. Hence, the symptoms of obstruction 
are usually late in onset in the proximal tumours. 
 
185 
 
Colorectal carcinomas can also grow as ulcerative or endophytic lesions with intramural 
invasion. It may infiltrate the bowel wall and cause constrictive growth. If the tumour 
growth is annular it can cause obstruction to the contents of the intestine as well by 
circumferential constriction. It can infiltrate deeply into the bowel wall and cause bowel 
perforation and peritonitis. The ulceration is usually associated with raised, indurated and 
sometimes everted edges. 
Tumours at the caecum and the ascending colon are usually large and exophytic tumours 
while those in the transverse and descending colons are usually endophytic. Fungating 
tumours may have papillary surface configuration. In a small proportion (~10%) of tumours 
there is secretion of mucin by tumour cells and this gives a mucoid appearance to some 
exophytic tumours located at the proximal colon. 
Carcinomas in the distal colon on the other hand are more likely to be endophytic tumours. 
They can cause stenosis of the lumen and are called ‘napkin-ring tumours’. At other times 
they are also known as ‘string carcinomas’ because of the effect they cause, which is 
similar to a string tied tightly around the bowel wall. They can produce constriction at the 
site of the tumour and dilatation proximal to the obstruction.  
Most of the colorectal carcinomas (70.4%) in this study were of the endophytic type. 
However, a significant percentage (22.2%) of the cases of exophytic tumours had mismatch 
repair defect. This study showed that tumours with mismatch repair defect were 
significantly associated with an exophytic growth appearance (p=0.007). The odds ratio 
was 2.42 with a 95% confidence interval of 1.26 to 4.67. This was also similarly reported 
by others. Feeley et al (Feeley, Fullard et al. 1999) and Messerini et al (Messerini, Vitelli et 
al. 1997) studied the growth appearance of tumours found in MMR-d colon cancers. They 
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noted that there was a significant correlation between mismatch repair deficient tumours 
and exophytic growth. This may be also related to the association of mismatch repair 
deficient tumours to the right side of colon as right sided tumours were more likely to be 
exophytic growths. 
 
4.3.4: SIZE OF TUMOURS 
The size of the tumour was measured 3-dimensionally and the largest diameter was taken as 
the size of the tumour. Several studies (Feeley, Fullard et al. 1999; Gafa, Maestri et al. 
2000; Chapusot, Martin et al. 2003) showed similar findings that MMR-d tumours were 
significantly associated with larger tumours. Our study and others (Feeley, Fullard et al. 
1999) used the cut-off point of 5.0cm to differentiate large from small tumours while others 
used various sizes as their cut-off point: ranging from 4.0cm (16cm
2
) to more than 7.0cm in 
diameter. More than half of the MMR-d tumours in our study were larger than 5.0cm in 
diameter as compared to 29.8% of non-MMR-d tumours (p=0.002). MMR-d tumours had 
an odds ratio of 2.71 (with 95% confidence interval of 1.41 to 5.22) of being large in size. 
When the mean sizes of MMR-d tumours and intact tumours were compared; mismatch 
repair defect tumours were larger than non-MMR-d tumours by a mean difference of 1.0 
cm (p=0.009). All the studies, despite the different sizes used, also found significant 
association between mismatch repair defect and large tumours.  
Hence, MMR-d tumours were more likely to be larger tumours with an exophytic growth 
appearance. 
In our study, larger colorectal tumours (tumours larger than or equal to 5.0cm in diameter) 
were also significantly associated with marked necrosis (p<0.001). The odds ratio was 2.77 
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with 95% confidence interval of 1.67 to 4.59. This would be expected as larger tumours 
grew beyond their blood supply and thus suffered necrosis more frequently than smaller 
tumours would.  
 
4.4: HISTOLOGICAL FEATURES  
4.4.1: HISTOLOGICAL TYPE AND GRADE 
Forty-one point nine percent of mismatch repair defect tumours were poorly differentiated 
colorectal carcinomas as compared to 13.3% of MSS tumours (p<0.001). Patients with 
MMR-d colorectal carcinomas were more likely to be poorly differentiated tumours than 
those tumours with intact mismatch repair protein staining with an odds ratio of 4.68 (95% 
CI 2.31 to 9.47). This was similarly reported by many studies (Gafa, Maestri et al. 2000; 
Chapusot, Martin et al. 2003; Wright and Stewart 2003; Lim, Jeong et al. 2004; Hameed, 
Goldberg et al. 2006) when they compared mismatch repair defect tumours with intact 
tumours.  
Chapusot et al (Chapusot, Martin et al. 2003) not only found that tumours with 
microsatellite instability were significantly associated with poorer differentiation but poor 
differentiation was the most accurate predictor of lack of MMR expression with a positive 
predictive value of 50% and negative predictive value of 89%. By multivariate analysis, 
they also demonstrated that poor differentiation was a significant independent factor 
associated with loss of expression of hMLH1 and hMSH2 proteins with an odds ratio that 
was much higher than this current study (OR=8.33, 95% CI 1.63 to 40.32). 
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TYPE OF MMR DEFECT 
Shashidharan et al (Shashidharan, Smyrk et al. 1999) found that poorly differentiated 
colorectal cancers were significantly associated with hMSH2 defect and not hMLH1 defect. 
They found that 57% of hMSH2 defective tumours were poorly differentiated compared to 
26% of hMLH1 defective CRCs. We also found that a higher proportion of hMSH2 or 
hMSH6 defective tumours (46.7%) were poorly differentiated compared to hMLH1 
defective tumours (39.3%). Our number of cases was small and statistical evaluation 
unfortunately cannot be done. 
In contrast to these previous reports stated, Wright et al (Wright and Stewart 2003) found 
that poorly differentiated carcinomas were predominantly hMLH1 defective tumours rather 
than hMSH2 defective tumours.  
MEDULLARY CARCINOMAS 
Gafa et al (Gafa, Maestri et al. 2000) further noted that a large majority (85.7%) of 
medullary adenocarcinomas were microsatellite instability tumours. Their results showed 
20 out of 28 cases of poorly differentiated MSI-H tumours were mucinous or medullary 
carcinomas but only 8 cases were poorly differentiated adenocarcinomas. This suggested 
that the excess of poor differentiation among the MSI carcinomas was determined by the 
presence of medullary and mucinous carcinomas. Medullary tumours were found to be 
nearly always associated with microsatellite instability (Kim, Jen et al. 1994; Ruschoff, 
Dietmaier et al. 1997; Jass 1998; Gafa, Maestri et al. 2000).  
Medullary carcinomas are characterised by trabecular to sheet-like growth of tumour cells 
with abundant esoinophilic cytoplasm, vesicular nuclei and prominent nucleoli. They are 
generally not classified separately from ordinary adenocarcinomas but typed as poorly 
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differentiated or undifferentiated carcinomas. This study also did not attempt to distinguish 
medullary carcinomas from the poorly differentiated carcinomas but in a review of the 
slides, two undifferentiated tumours with features of medullary histology were noted in the 
study. These cases were actually found to be mismatch repair deficient as well, thus 
supporting the association between medullary carcinomas and mismatch repair deficient 
tumours as reported by other researchers. However, the numbers were small and no 
statistical evaluation was done in our study. 
 
4.4.2: MUCIN PRODUCTION 
In this study, there was a significant association between tumours with large amount of 
extracellular mucin and mismatch repair defect tumours (p=0.007). MMR-d tumours 
produced more mucin than non-MMR-d tumours. The odds ratio was 2.49 (95% CI 1.26 to 
4.93). 
Many reports (Kim, Jen et al. 1994; Risio, Reato et al. 1996; Messerini, Vitelli et al. 1997; 
Jass 1998; Gafa, Maestri et al. 2000; Ward, Meagher et al. 2001) also claimed that 
mucinous histology was the hallmark of MMR-defective carcinomas. In our study although 
a higher proportion of mucinous type carcinomas was observed in patients with MMR–d 
tumours: 11.6% of patients with MMR-d tumours as compared to 7.8% of patients with 
non-MMR-d tumours) but this was not statistically significant (p=0.379).  
Chapusot et al (Chapusot, Martin et al. 2003) demonstrated in a univariate analysis that 
MMR-defective tumours were shown to be significantly associated with a distinct pattern 
of extracellular mucin production (p=0.0001) but was not significant when adjusted for 
other factors on multivariate analysis. Messerini et al (Messerini, Vitelli et al. 1997) studied 
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mucinous sporadic tumours with non-mucinous sporadic tumours as controls and found that 
mucinous carcinomas showed microsatellite instability more frequently than the controls. 
In addition they noted this was more marked when the tumours had lost two or more 
microsatellite alterations. This association may be because mismatch repair defects or 
replication errors may directly influence mucus production both in sporadic and familial 
cases (HNPCC). Altered mismatch repair genes may be involved in mucin synthesis or 
degradation resulting in increased amount of mucin in these tumours compared to stable 
tumours. 
 
4.4.3: TUMOUR ADVANCING PATTERN 
In earlier studies, Jass et al (Jass, Love et al. 1987; Jass, Ajioka et al. 1996) found that the 
character of invasive growth pattern (expanding vs. infiltrating) played an important and 
independent influence upon survival. In their study of over 200 cases of colon cancer, Gafa 
et al (Gafa, Maestri et al. 2000) also found the pattern of growth was an independent 
prognostic factor for disease specific survival by multivariate analysis. They found that 
nearly 90% of patients with tumours that had  diffuse infiltration pattern died in the 
observation period of their study but less than a quarter (24.3%) of patients with expansive 
type of tumours died within the same period. 
Diffuse infiltration of tumour was associated with a poorer outcome than expansive type of 
growth pattern in a tumour. Tumours that diffusely infiltrated surrounding tissue with 
irregular invasive borders would ramify beyond the limits and thus were more prone to 
spreading freely and metastasising as compared to tumours with expansive border that was 
circumscribed and walled off easily by the surrounding lymphocytic response.  
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We found that patients with tumours with expansive borders had better survival (mean 
survival = 35.0 + 2.1 months) compared to patients with tumours with diffuse infiltrating 
borders (mean survival 26.8 + 2.1 months). The p-value was 0.014. 
There was also a non-significant trend towards an association between mismatch repair 
defect tumours and expansive borders. However, this was statistically not significant 
(p=0.056). Other published studies (Messerini, Vitelli et al. 1997; Gafa, Maestri et al. 2000; 
Wright and Stewart 2003; Valentini, Armentano et al. 2006) found that expansive type of 
tumour growth pattern was significantly associated with tumours defective for mismatch 
repair protein. Wright et al further added that both hMLH1 and hMSH2 defective tumours 
were equally as likely to be associated with an expansive type of border. They also found 
that the association was independent of the stage of presentation of the disease but added 
that an expansive-type border was less frequently seen with increasing stage of the tumour.  
 
4.4.4: LYMPHOCYTIC RESPONSE 
In response to the tumour neoantigens, lymphoid components may be produced which are 
intimately admixed with the tumour (Figure 4.4). These are largely CD3/CD8 co-
expressing cytotoxic T cells. They are also called tumour-infiltrating lymphocytes (TIL).  
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Figure 4.4: Colorectal carcinoma with tumour-infiltrating lymphocytes.  
A: Colorectal carcinoma with tumour-infiltrating lymphocytes (Haematoxylin and eosin stain, 
original magnification x 200).  
B: MMR-d colorectal carcinoma with tumour-infiltrating lymphocytes. Lymphocytes are present 
with brown nuclear staining (single arrow) within tumour cells with negative nuclear staining 
(double ended arrow) in a case of MMR-d tumour (IHC stain with hMLH1, original magnification x 
200). 
B 
A 
Tumour cells showing 
negative nuclear staining 
Tumour infiltrating 
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nuclear staining 
 
193 
 
In some studies, various methods were utilised to count these tumour-infiltrating 
lymphocytes (TILs), including evaluation of H&E stained slides or immunohistochemical 
staining methods with markers for T-lymphocytes, namely CD3 immunostained slides. In 
those studies five consecutive fields under 40x magnification views of H & E stained slides 
were examined microscopically to look for tumour-infiltrating lymphocytes. The number of 
lymphocytes present was counted. The mean number of TIL/HPF was calculated and was 
considered positive result if there were more than 2TIL/HPF (Greenson, Bonner et al. 2003; 
Greenson, S.C. et al. 2009).  
Instead of using routine H&E stained slides to study for TIL, Jass et al (Jass 2000) used the 
immunoperoxidase methods to stain for the lymphocytes. Jass et al (Jass 2000) and 
Alexander et al (Alexander, Watanabe et al. 2001) also used different values of cut-off as 
positive lymphocytic response namely 5 and 8 TIL per high power field respectively. 
Aside from tumour-infiltrating lymphocytes, other lymphocytic responses associated with 
tumours included peri-tumoural lymphocytic and Crohn-like lymphocytic responses. 
Our study looked into the peri-tumoural lymphocytic and Crohn-like lymphocytic 
responses but did not look into tumour-infiltrating lymphocytes. Neither peri-tumoural 
lymphocytic or Crohn-like lymphocytic response was associated with MMR-d tumours 
(p=0.242 and 0.564 respectively). 
Although our study did not show any relationship between the MMR-d tumours and the 
lymphocytic response (either the peri-tumoural or Crohn-like lymphocytic response) other 
workers (Chapusot, Martin et al. 2003; Greenson, Bonner et al. 2003; Wright and Stewart 
2003; Valentini, Armentano et al. 2006) showed that both peri-tumoural and Crohn-like 
lymphocytic responses were seen frequently in mismatch repair defect tumours. Peri-
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tumoural lymphocytic response was significantly more common in these tumours with 
MMR protein deficient, as was Crohn-like lymphocytic response.  
In addition, Wright’s group (Wright and Stewart 2003) found no difference between the 
two mismatch repair proteins. hMLH1 and hMSH2 deficient tumours were found equally 
as significant to be associated with a brisk lymphocytic response. Greenson et al (Greenson, 
Bonner et al. 2003) studied tumour infiltrating lymphocytes and showed that positive 
tumour-infiltrating lymphocytes were significantly associated with high microsatellite 
instability tumours. The positive predictor value in their study for the MSI-H status was 
30.1% and its negative predictor value was 98.6%. 
LYMPHOCYTIC RESPONSE AND SURVIVAL 
In our study, patients with tumours showing marked peri-tumoural lymphocytic response 
had longer mean survival (mean survival 32.0 + 1.8 months) than patients with minimal 
lymphocytic response (mean survival 27.7 + 3.1 months). Unfortunately this was not 
statistically significant (p=0.293) and we were not unable to demonstrate a significant 
association of patients with brisk lymphocytic response and a better survival. 
However, earlier studies by Graham et al (Graham and Appelman 1990) and Harrison et al 
(Harrison, Dean et al. 1995) showed that Crohn-like lymphoid response in colorectal 
cancers was an independent predictor of a good outcome in patients with colorectal cancers. 
Presence of Crohn-like lymphoid reaction in colon cancers was more frequently seen in 
cases with a lowered incidence of nodal metastases and a statistically significant increase in 
10-year survival. This response was evident of a favourable host response towards the 
tumour which attempts to limit the tumour and prevent it from spreading.  
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The significant association of mismatch repair tumours with marked lymphocytic response 
as reported in the forms of peri-tumoural lymphocytic, Crohn-like lymphocytic response or 
tumour-infiltrating lymphocytes demonstrated the increased host defence mechanisms in 
limiting these tumours. Therefore this explained why patients with MMR-d tumours 
showing a higher incidence of marked lymphocytic response were associated with a better 
outcome than patients with tumours which were microsatellite stable with less lymphocytic 
response.  
 
4.4.5: NECROSIS 
This study examined the amount of necrosis in colorectal cancer. We did not study the type 
of necrosis present (dirty necrosis). We found that MMR-d tumours were associated with 
more extensive necrosis. Tumours with marked necrosis were significantly more likely to 
have deficient mismatch repair protein staining by IHC (p=0.001). 
The reason for this can be explained by the association of marked necrosis with size of 
tumours, as previously stated. Larger sized tumours outgrew their blood supply and 
suffered extensive necrosis more often than smaller tumours. As larger tumours were more 
frequently seen in mismatch repair deficient tumours, thus there was also more necrosis 
seen in MMR-d tumours. 
The association between the degree of necrosis and MMR-d tumours may also suggest that 
MMR-d tumours were proliferating at a much faster rate compared to their blood supply. 
An alternative explanation may be that there were less angiogenesis initiated to support the 
tumour growth.  
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Most studies (Greenson, Bonner et al. 2003; Raut, Pawlik et al. 2004; Halvarsson, 
Anderson et al. 2008) specifically looked at dirty necrosis and not the amount of necrosis. 
Greenson et al (Greenson, Bonner et al. 2003) found that tumours with mismatch repair 
defect were significantly lacking dirty necrosis that was characteristic of colorectal 
carcinomas. Dirty necrosis consists of fragmented destruction of glands and cellular debris. 
Thus, it can be argued that poorly differentiated cancers and mucinous tumours having less 
gland formation would hence lack dirty necrosis. As tumours with microsatellite instability 
were more likely to be poorly differentiated, thus the lack of dirty necrosis in tumours with 
microsatellite instability may be due to their poorer differentiation. Halvarsson et al 
(Halvarsson, Anderson et al. 2008) in studying the clinicopathological features that identify 
mismatch repair defect tumours found that lack of dirty necrosis was associated with a 
relative risk of 7.5 for MMR-d tumours. Greenson et al demonstrated that a lack of dirty 
necrosis was an independent predictor of microsatellite instability, independent of tumour 
grade and mucin production. These findings together with other studies (Dolcetti, Viel et al. 
1999; Jass 2000) showed that there was a higher rate of cell death in MSI-H tumours than 
stable tumours, suggesting that the mechanism of cell death in these tumours was different 
from that in microsatellite stable tumours. These may help to explain the different response 
to chemotherapy in MSI tumours and stable tumours. Different chemotherapy would target 
at different mechanisms of cell death and help promote cell death thus shrinking the size of 
the tumour. 
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4.5: STAGING  
4.5.1: LYMPH NODES STATUS 
Lymph node metastases are common in colorectal carcinomas. The staging of colon 
carcinomas is dependent on the status of the nodes. It was thus imperative to dissect out all 
lymph nodes during the processing of the resected colectomy specimens as examination of 
all colectomy specimens should include a careful examination of peri-colic lymph nodes. A 
standard resection of a colectomy specimen for colon cancer should contain between 10 to 
25 lymph nodes (Petrias and Frankel 2009). Although this procedure of searching for 
lymph nodes is tedious and time consuming, but the yield of lymph nodes for examination 
to determine the presence or absence of lymph node metastases is very important. The 
status of the lymph nodes determines the prognosis of the patients.  
In the 287 patients with lymph nodes retrieval in this study, the mean number of nodes was 
8.8. This was lower than the recommended number of nodes (12) for proper assessment. 
The possibility of a lower yield of lymph nodes retrieval could be due to pre-operative 
pelvic radiation therapy in some of the cases (Sermier, Gervaz et al. 2006). Another reason 
was that fewer lymph nodes could be found for anterior resection of rectal carcinomas 
which were included in this study. 
It was unfortunate in our study that lymph nodes were not found in 11 other cases. The 
possible reasons for this unsatisfactory processing of colectomy specimens could be due to 
new change-over of medical officers in training in the Pathology department who routinely 
processed (grossed) the specimen. Another possibility could be from the surgical 
department where trainee surgeons may have missed removing lymph nodes together with 
the colectomy specimens. 
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4.5.2: STAGING AND MMR-d TUMOURS 
Some studies (Cunningham, Kim et al. 2001; Wright and Stewart 2003) found that patients 
with MMR-d colon cancers presented at a significantly earlier stage than intact tumours. 
Their studies found that although MMR-d tumours and intact tumours had similar levels of 
tumour invasion, MMR-d tumours were less likely to have lymph nodes involvement and 
metastases. Thus, MMR-d tumours were more likely to present at an earlier stage. This can 
also be explained by association of MMR-d tumours with peri-tumoural or Crohn-like 
lymphocytic response that may help limit the spread. Extramural vascular, lymphatic and 
perineural invasion were also less likely to be seen in MMR-d tumours but were frequently 
associated with microsatellite stable tumours. However, this study showed no statistical 
difference in patients with MMR-d tumours and patients with intact tumours when the 
staging of disease was compared (p=0.622). There was no difference in nodal metastases in 
these two groups (p=0.746). 
Some studies (Gryfe, Kim et al. 2000; Truninger, Menigatti et al. 2005) on the other hand 
showed that tumours with mismatch repair defect had a lowered frequency of nodal 
metastases and hence a better survival. Gryfe et al (Gryfe, Kim et al. 2000) found that there 
was a decreased likelihood of MMR-d tumours metastasising to regional lymph nodes with 
an odds ratio of 0.33 and 95% confidence of 0.21 to 0.53. Others (Cunningham, Kim et al. 
2001; Wright and Stewart 2003) reported that MMR-d tumours were more likely to present 
at an earlier stage and hence, by inference, less likely to be associated with nodal 
metastases.  
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Hemminki et al (Hemminki, Mecklin et al. 2000) found that presence of distant metastases 
at time of diagnosis was rare in MSI tumours. This was similarly seen in our study. Five 
point two percent of the patients with non-MMR-d tumours developed metastasis at 
presentation as compared to 2.6% of patients with MMR-d tumours in our study. The 
number of cases was small and it could not be statistically compared. 
Hemminki et al (Hemminki, Mecklin et al. 2000) found that patients in their study with 
MSI colon cancers were associated with excellent survival and had overall survival of 90% 
at 3 years as compared to patients with intact tumours at overall survival of 62%. Wright et 
al (Wright and Stewart 2003) also found that when they compared MMR-d tumours against 
their pattern of gene defect, hMSH-2-defective colon cancers more frequently presented at 
an earlier stage than hMLH1-defective tumours. Half of their hMSH2-defective tumours 
presented Stage I compared to less than a quarter of hMLH1-defective tumours. They found 
that hMSH2-defective tumours were more likely to be confined to bowel wall (T1-T2) as 
compared to hMLH1-defective tumours. However, a few reports including our study 
showed no significant difference in the staging between the types of gene defect in MMR 
defective tumours. We found 53.8% of MMR-d tumour cases as compared to a slightly 
lesser proportion (49.6%) of non-MMR-d tumours were in early stages (Stage I and II) and 
46.2% of MMR-d tumour cases as compared to slightly more (50.4%) non-MMR-d 
tumours in the later stages (Stage III & IV). There was hardly any difference in the 
proportion of cases found in each stages when we compared the mismatch repair defect 
status (p=0.622). 
Shashidharan et al (Shashidharan, Smyrk et al. 1999) did not find any difference in nodal 
involvement between colon cancers with mismatch repair gene mutations and sporadic 
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stable tumours but found instead that lymph node involvement was more frequently seen in 
hMSH2 defective tumours than hMLH1 defective tumours (p=0.03). hMLH1 defective 
tumours were reported to elicit more Crohn-like lymphocytic response. This may explain 
the absence of nodal involvement by tumour in hMLH1 defective tumours. In their study, 
there was suggestion that the association of tumour-free nodes with MMR-d tumours could 
be more due to hMLH1 and not hMSH2 defective tumours. 
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4.6: SURVIVAL 
Many studies have looked at patients with colorectal carcinomas to determine the possible 
prognostic factors for survival. The results had been conflicting and this was because of the 
different pathogenetic mechanisms of tumorigenesis involved in sporadic and familial types 
of colorectal carcinomas. Different genetic alterations such as chromosomal instability 
either due to inactivation of tumour suppressor gene p53 or deletion of the mismatch repair 
genes resulted in different clinical pathological features and types of neoplasia.  
 
4.6.1: ANATOMICAL LOCATION 
Localisation of tumour is an important factor for survival; some studies predicted that the 
right side had a worse prognosis compared to the left side. The reason may be due to a 
more delayed time to detection of the tumour and presentation if it was localised at the right 
side.  
In our study there was no difference in survivals of patients with regards to the location of 
the tumours. Although we found that the survival of patients with left sided tumours was 
slightly better (mean survival = 30.6+1.80 months) as compared to patients with right sided 
tumours (mean survival = 32.2+3.00 months) it was not statistically significant (p=0.724). 
On the other hand, Meguid et al (Meguid, Slidell et al. 2008) demonstrated that right sided 
tumours had a worse prognosis than left sided tumours when they did not take into account 
the MMR status of the tumours. The reason for this was unclear but possible explanations 
included differences in time to detection of tumour, differences in embryologic origin as 
well as exposure to different faecal content. Tumours on the right side of the colon, because 
of their proximal location, manifested themselves later and detection of tumours in these 
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patients was frequently delayed. This may mean the tumours would have progressed to a 
later stage at time of diagnosis and thus had a worse prognosis. 
However, tumours with mismatch repair defects were noted to be more on the right side 
with better prognosis and survival (Ionov, Peinado et al. 1993; Lothe, Peltomaki et al. 
1993; Thibodeau, Bren et al. 1993; Kim, Jen et al. 1994) for various reasons including a 
more prominent lymphocytic response and less likelihood of metastasis to lymph nodes as 
discussed previously. This may be the reason for our results obtained with a slightly better 
survival for patients with right sided tumours that included many cases of mismatch repair 
defect tumours. 
 
4.6.2: MMR-d TUMOURS 
The mean period of survival of patients with MMR-d tumours (31.4 months) was almost 
the same as that of patients with intact tumours (31.0 months, p=0.615). However, when 
colon cancers were compared after separately removing rectal tumours from the group, the 
mean survival of patients with mismatch repair defect by IHC was better (32.7 months) 
compared to those with normal protein pattern (29.1 months). Nonetheless, this was not 
statistically significant either (p=0.377).  There were various possible reasons to explain the 
difference of our findings compared to other previous published reports (Ionov, Peinado et 
al. 1993; Lothe, Peltomaki et al. 1993; Thibodeau, Bren et al. 1993; Kim, Jen et al. 1994; 
Gafa, Maestri et al. 2000; Gryfe, Kim et al. 2000; Lim, Jeong et al. 2004) that found 
patients with mismatch repair defect tumours demonstrated better disease specific survival 
than patients with microsatellite stable tumours. Many of our patients were not subjected to 
close follow-up and rigorous chemotherapy after diagnosis or surgery. In the data collection 
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we found many patients were lost to follow-up after the major surgery.  Some of these 
patients may have resorted to traditional therapy at home while others accepted the fate of a 
terminal illness and seek no further treatment elsewhere. However, these were postulations 
and further in-depth study need to be carried out in future to look into the real possible 
reasons for the difference.  
Gafa et al (Gafa, Maestri et al. 2000) found that patients with MSI-H tumours had a 
significant survival advantage even when only patients with tumours localised to the right 
side were included in their analysis. The prognostic significance became more evident in 
the subgroup of those with poorly differentiated carcinomas. In their report, the 5-year 
survival rate of patients with MSI-H poorly differentiated tumours was 79.2% compared to 
patients with MSI-L/MSS poorly differentiated tumours of 36.7% (p<0.05). Lim et al (Lim, 
Jeong et al. 2004) reported that the overall 5-year survival for patients with MSI was more 
than 90% but those with microsatellite stable tumours was less than 60% (p<0.05). This 
improved prognosis and longer survival were seen together with a lower number of distant 
metastases in these tumours. Other investigators (Hutchins, Southward et al. 2011; 
Sinicrope, Foster et al. 2011) also found these patients with MMR defective colorectal 
carcinomas had significantly reduced rates of tumour recurrences as compared to those 
without the defect. 
Improved prognosis and better survival in sporadic MSI tumours may be due to the up-
regulated immune response as demarcated by prominent peri-tumoural and Crohn-like 
lymphocytic responses or presence of tumour-infiltrating lymphocytes. Alternatively, it 
may be due to the high mutation rate of defective DNA mismatch repair genes that did not 
allow time for emergence of the genes contributing to tumour metastases. All these would 
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have prevented emergence of metastatic deposits and restricted growth of the tumour with a 
final better outcome and prolonged survival. 
On the other hand, similar to our study, a few other studies (Feeley, Fullard et al. 1999; 
Hameed, Goldberg et al. 2006) found no significant difference in survival between MMR-d 
tumours and intact tumours. Possible reasons postulated may be that MMR-d tumours 
being at a proximal site may have similar behavioural features as the sporadic tumours with 
intact MMR pattern that were associated with a poorer outcome.  
 
4.6.3: TUMOUR ADVANCING PATTERN 
Tumours which infiltrated in an indistinctive manner splaying the muscular layer would 
spread further and faster compared to tumours with an expanding or circumscribed border 
that grew in a pushing manner. Hence the survival and outcome would be poorer for 
patients whose tumours display an infiltrating pattern.  
Our study found there was a significant difference between the survival rates of patients 
with different tumour advancing patterns.  Patients who had tumours with a diffuse 
infiltrating pattern of growth had a significantly poorer survival. Patients with tumours with 
expanding borders survived longer (mean survival = 35.0 + 2.1 months) compared to 
patients with diffusely infiltrating borders (mean survival = 26.8 + 2.1 months). The 
probability value was 0.014. 
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This was similarly reported by Gafa et al (Gafa, Maestri et al. 2000) where they found 
nearly 90% of patients with tumours having a diffuse infiltrating pattern of growth died of 
the disease whereas only less than a quarter (about 24%) of patients who had tumours with 
an expanding growth pattern died of the disease in the same period (p<0.0001). They also 
reported that extramural vein invasion was a strong predictor of adverse outcome whereas 
intense lymphocytic response was associated with a better outcome. 
 
 
 
206 
 
4.7: P53 POSITIVE COLORECTAL CARCINOMAS 
4.7.1: INTRODUCTION: P53  
Development of colorectal cancers is driven by loss of genomic stability from the 
acquisition of multiple tumour associated mutations. One of the more common forms of 
genomic instability in colorectal cancer is chromosomal instability. This can result from 
loss of wild-type copy of a tumour suppressor gene such as p53 or APC gene.  
P53 is a tumour suppressor gene. It stops neoplastic transformation by various ways. It 
activates temporary cell cycle rest (quiescence) or induces permanent cell cycle rest 
(senescence). Lastly, it also triggers programmed cell death (apoptosis). Damage to 
integrity of DNA or any form of stress can trigger off p53 response pathways. P53 acts to 
help maintain the integrity of the DNA. P53 thus has been rightly called the guardian of the 
genome. The wild-type p53 protein usually resides in the cell nucleus and has a short life-
time. It is present in low quantities and cannot be detected by routine 
immunohistochemistry.  
When there is homozygous loss of p53, DNA damage goes unrepaired and mutations 
become fixed and passed on to dividing cells. The cells then transform into malignant 
tumour. Both p53 alleles have to be inactivated, usually by a combination of missense 
mutations that inactivate the activity of p53 and a 17p chromosomal deletion that eliminates 
the second allele.  
The majority of mutations in the p53 gene will lead to loss of the wild-type phenotype of 
p53 due to conformational changes as well as 17p allelic loss. This will result in increase in 
half-life of p53 and ensuing nuclear accumulation.  
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4.7.2: P53 AND MMR-d COLORECTAL CARCINOMAS 
Our study together with other publications (Edmonston, Cuesta et al. 2000; Gafa, Maestri et 
al. 2000) found that there was significant inverse correlation between MMR-d protein and 
p53 over-expression. Our study showed 74.4% of mismatch repair defect tumours did not 
stain for p53. Conversely, 92.7% of tumours with p53 over-expression were found to be 
non-MMR-d tumours. This was statistically significant (p<0.001). The odds ratio was 3.54 
with 95% confidence interval of 1.71 to 7.34.  
Sinicrope et al (Sinicrope, Rego et al. 2006) furthermore found that MSI-H tumours were 
more likely to have negative expression for p53 as compared to MSS/MSI-L tumours 
(p<0.001). MSI and alterations in p53 protein expression seemed to be mutually exclusive.  
All these findings supported the suggestion that there are two different pathways of 
colorectal carcinogenesis (Perucho 1996). The two alternative genetic pathways described 
in colorectal carcinogenesis are the APC gene pathway and the MMR gene inactivation 
pathway. One of the pathways, the APC pathway starts with a defective APC protein which 
is unable to promote proteolytic degradation of b-catenin thus leading to accumulation of b-
catenin (Munemitsu, Albert et al. 1995). The over-expression of b-catenin results in 
accumulation of p53. This was possibly due to interference with its proteolytic degradation 
(Damalas, Ben-Ze've et al. 1999). This pathway thus results in accumulation or over-
expression of tumour suppressor gene such as p53 and accounts for the majority 
(approximately 80%) of sporadic colorectal carcinomas. These tumours do not express 
microsatellite instability but instead show chromosomal instability reflected by losses of 
heterozygosity especially at the loci of the APC gene, chromosomal 17q and 18q. These 
tumours would exhibit chromosomal instability and aneuploidy. Additionally, mutations in 
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the APC gene and activation of other oncogenes such as k-ras had been described  (Becker, 
Ruschoff et al. 1999).  
 The other pathway for colorectal carcinogenesis is the inactivation of MMR genes and this 
pathway accounts for 15% of all colorectal carcinomas. In these tumours, there is 
inactivation of both alleles of a MMR gene with possible secondary mutations in genes for 
growth control and apoptosis (TGFβRII, IGFR, BAX). In such tumours, there may be 
germline mutations of hMSH2 or hMLH1 with subsequent somatic mutation of the second 
allele. This would lead to loss of protein expression and may be detected by 
immunohistochemical staining. In some sporadic cases, inactivation results from 
hypermethylation of hMLH1-promoter with loss of immunohistochemical staining. All 
these tumours were said to be mismatch repair defect tumours which were typically p53 
negative. There was thus strong correlation of microsatellite stable tumours that have no 
MMR gene inactivation but probable APC gene inactivation with p53 accumulation. 
 
4.7.3: P53 AND ANATOMICAL LOCATION OF TUMOURS 
P53 positive tumours were found to be significantly localised to the left side of colon, in 
contrast to MMR-d tumours which localised to the right side. We found 78.8% of p53 
positive tumours were left sided as compared to the right side (p<0.001). These findings 
were also noted by others (Gervaz, Bouzourene et al. 2001). This may be related to 
prolonged faecal exposure time in the distal colon where stool collection before defecation 
occurred; resulting in left sided tumours with higher incidence of p53 positive tumours. The 
prolonged contact with exogenous carcinogens could induce point mutations of p53 (Jones, 
Buckley et al. 1991). It had been found that different carcinogens present in our diet could 
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be linked to the higher incidence of nuclear accumulation of p53 (Ishioka, Suzuki et al. 
1992; Freedman, Michalek et al. 1996). This also explained the predilection of p53 positive 
tumours to the left side considering the left colon has a longer faecal exposure time to 
different types of carcinogens.  
 
4.7.4: P53 AND SURVIVAL 
The correlation of p53 mutations in colorectal carcinomas with patient survival had been 
debated. In some reports, p53 protein expression was correlated with poorer survival 
(Leahy, Salman et al. 1996; Manne, Myers et al. 1997; Gervaz, Bouzourene et al. 2001) 
while others did not find this to be the case. Manne et al (Manne, Weiss et al. 1998) noted 
that nuclear accumulation of p53 was correlated to poorer survival in white patients with 
adenocarcinomas of the proximal colon but not in African-Americans. When the results of 
the two major ethnic races were grouped together they found no differences in survival. 
These findings reflect differences in the type of mutation of the p53 gene. Goh et al (Goh, 
Yao et al. 1995) reported that patients with point mutations in conserved regions of the p53 
gene were associated with a more aggressive tumour and thus had a significantly poorer 
prognosis than those with base changes outside these areas. These point mutations were 
more related to distant organ metastases and lymphatic dissemination.  
Our study did not find any difference in survival between patients with p53 positive 
tumours and p53 negative tumours. The mean survival of patients with p53 positive and 
p53 negative tumours were almost similar (p=0.741). However, when the patients were 
stratified without rectal tumours, there was a poorer survival if patients had tumours with 
p53 over-expression. The mean survival was 27.7 months as compared to 30.8 months for 
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patients with negative p53 over-expression. The probability value was not significant 
(p=0.495). 
Locally, Goh et al (Goh, Ong et al. 2004) in Malaysia studied p53 staining in 116 colorectal 
carcinomas and did not find any difference in survival between  patients with p53 positive 
and p53 negative tumours. Their study (Goh, Ong et al. 2004) together with that of Manne 
et al (Manne, Weiss et al. 1998) also did not demonstrate evidence of  any difference in 
survival between tumours with and without p53 abnormalities when the studies included 
different races in a multi-ethnic population of people.  
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4.8: MANAGEMENT OF COLORECTAL CARCINOMAS 
4.8.1: SURGERY 
Definitive surgery is the main modality of treatment in most patients with or without 
adjuvant chemotherapy or radiotherapy. The aim of surgery is mainly curative to remove 
the tumours but to preserve as much normal bowel, bladder and sexual function as possible. 
For patients in early stages of cancer, curative surgery is possible and may involve only 
local excision but for others in the advanced stages cure may not be possible even with 
wide excision.  
Thus major surgery may be associated with significant mortality and morbidity especially 
for elderly patients with advanced or metastatic diseases who may be unfit for surgery. For 
patients in advanced stages of cancer, surgery may not be curative but to relieve local 
symptoms like obstruction or bleeding. 
A total surgical excision should adequately remove the tumour with clear margins and 
reduce local recurrences. This hence improves the survival of the patient. 
Surgical treatment of colorectal carcinoma depends on the location of the tumour and 
includes hemicolectomy, anterior resection, and abdominoperineal excision. Total 
mesorectal excision for rectal cancers has also been performed with varying results. 
In any form of surgery, clearance of the circumferential resection margins (CRM) free of 
tumours is a very important prognostic factor that can be manipulated by surgical treatment. 
Other prognostic factors such as nodal involvement, differentiation of tumour, or vascular 
or lymphatic involvement undoubtedly play major roles in determining the survival of the 
patient but cannot be altered by treatment.  
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4.8.2: ADJUVANT CHEMOTHERAPY 
The results of reported studies had been inconsistent on the response of patients with 
mismatch repair deficient tumours to chemotherapy. One published study (Rosty, Chazal et 
al. 2001) showed that treatment with 5-fluorouracil (5-FU) patients with metastatic disease 
did not show any difference in response between patients with MSI tumours and patients 
with MSS tumours. On the other hand, another larger series (Liang, Huang et al. 2002) 
found that MSI status and administration of chemotherapy were independent favourable 
prognostic parameters and suggested that this was due to increased chemo-sensitivity of 
MSI tumours. 
Hemminki et al (Hemminki, Mecklin et al. 2000) found that patients with MSI colorectal 
cancers who were treated with the same adjuvant 5-fluorouracil based chemotherapy which 
was the standard treatment for Stage III colon cancers performed significantly better when 
compared with patients with microsatellite stable tumours. These results suggested that 
patients with MSI tumours were potentially curable despite loco-regional lymph node 
metastases. It also supported the hypothesis that MSI tumours were more sensitive to 5-FU. 
However, several other studies, (Aebi, Fink et al. 1997; Fink, Aebi et al. 1998; Carethers, 
Smith et al. 2004) suggested that there was association between hMLH1/hMSH2 deficiency 
in cell lines and resistance to chemotherapeutic agents. These studies found that mismatch 
repair deficient cells were resistant to various cytotoxic drugs including 5-fluorouracil. 
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4.8.3: NEW TREATMENT AND TRIALS 
Studies by Ruschoff (Ruschoff, Wallinger et al. 1998) and Yamamoto (Yamamoto, Itoh et 
al. 1999) demonstrated a reduction of proportion of hMLH1 or hMSH2 deficient cell lines 
exhibiting microsatellite instability when treated with nonsteroidal antiinflammatory drugs 
(NSAIDs). This had led to new drug trials to change the phenotypic manifestation of this 
mismatch repair deficiency and hence hopefully alter the course of cancers. Steinbach et al 
(Steinbach, Lynch et al. 2000) found that there was an actual reduction in the number of 
adenomas in patients with colorectal cancers when treated with NSAIDs. This may reduce 
the recurrences of tumours in these patients with colorectal carcinomas.   
As the number of cases studied in this study was small and the types of chemotherapeutic 
agents used namely: fluorouracil (5-FU) combined with leucovorin (folinic acid), Folfox 
(oxaliplatin) or Folfiri; were varied it was difficult to obtain a statistical evaluation of 
patients for each type of treatment received. 
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4.9: LIMITATIONS OF STUDY 
In our current investigation the sample of about 300 patients collected retrospectively was 
not large. A significantly larger cohort may improve the results of the study statistically. 
However, we encountered difficulty when we tried to expand the study retrospectively for a 
longer time period. A greater percentage of clinical notes were non-retrievable and many 
patients were lost to follow-up. Over the years, the contact of patients or relatives of 
deceased patients were lost or changed and this made our collection of data very difficult or 
impossible. 
We realised that our investigation was limited as it was not an epidemiological study. We 
have concentrated on looking at a sample of patients who had been operated in our local 
hospital for a period of time and the data collected was mostly from clinical notes and 
interviews from patients or next of kin. The results thus may not have represented the 
Malaysian population or subpopulation. We instead had placed emphasis on 
histopathological methods carried out to determine the mismatch repair defects by 
immunohistochemical tests and compared these with the clinical data obtained. 
We were aware that the clinical follow-up was for a short interval with a mean follow-up of 
18.1 months. Accurate prognostic assessment was not possible. It would be more ideal if 
the duration of follow-up was for a longer duration. However, we were not able to carry 
this study for a longer time period as time of study and available finances were limited. 
Immunohistochemical testing was used to detect the protein products of the mismatch 
repair genes and p53 gene in this study. However, we had not validated the group of 
patients with abnormal immune-staining with gene sequencing for p53 or molecular testing 
(PCR) for mismatch repair genes. Our laboratory did not have the facility for the molecular 
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testing or genetic testing and our limited financial resources had made it impossible to 
outsource the tests.  
Immunohistochemistry testing for mismatch repair gene protein is robust and gave a high 
specificity of 100% as reported by most investigators and over 90 to 95% for sensitivity. In 
some of these false negative cases non-functional mismatch repair protein may retain their 
antigenicity and appeared as non mismatch repair defect tumours when they were actually 
not. These cases could be detected by molecular testing using the PCR method.  
We used immunohistochemical methods to check for nuclear accumulation of p53 protein 
when there was presence of p53 mutation. However, immunoreactivity for p53 protein did 
not always indicate p53 mutations. Dysregulation of wild-type p53 protein may cause 
nuclear accumulation of the protein and resulted in a false positive test despite absence of 
mutation. In addition, not all cases of p53 mutations resulted in protein accumulation. 
Nonetheless, there was strong positive correlation of immunoreactivity and p53 mutations 
(Cordon-Cardo, Dalbagni et al. 1994) and hence the test could be used with limitations. 
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CHAPTER 5  
CONCLUSION AND FUTURE DIRECTIONS 
Colorectal carcinomas arise from the mutator and suppressor pathways that include 
inactivation of mismatch repair genes namely hMLH1, hMSH2, hMSH6, hPMS1 and 
hPMS2 and inactivation of p53, the tumour suppressor gene. 
Forty-three cases or 14.4% of 298 patients with colorectal carcinoma studied showed loss 
of one or more mismatch repair gene. MMR-d tumours were mostly due to hMLH1 
(65.1%) and to a lesser extent hMSH2 or hMSH6. About half of the colorectal carcinomas 
(50.7%) were found to be associated with p53 over-expression. Tumours with mismatch 
repair defect were inversely related to tumours with p53 over-expression. Ninety-two point 
seven percent of tumours with p53 over-expression were found to have intact mismatch 
repair whereas 74.4% of tumour with mismatch repair did not show p53 expression 
(p<0.001). Similarly, MMR-d tumours and tumours with p53 over-expression were 
significantly localised to different sites. Mismatch repair defect tumours were found at the 
right sided colon (p<0.001) whereas tumours with p53 accumulation were significantly 
localised to the left side of colon (p<0.001). This study showed that MMR-d tumours were 
not only more likely to be right sided but were larger, exophytic tumours producing mucin 
with large areas of necrosis. The tumours were more likely to be poorer differentiated and 
the patients were significantly associated with having multiple malignancies either 
synchronous or metachronous malignancies.  
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Multivariate analysis showed that four independent variables were significantly associated 
with loss of expression of one of the mismatch repair protein tested. Poor differentiation in 
tumour grade, right sided location, exophytic growth and poor p53 expression were 
independent predictors of loss of expression of hMLH1, hMSH2 or hMSH6 in the tumours. 
Our study showed patients with MMR-d tumours did not have a better survival compared 
to tumours with intact mismatch repair. It was also found that the tumours were not 
associated with any lymphocytic response (peri-tumoral or Crohn-like) and were not 
significantly associated with an earlier stage of disease. However, this was in contrast to 
many other reports (Gryfe, Kim et al. 2000; Truninger, Menigatti et al. 2005) which 
showed patients with MMR-d tumours had better survival as in those studies the tumours 
presented at an earlier stage and were associated with lymphocytic response. There were 
various possible reasons for the non-significant survival of these patients that were not 
looked into in our study. The local people generally accepted their fate readily and some 
resorted and preferred traditional therapy rather than seek the prescribed treatment for their 
tumours. There were also many patients who were lost to follow-up. 
Our study showed that immunohistochemical testing for hMLH1, hMSH2 and hMSH6 
could be done in a routine histopathology laboratory to detect the group of mismatch repair 
defect colorectal tumours associated with characteristic features as mentioned. It is 
important to delineate this group of patients for the management and the prognosis differs 
from the general group of patients with colorectal carcinomas. It can thus be proposed to 
include immunohistochemical testing for mismatch repair defect proteins in a routine 
histopathological reporting of all colorectal carcinomas or limit it to colorectal carcinomas 
with characteristic associated features that are highly be suspicious of mismatch repair 
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defect tumours. This preliminary testing can then be confirmed with a more sophisticated 
and expensive test, PCR test for the mismatch repair gene. On the other hand, immuno-
staining for p53 expression did not give any added usefulness to the report and may not be 
done routinely. 
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APPENDICES 
 
APPENDIX 1:  
Clinical Criteria for diagnosis of Hereditary Non-Polyposis Colorectal Cancer 
Name of Criteria Specific criteria 
Published 
reference 
Amsterdam 
Three relatives with colorectal cancer, one 
of which is a first-degree relative of the 
other two; colorectal cancer affecting more 
than one generation; at least one colorectal 
cancer case diagnosed before age  50 years 
(Vasen, 
Mecklin et al. 
1991) 
      
Modified 
Amsterdam
#
 
Two colorectal cancer cases in first-degree 
relatives in very small families that cannot 
be expanded further; colorectal cancer 
affecting more than one generation; at least 
one colorectal cancer case diagnosed before 
age 55 years 
(Bellacosa, 
Genuardi et 
al. 1996) 
      
Amsterdam 
Criteria II 
> 3 relatives with an HNPCC-associated 
cancer
a
 and > 2 successive generations 
affected and > 1 diagnosed before age 50 
years and one should be a first-degree 
relative of the other two. Familial 
adenomatous polyposis should be excluded 
and the tumours should be verified by 
histopathological examination. 
(Vasen, 
Watson et al. 
1999) 
 
(HNPCC-associated cancers
a
 = colorectal 
cancer, cancer of endometrium, small bowel, 
ureter or renal pelvis.) 
      
Bethesda
#
 
Individuals from families that fulfil the 
Amsterdam criteria 
(Rodriguez-
Bigas, Boland 
et al. 1997) 
   
 
Individuals with two HNPCC-related 
cancers, including synchronous and 
metachronous colorectal cancers or 
associated extra-colonic cancers  
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Individuals with colorectal cancer, plus 
colorectal cancer and/or HNPCC-related 
extra colonic cancer and/or colorectal 
adenoma in a first-degree relative; at least 
one of the cancers diagnosed before age of 
45 years and the adenoma diagnosed before 
age of 40 years  
   
 
Individuals with colorectal or endometrial 
cancer diagnosed before age 45 years  
   
 
Individuals with right-sided colorectal 
cancer with an undifferentiated 
histopathological pattern (solid/ cribriform) 
diagnosed before age 45 years  
   
 
Individuals with signet-ring cell type 
colorectal cancer diagnosed before age 45 
years  
   
 
Individuals with colorectal adenomas 
diagnosed before age 40 years  
      
Japanese
##
 
Three or more colorectal cancer cases 
among first-degree relatives 
(Fujita, 
Moriya et al. 
1996) 
   
 
Two or more colorectal cancers among first-
degree relatives and any of the following: 
diagnosis before age 50 years; right colon  
 
involvement; synchronous or metachronous 
multiple colorectal cancers; association  
 with extra colonic malignancy  
      
# 
Fulfilment of all criteria listed in any paragraph in this section 
is sufficient.  
##
Cases can be classified as fulfilling either the first set of criteria or the second 
set and can be diagnosed with hereditary non-polyposis colorectal cancer if they 
fulfil either set of criteria. 
 
   
 
APPENDIX 1: Continued 
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APPENDIX 2:  
Clinical Questionnaire form 
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APPENDIX 2: Continued 
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APPENDIX 2: Continued 
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APPENDIX 3:  
Definitions of TNM  
 
Primary Tumour (T) 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma-in-situ: intraepithelial or invasion of lamina propria* 
T1 Tumour invades submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades through the muscularis propria jnto pericolorectal tissues 
T4a Tumour penetrates to the surface of visceral peritoneum 
T4b Tumour directly invades or is adherent to other organs or structures. 
    
Regional Lymph nodes (N) 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in one regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c Tumour deposit(s) in the subserosa, mesentery, or nonperitonealized  
  pericolic or perirectal tissues without regional nodal metastasis 
N2 Metastasis in four or more regional lymph nodes 
N2a Metastasis in 4-6 regional lymph nodes 
N2b Metastasis in seven or more regional lymph nodes 
    
Distant Metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
M1a 
Metastasis confined to one organ or site (e.g. Liver, lung, ovary, 
nonregional node) 
M1b Metastasis in more than one organ/site or the peritoneum 
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APPENDIX 3: Continued 
Staging 
 
Anatomic Stage       
Stage T N M 
0 Tis N0 M0 
I T1 N0 M0 
  T2 N0 M0 
IIA T3 N0 M0 
IIB T4a N0 M0 
IIC T4b N0 M0 
IIIA T1-T2 N1/N1c M0 
  T1 N2a M0 
IIIB T3-T4a N1-/N1c M0 
  T2-T3 N2a M0 
  T1-T2 N2b M0 
IIIC T4a N2a M0 
  T3-T4a N2b M0 
  T4b N1-N2 M0 
IVA Any T Any N M1a 
IVB Any T Any N M1b 
        
 
 
 (Source: AJCC Cancer Staging Manual (Edge, Byrd et al. 2010) . 
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APPENDIX 4: 
Haematoxylin and eosin staining: Program set for Leica Autostainer XL 
1. Slides are sectioned from respective paraffin blocks and placed in oven briefly for  
10 seconds. 
2. Slides go through a series of xylene 1 to 4 for duration of 10 seconds, 30 seconds, 4  
minutes and 4 minutes respectively. 
3. The slides are taken to absolute alcohol 1 and 2 for 3 minutes each. 
4. They then go through a decreasing concentration of alcohol from 95% to 70%  
alcohol for 3 minutes each. 
5. The slides are brought to water for 3 minutes and stained with Haematoxylin for 12  
minutes. 
6. They are washed with water again for 3 minutes and then dipped into 0.2% acid  
alcohol. 
7. They are immersed into water again for 12 minutes and then counter-stained with  
eosin for 1 minute. 
8. The slides are briefly washed with water for 1 second and then dehydrate with  
increasing alcohol starting from 70% alcohol through 90% alcohol to two-times  
absolute alcohol for 10 seconds, 10 seconds, 1 minute and 2 minutes respectively. 
9. The slides go through 4 different troughs of xylene for 2 minutes each trough. 
10. The slides are then taken out from the last (fourth) trough of xylene and  
immediately mounted with DPX. 
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APPENDIX 5: 
Preparation for: 3-aminopropyltriethoxysilane (APES) treated slides 
1. Wash glass slides in Detergent for 30 minutes 
2. Wash glass slides in running tap water for 30 minutes 
3. Wash glass slides in distilled water for 5 minutes (twice). 
4. Wash glass slides in 95% alcohol for 5 minute (twice). 
5. Air dry the slides for 10 minutes. 
6. Immerse slides into freshly prepared 2% 3-aminopropyltriethoxysilane in dry  
acetone for 5 seconds. 
7. Wash briefly in distilled water twice. 
8. Dry overnight at 42oC. 
9. Store at room temperature. Treated slides can be kept indefinitely. 
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APPENDIX 6: 
Immunohistochemistry staining 
1. Diluted PT module solution is prepared accordingly: 15 ml. of PT module solution  
is made up to 1500 ml. by adding distilled water. Prepared solution is poured into  
the PT module instrument, pre-heated to 65
o
C for 10 to 15 minutes. 
2. Slides are sectioned from respective paraffin blocks and placed on glass slides pre- 
treated with 3-aminopropyltriethoxysilane. They are labelled accordingly and put 
into oven (set at melting point of wax i.e. 56
o
C) for about 2 hours 
3. The slides are taken out and arranged in a special rack and are immediately  
immersed into the PT module solution. The PT module solution is warmed to 100
o
C 
for 35 minutes. 
4. The temperature of the PT module instrument is cooled down to 65 oC. The cooling  
phase takes about 15 minutes. 
5. The rack and slides are taken out and flushed with Citrate Buffer Tween 20. 
6. They are then treated with hydrogen peroxide for 5-10 minutes. 
7. The slides are washed with Citrate Buffer Tween 20 for 3 times. Each wash takes 2  
minutes. 
8. The slides are treated with UV block for 5 minutes and then washed once again with  
Citrate Buffer Tween 20. 
9. The respective primary antibody is added at the recommended dilution and  
incubated for 30 minutes. Step 8 is repeated. 
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APPENDIX 6: continuation 
10. The antibody enhancer is added and incubated for 20 minutes. Step 8 is repeated. 
The polymer is added and incubated for 30 minutes. Step 8 is repeated. 
11. Freshly prepared DAB chromogen is added to slide and colour development is  
observed, which takes about 5 minutes.  
12. The slides are washed with buffer and arranged in a staining rack. 
13. The slides are dipped (one to two dips) into Harris Haematoxylin. 
14. The slides are put under running tap water for 5 minutes. 
15. The slides are dehydrated in series of alcohol in ascending order from 70% alcohol  
to absolute alcohol and then in xylene. 
16. The slides are mounted with DPX and labelled accordingly. 
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APPENDIX 7: 
Electronic-Database Information (Internet sites) 
1. SEER Cancer Statistics Review, 1973-1994, http://www-
seer.ims.nci.nih.gov/Publications/CSR7394/ 
2. Surveillance, Epidemiology, and End Results Program, http://seer.cancer.gov/ 
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APPENDIX 8: 
Pathologist worksheet 
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